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ABSTRACT 
JOANA PORTO ROCHA SOARES: Chemical and Pharmacological Modulation of 
Telomerase 
(Under the direction of Michael B. Jarstfer, Ph.D.) 
 
Telomerase is a specialized ribonucleoprotein complex that uses its RNA subunit to 
synthesize the repetitive G-rich DNA found at the 3′ ends of chromosomes. Most cancer 
cells, approximately 90%, upregulate telomerase to attain cellular immortalization, whereas, 
telomerase activity is undetected in normal somatic cells. Due to the differential expression 
pattern of telomerase between normal and tumor cells, telomerase has received significant 
attention as a universal cancer target. Additionally, since telomerase is expressed in stem 
cells during all stages of life, telomerase has been linked to the process of aging and age-
related diseases. Despite the great interest in telomerase, current understanding of telomerase 
and its regulation remains limited. The research presented here elucidates how important 
factors of different cellular processes play a role in the regulation of telomerase at the post-
translational level. 
In the first part of this dissertation, we identified and characterized promising 
compounds as telomerase inhibitors. One such class of compounds, tanshinone derivatives, 
proved to inhibit telomerase due to their ability to undergo redox cycling and generate 
reactive oxygen species. Studies using ortho-quinone containing compounds further 
indicated that reactive oxygen species can damage telomerase by oxidizing its protein 
 iv 
subunit. Inactivation of telomerase by these compounds was sensitive to catalase, suggesting 
that H2O2 is a mediator of their inhibition. Results from these studies, reported in Chapter 3, 
indicate that telomerase is sensitive to oxidative damage and that this regulation can be 
implicated in both cancer and aging. 
In addition to identifying telomerase inhibitors, we were interested in the 
identification of cellular pathways that control telomerase function. Chapter 4 reports studies 
showing that caspases are negative regulators of telomerase. Telomerase was shown to be 
cleaved by caspases-6 and -7 both in vitro and in apoptotic cancer cells. Additionally, 
mutagenesis studies suggested that caspase resistant hTERT mutants have different effects on 
apoptosis threshold in cancer cells. 
These studies provide a basis to better understand how telomerase is regulated in the 
processes of cancer, aging, and age-related disorders. Further understanding of the biological 
significance of such post-translational regulations of telomerase will provide a rational 
approach toward modulating the enzyme and improving therapeutic treatment. 
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CHAPTER I 
 
TELOMERE AND TELOMERASE OVERVIEW 
 
        
 
A. Telomerase Function in Cancer and Aging 
Each year millions of people are expected to die from cancer worldwide.  Cancer 
accounts for 1 out of every 4 deaths and is therefore the second most common cause of death 
in the United States, exceeded only by heart disease.
1,2
  As a result, there is a strong need for 
new anticancer therapies.  Most cancer research and existing cancer treatments focus on 
targeting a specific type of cancer thus limiting their therapeutic potential.  Identifying and 
exploiting biological targets that are universal to and specific for cancer cells is an arduous 
task.  Though biologically different, a commonality has been identified among cancer cell 
types; approximately 90% of all human tumors express telomerase activity.
3,4
  As telomerase 
is observed in most cancers, there is an emerging consensus that telomerase-targeted 
therapies offer a promising and novel approach to cancer treatment.  In addition to 
telomerase’s role in cancer immortalization, telomerase has been linked to the process of 
aging and some age-related diseases.  Furthermore, non-canonical effects of telomerase in 
aging and cancer independent of telomere lengthening have also been described such as 
telomerase roles in apoptosis, DNA repair, stem cell function, and in the regulation of gene 
expression.
5
  This makes telomerase modulation a highly researched area as telomerase has 
several important roles in cellular processes.  
 2 
1. Telomerase 
Telomerase is a ribonucleoprotein complex responsible for maintaining the length and 
integrity of chromosome ends by extending telomeres.  In humans, telomerase consists 
minimally of two subunits: an integral RNA component (TR) that serves as a template for 
telomeric DNA synthesis and a catalytic protein subunit (TERT) that uses its reverse 
transcriptase activity to add telomeric repeats onto the end of chromosomes
3,6-10
 (Figure 1.1). 
Telomerase is an unusual reverse transcriptase as it contains its own RNA template as an 
integral part of the enzyme and can reverse transcribe multiple copies of its template through 
repeated cycles of extension and translocation reactions. 
 
Figure 1.1  Mechanism of telomere extension by telomerase.   Human telomerase ribonucleoprotein 
consisting of telomerase reverse transcriptase (hTERT) and telomerase RNA (hTR) is illustrated.  The 
processive cycle of telomere binding to telomerase RNA template (blue), extension through addition of dNTPs 
(red), and translocation adds GGTTAG repeats to the 3' telomeric terminus.  The process is interrupted when 
the extended telomere dissociates from telomerase (dotted red line).  This figure was adapted from reference 
7
.  
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Telomerase activity is present in the early stages of human life in order to maintain 
telomere length and thus chromosomal integrity of frequently dividing cells.  However, 
telomerase becomes dormant in most somatic cells during adulthood due to transcriptional 
repression of the catalytic subunit hTERT during early embryonic development.
11-14
  Though 
telomerase activity is repressed in most human tissues, germline cells and some stem cells 
retain telomerase activity during all stages of life.
14
  Without telomerase activity in normal 
somatic cells, telomeric DNA is lost during each cell cycle, due to an inability of the DNA 
machinery to completely replicate the ends of the chromosomes, a process known as the end-
replication problem.
15-21
   As a result of the end-replication problem, telomeres shorten with 
each mitotic cycle resulting in cumulative telomere attrition.  When telomeres reach a critical 
length, known as the Hayflick limit, the protective function of the telomere is compromised 
and cells will no longer undergo cell divisions and become senescent.
22,23
  The senescence 
phenotype can also be induced by other forms of stress including overexpression of certain 
oncogenes, oxidative stress, and DNA damage signals.
5
  Cell cycle tumor suppressors such as 
p53/p21 and pRB/p16 play critical roles in the initiation and maintenance of the senescence 
state.
24
  Mutations of these cell cycle checkpoint proteins allow cells to overcome senescence 
and continue to proliferate leading to genetic instability and in most instances to programmed 
cell death, a process known as apoptosis.  However, rare survivor cells (10
-5
-10
-6
) can escape 
this crisis period and acquire the ability to elongate and maintain telomere length leading to 
cellular immortalization and cancer.
4,25
  In the majority of cases, this is accomplished by up-
regulating or reactivating the enzyme telomerase. 
Telomerase is necessary for the long-term proliferation potential of stem cells, cancer 
cells, and for normal tissue renewal.  It has been reported that ectopic expression of 
 4 
telomerase in normal cells leads to extended life-span or immortalization of several cell 
types.
7,26
  Additionally, inhibition of telomerase activity in telomerase expressing cell lines 
can lead to the induction of apoptosis or senescence.
27,28
  Mutations in either hTR or hTERT 
are associated with several aging phenotypes leading to human diseases such as aplastic 
anemia, dyskeratosis congenita, and idiopathic pulmonary fibrosis.
29-31
  Though telomerase 
was previously believed to have a sole role in elongating and maintaining telomeres, 
increasing evidence implicates telomerase in purposes beyond the chromosome ends in 
cancer and aging.  The antagonistic effects of telomerase in aging and cancer make it an 
important target for the development of therapies to treat cancer and other age-associated 
diseases.  Despite the great interest in telomerase, the understanding of telomerase regulation 
lags behind that of other nucleic acid polymerases.  Therefore, elucidating post-translational 
modulations of telomerase (one of the main goals of this thesis) would make a dramatic 
impact on the fields of cancer research, aging and age-related diseases, and telomerase 
biology.  
 
 
2.  Telomere structure and T-loop 
 
Telomeres are nucleoprotein structures composed of repetitive DNA sequences at the 
ends of eukaryotic chromosomes that protect the chromosome ends from degradation, inhibit 
end-to-end fusion, and prevent the recognition of chromosome ends as double strand 
breaks.
32
  Telomere length is highly variable among species, within species, within an 
organism, and even between chromosomes.  In humans, telomere length ranges from 5-15 kb 
of the repetitive G-rich sequence 5'-T2AG3-3' and 75-600 nucleotides of a 3' single-stranded 
overhang.
33,34
  Human telomeric DNA shortens 30-150 bp per replication cycle in cells with 
 5 
limited telomerase activity due to the end replication problem.
35
  During the non-mitotic 
phase of the cell cycle, both the double and single-stranded telomeric DNA is protected by 
the six-protein shelterin complex, composed of telomeric-repeat binding factor 1 (TRF1), 
TRF2, RAP1, TERF1-interacting nuclear factor 2 (TIN2), TPP1 and POT1 (Figure 1.2).
32
 
Deletion of any of these proteins leads to disruption of telomere-length regulation and end 
protection.  The telomeric repeat binding factor, TRF1 and TRF2 bind to double stranded 
telomeric DNA and have a role in telomere stabilization and telomere-length regulation,
36,37
 
while POT1, protection of telomeres 1, can bind directly to single stranded DNA and is 
important for forming the D-loop.
38,39
  Shelterin proteins that do not directly interact with 
telomeric DNA include TIN2, which associates with TRF1 and TRF2, and TPP1, which 
forms a heterodimer with POT1 (Figure 1.2B).
40
  Additionally, RAP1 is recruited to 
telomeres via TRF2 and it is known to negatively regulate telomere length.
32
  The telomere 3' 
single-stranded overhang can invade the double-stranded telomeric tracts thus forming two 
internal loops, the D-loop and the T-loop 
39
 (Figure 1.2A).  Presumably, the T-loop acts like a 
protective cap at the end of the chromosomes by preventing recognition by the DNA damage 
machinery as DNA double-strand breaks and initiation of inappropriate activation of DNA 
damage checkpoints.
32,41,42
  However, cell division will inevitably lead to telomere 
shortening and thus the destabilization of the telomeres due to the inability to recruit the 
proteins of the shelterin complex.  Consequently, the T-loop will no longer form properly, 
the chromosome ends will be left uncapped, and the cells will either trigger senescence or 
apoptosis.   
 
 6 
 
 
 
Figure 1.2 The T-loop structure formation.  (A) The telomere DNA loops back on itself forming a lariat 
structure. The 3’ overhang is strand-invaded into the adjacent duplex telomeric repeat array, forming a D-loop. 
Duplex DNA telomere–binding proteins bind along the length of the telomere.  A specialized telomere-binding 
protein, POT1, binds the D loop at the junction of the lariat. This figure was adapted from references 
32,43
.  (B) 
Several proteins are associated with telomeres.  Some of these proteins bind directly and specifically to 
telomeric DNA (TRF1, TRF2, and POT1), while other proteins are localized to telomeres through protein-
protein interactions.  This figure was adapted from reference 
40
. 
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3. The catalytic subunit of human telomerase, hTERT 
The catalytic subunit of human telomerase is composed of 1132 amino acids and can 
be divided into four functional domains: the reverse transcriptase domain, the poorly 
conserved C-terminus, a telomerase-specific region (T-motif), and a large N-terminal region 
composed of conserved, functionally important domains 
3
 (Figure 1.3 and 1.4).  The T-motif 
is required for hTR binding in vitro, is involved in the recruitment of hTERT to the 
nucleolus, which is an important step in telomerase biogenesis, and is critical for telomerase 
activity both in vitro and in vivo.
44,45
  The reverse transcriptase domain contains all seven RT 
motifs characteristic of other reverse transcriptases and it shares significant structural 
homology with other polymerases including the p66 subunit of HIV reverse transcriptase.
46,47
 
Remarkably, even residues crucial in nucleotide binding, dNTP discrimination, and 
nucleotide-addition processivity appear conserved between telomerases and viral reverse 
transcriptases.
48
  Recently, the first high-resolution structure of the catalytic subunit of 
telomerase has been solved, that of T. castaneum TERT.  Structural comparison of the TRBD 
domain of the ciliate Tetrahymena thermophila with that of T. castaneum suggests that a high 
degree of structural conservation in this region occurs across different organisms
49
 (Figure 
1.3A and C).  The T. castaneum TERT is organized into a ring configuration that resembles 
the HIV reverse transcriptases, viral RNA polymerases, and B-family DNA polymerases 
suggesting that these classes of enzymes are evolutionary related.
49
  
In humans, the N-terminal region is important for telomerase ribonucleoprotein 
assembly and catalysis, telomerase RNA binding, interaction with p23, multimerization, 
hTERT nucleolar localization, and cellular immortalization.
48,50,51
  Additionally, the N-
terminal region contains the RNA binding domain composed of RID1 and RID2 individually 
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or TRBD together. RID2 contains a vertebrate-specific RNA binding motif while RID1 
contains a DAT (dissociates activities of telomerase) domain, which is essential for telomere 
elongation but dispensable for catalytic activity.
52
  Studies have shown that mutations in 
RID2 reduced the association of hTR with hTERT by 50-70%, suggesting that RID2 is the 
major hTR binding motif.
50
  Functionally, the C-terminal residues are critical for 
immortalization, telomere recruitment, nucleolar localization, primer binding, processive 
elongation, and telomerase length maintenance.
53-55
  Like the N-terminus, the C-terminal 
region also contains a DAT (dissociates activities of telomerase) motif. C-DAT does not 
appear to be involved in nuclear localization or protein multimerization, instead, it appears 
that this region is involved in a step of in vivo telomere synthesis after the assembly of a 
catalytically active enzyme.
56
  Studies have determined that the first 300 amino acids of 
hTERT are dispensable for telomerase activity both in vitro and in vivo.
57
  Furthermore, it 
has been shown that the deletion of the last 204 amino acids in the C-terminal region did not 
affect telomerase activity in 293T cells, whereas all but the last 20 amino acids in the C-
terminus are absolutely required for telomerase activity in rabbit reticulocyte lysate.
58
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Figure 1.3 Organization of hTERT domains and their functions.  (A) All telomerase catalytic subunits, 
TERTs, contain the RNA binding domain (motifs CP and T), the reverse transcriptase domain (motifs 1, 2, A, 
B´, C, D, and E), and the C-terminal region (the thumb domain).  Some TERTs also contain a TEN domain in 
the N-terminal region. The p66 subunit of HIV reverse transcriptase is shown for comparison.  (B) High 
resolution of T. castaneum TERT (rendered from PDB code 3DU5).  (C) The RNA-binding domains of TERT 
from T. thermophila and T. castaneum are structurally similar. The TRBD is a slightly bent and highly helical 
structure with conserved elements, the CP and T motifs, splitting two helical sections at the kink.  The CP motif 
is in hot pink and the T motif is in royal blue.  The T motif forms a structurally conserved β-hairpin. The 
structure of TRBD of T. thermophila TERT was rendered from PDB code 2R4G.  The TRBD of T. castaneum 
TERT was solved as part of the full length protein, and the sequence was isolated using Pymol form the full 
length structure and rendered from PDB code 3DU5.  hTERT domains and their respective functions.  This 
figure was adapted from reference 
46
.  
 
 
Figure 1.4 hTERT domains and their respective functions.  This figure was adapted from references 
3,46,51
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4. The RNA subunit of human telomerase, hTR 
The human telomerase RNA is expressed in many tissues and throughout 
development, even in tissues without telomerase activity.
59
  In humans, hTR is transcribed by 
RNA polymerase II and is composed of 451 nucleotides.
60
  Telomerase RNA contains the 11 
nucleotide template (CAAUCCCAAUC) sequence required for telomere repeat elongation, 
and is intrinsic for telomerase biological function.
53,61
  Though its size, primary sequence, 
and overall structure is highly divergent among eukaryotes, the secondary structure of 
telomerase RNAs has been demonstrated to be phylogenetically conserved between similar 
species and contains similar structural elements.
46,53,60,62
  Vertebrate telomerase RNA 
secondary structure contains four conserved functional elements, including the pseudoknot 
domain, a CR4-CR5 domain, a box H/ACA domain, and a CR7 domain
61
 (Figure 1.5).  The 
5´ domain folds into a pseudoknot structure, contains the template for telomere repeat 
addition, and binds the catalytic subunit hTERT.
62
  The 3´ domain contains an H/ACA motif 
and is recognized by the four H/ACA associated proteins: Dyskerin/Cbf5, Nhp2, Nop10, and 
Gar1.
63,64
 The H/ACA motif is essential for proper RNA cellular localization, hTR 
stabilization, and accumulation in vivo.
65
  Mutations in the H/ACA box and CR7 region of 
the telomerase RNA destabilize the RNA component and prevent its localization to the 
nucleus in vivo.
63
  The CR4-CR5 domain contains a high affinity site for hTERT and is 
essential for catalytic activity.
66
  Perhaps, the most scrutinized region of the CR4-CR5 
domain is the p6.1 helix (nucleotides 302-314), which seems to be critical for telomerase 
activity as well as for binding to hTERT, though the exact sequence of the stem does not 
appear to be essential.
62,67-71
  It has been reported that two regions of hTR, one containing the 
template region (nucleotides 1-209) and the other containing the box H/ACA domain and 
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CR4-CR5 domain (nucleotides 241-330), interact independently with hTERT in a non-
cooperative manner.
70
  In addition, previous experiments have shown that a region from 
nucleotides 10 to 159 is the minimal sequence requirement for telomerase activity in vitro 
72,73
 and that two inactive fragments of hTR, nucleotides 33 to 147 and nucleotides 146 to 
325, reconstitute in trans telomerase activity in vitro, suggesting that telomerase RNA 
sequence or the structure involved in binding to hTERT and its catalysis are functionally 
separated.
3,58,70,72,74
 
Several studies using FISH have reported that hTR accumulates in Cajal bodies in 
cancer cells.
75,76
  Cajal bodies are subnuclear structures involved in the maturation and 
assembly of small nuclear and nucleolar RNPs (snRNPs and snoRNPs), which are important 
in mRNA splicing and rRNA biogenesis.
77
  Localization of hTR to Cajal bodies is dependent 
on a specific localization motif, known as the CAB box, which is located in the 3´ end of the 
RNA.
75
  While it was previously believed that the accumulation of hTR in Cajal bodies was 
implicated in the assembly of the telomerase holoenzyme,
75,76
 more recent publications do 
not support this hypothesis.
78,79
  Perhaps hTR and hTERT are separated during most of the 
cell cycle and assembled only in the S phase.  This separation may be necessary in order to 
prevent unregulated telomerase activity, though telomerase activity can be detected in all 
phases of the cell cycle.
80
  Interestingly, accumulation of hTR in Cajal bodies is dependent 
on the presence of hTERT, even if hTERT is not found in these bodies.
76
  As a result, 
telomerase biogenesis involves a complex trafficking pathway of its RNA and protein 
subunits.  
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Figure 1. 5 Phylogenetically derived secondary structure of human telomerase RNA (hTR)..  Highly 
conserved motifs of hTR such as the pseudoknot domain (CR2/CR3), conserved regions (CR) 4, 5, 7, and the 
H/ACA box are indicated.  This figure was adapted from reference 
60
.  
 
 
 
B.  Telomere length, telomerase, and aging 
 
 There is a direct relationship between telomere length and cellular aging.  Telomeres 
are referred to as a universal biological clock that shortens in parallel with organism aging. 
As previously mentioned, normal cells undergo a limited number of cell divisions before 
entering a state of replicative senescence in which cells remain viable but are unable to 
divide further.  One of the major mechanisms of replicative senescence is thought to be 
telomere shortening as the introduction of the TERT gene was sufficient to bypass 
senescence and to confer immortalization on human primary cell lines.
26
  It has been 
proposed that this limited replicative capacity is related to some aging phenotypes, such as 
reduced wound healing and weakened immune system.
81-83
  Additionally, diseases, such as 
    CAAUCCCAAUC  
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acquired immunodeficiency disease (AIDS) and cirrhosis, are believed to be at least partially 
a result of the limited ability of tissues to regenerate themselves.
81,84
         
 The relationship between aging and telomere is highlighted by the biological impact 
of telomere length on human health.  Telomere length has shown to vary between men and 
women and can be influenced by socioeconomic status, perceived stress, smoking, poor diet, 
lack of exercise, and obesity.
19
  A number of age-related pathologies and premature aging 
syndromes exhibit a faster than normal rate of telomere shortening.  Reduced telomere length 
has been observed in various age-related diseases such as cardiovascular disease,
85
 
diabetes,
86,87
 atherosclerosis,
88
 heart failure,
89
 infections,
90
 and cancer.
91
  Similarly, telomere 
length can serve as a predictor of dementia and cognitive impairment.
92
  Several human 
syndromes characterized by premature loss of tissue renewal and premature death, such as 
dyskeratosis congenita,
93-95
 aplastic anemia,
96
 and idiopathic pulmonary fibrosis,
97
 are linked 
to mutations in either hTR or hTERT, which result in decreased telomerase stability and 
accelerated telomere shortening.  Moreover, some diseases that originate from mutations in 
genes of the DNA repair system also result in a phenotype characterized by accelerated 
telomere shortening and premature aging.
98
  Most of these DNA repair genes (i.e. Ataxia 
telangiectasia, Werner syndrome, Bloom syndrome, and Fanconi anemia genes) also have a 
role in telomere biology. 
A role for telomerase in tissue renewal and organism lifespan has been supported by 
telomerase knockout mouse models, which showed a decrease in the mice’s lifespan with 
each successive generation.
99,100
  Furthermore, mice lacking the telomerase RNA component 
showed accelerated telomere shortening and a shorter lifespan, which became aggravated 
with each subsequent generation until infertility finally occurred.
101-103
  Over-expression of 
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TERT in cancer resistant mice delayed aging and increased lifespan, thus demonstrating a 
parallel correlation between TERT expression and organism survival.
104
  Mounting data 
support a direct relationship between telomerase and aging; telomerase exerts its anti-aging 
activity mainly by preventing or slowing telomere attrition and by preserving the 
proliferative potential of stem cells.  
 
 
C. Reactive oxygen species affect telomere biology, aging and cancer 
 
In normal human somatic cells, telomeres gradually shorten after each cell division 
due to incomplete replication at distal ends of chromosomes.  Once telomeres become too 
short, cells enter senescence.  Therefore, telomeres limit the number of cell divisions and act 
as a mitotic clock.  Even though the progressive shortening of telomeres is expected after 
each cell division, the speed at which telomeres shorten depends on many factors.  Cellular 
environment is crucial for regulating telomere length and telomerase activity.  In particular, 
oxidative stress is one of the main contributors to the shortening of telomeres.
105
  When 
mitochondrial dysfunction occurs concomitant with increased reactive oxygen species (ROS) 
generation, the susceptibility of telomeres to oxidative damage leads to accelerated telomere 
shortening, increased probability of uncapping, activation of a DNA damage response, and 
irreversible cell cycle arrest.
106,107
  Therefore, abnormal accumulation of ROS is believed to 
accelerate cellular aging while the ability to tolerate oxidative stress is correlated with 
enhanced longevity in several species.
108
  
Free radicals and other ROS are produced in a wide range of physiological processes. 
Mitochondrial respiration is a major endogenous source of ROS.  The electron transport 
chain or oxidative phosphorylation system is located in the mitochondrial inner membrane 
and is responsible for the production of ATP, generation of ROS, and regulation of 
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programmed cell death.  Chronic elevation in the levels of ROS causes damage to the 
electron transport system, which in turn produces ROS at an even higher rate.  In addition to 
the mitochondria, various enzymes including NADPH oxidases, xanthine oxidase, nitric 
oxidase synthase, and peroxisomal constituents generate ROS.
109
  Oxidants can also be 
generated in the endoplasmic reticulum during protein folding and disulfide bond formation. 
Furthermore, ROS can be produced by ionizing and UV radiation and from the metabolism 
of drugs and xenobiotics.  Oxidative stress results in damage to cellular components 
including mitochondria and therefore leads to apoptosis.  Reactive oxygen species can also 
cause mutations in DNA and lead to cancer.  Thus oxidative stress plays an important role in 
cell death, which can lead to precocious aging and various pathologies including neoplastic, 
cardiovascular, inflammatory, and degenerative diseases.
110
  
Reactive oxygen species such as superoxide anion, hydrogen peroxide, and hydroxyl 
radicals can attack numerous cellular entities, causing damage that compromises cell 
integrity and function.
111
  In order to decrease the damage generated by ROS, cells contain 
complex defense mechanisms, including enzymes superoxide dismutase and catalase, and 
antioxidants including vitamin C, vitamin E, and glutathione.
112,113
  Previous reports have 
shown that targeting of antioxidants directly to the mitochondria counteract telomere 
shortening and increase lifespan in fibroblasts.
114
  Also, mild chronic uncoupling of 
mitochondria reduced superoxide anion, improved telomere maintenance, and extended 
telomere dependent lifespan.
106
  
Numerous studies have documented the oxidation of various biological substrates as a 
consequence of an interaction with reactive oxygen species.  Hydrogen peroxide reacts with 
thiol proteins such as peroxiredoxins, GSH, protein tyrosine phosphatases, and related 
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enzymes.  Studies have demonstrated that protein tyrosine phosphatases (PTP) are highly 
sensitive to redox cycling and that the catalytic cysteine of PTP is oxidized in the presence of 
reactive oxygen species thus inhibiting their activity.
115,116
  It has been documented that 
oxidative stress interferes with telomere maintenance also via its effect on telomerase 
activity.  Additionally, oxidative stress diminished telomerase activity in endothelial 
cells,
117,118
 vascular smooth muscle cells,
119
 and leukemic cancer cells
120
 in conjunction with 
an acceleration of telomere attrition.  Given the fact that ROS can inhibit specific proteins 
and can cause telomere erosion, it is possible that telomerase itself is an ROS target.  This 
will be explored in chapter III of this dissertation. 
 
D. Telomerase actions beyond the chromosome ends 
Though telomerase is primarily known for its role in telomere lengthening, increasing 
evidence suggests other functions of telomerase independent of telomere maintenance. 
Telomerase has been implicated in several important cellular processes including apoptosis, 
DNA damage response, tumorigenesis, and gene expression control that are not involved in 
telomere extension.
5
  It has been shown that hTERT contains a mitochondrial localization 
signal peptide located in the first 20 amino acids at its N-terminal region, which targets 
hTERT to the mitochondria.
121
  Further analysis using seven different human cell lines 
showed that mitochondrial telomerase increased hydrogen-peroxide-mediated mitochondrial 
DNA damage.
122
  In addition, mutations in the hTERT N-terminal mitochondrial leader 
sequence resulted in reduced level of mitochondrial DNA damage induced by hydrogen 
peroxide treatment, suggesting a pro-apoptotic role of hTERT in mitochondria.
122
  These 
observations were consistent with experiments showing that oxidative stress induced nuclear 
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export of hTERT to the cytosol, which might contribute to the mitochondrial proapoptosis 
activity of hTERT.
118
  Santos et al. suggested that the reason for this paradoxical finding 
might be to ensure the quality of the stem cell pool by driving stem cells with high oxidative 
damage into apoptosis.
122
   However, a different group has reported contradictory 
observations, their results showed lower mtDNA damage and superoxide production, 
increased mitochondrial membrane potential, and lower cell peroxide levels in response to 
oxidative stress in fibroblasts expressing telomerase, suggesting a protective role by 
telomerase.
123
  
The majority of reported studies to date have demonstrated a pro-survival function of 
hTERT in cells, rendering cells more resistant to apoptosis.  For example, it has been shown 
that expression of telomerase did not prevent stress-induced senescence in human fibroblasts 
but protected cells from apoptosis and necrosis.
124
  In addition, overexpression of hTERT 
suppressed apoptosis at a premitochondrial step before the release of cytochrome c by a 
mechanism requiring reverse transcriptase activity and 14-3-3 protein-binding ability.
125
 
Down-regulation of hTERT using siRNA sensitized the mitochondrial apoptosis pathway 
without apparent involvement of telomere erosion due to telomerase, but rather by post-
translational activation of Bax.
126
  Furthermore, overexpression of TERT in cell culture and 
transgenic mice increased organism survival and resistance to apoptosis induced by 
staurosporine or N-methyl-D-aspartic acid (NMDA) treatment independently of telomerase 
activity and telomere maintenance.
127
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E. Caspases and the induction of apoptosis 
Apoptosis, or programmed cell death, is essential for development and tissue 
homeostasis.  Inappropriate induction of apoptosis has been implicated in various 
pathological disorders including neurodegenerative diseases,
128
 cardiovascular disorders,
129
 
transplant rejection, cancer,
130
 and AIDS.
131
  The induction of apoptosis is a highly regulated 
process that can be initiated by a variety of extracellular ligand-directed or intracellular 
stress-induced stimuli.  One of the earliest and most consistent observed features of apoptosis 
is the induction of caspases.  Caspases are cysteine proteases that specifically cleave their 
substrates following an aspartic acid residue, though recent studies also suggest that caspases 
can cleave substrates after a glutamic acid residue.
132,133
  Each caspase has a specific 
consensus recognition sequence; therefore, they have different substrate preferences.  Almost 
all healthy cells contain caspases as inactive precursors, termed caspase zymogens.  Upon 
receiving an apoptotic signal, the caspase zymogens undergo protelolytic processing in order 
to generate active enzyme.
134
  In vitro, caspases are known to cleave a number of structural 
proteins as well as RNA splicing and DNA repair-associated proteins and can also cleave 
other caspases.
135
  At least 14 distinct mammalian caspases have been identified.
136
  Caspases 
involved in apoptosis can be separated into two groups: initiator caspases and effector 
caspases.  The caspases that are activated via recruitment to signaling complexes are known 
as the initiator caspases as they provide a link between cell signaling and execution of 
apoptosis.  The main initiator caspases in humans are caspase-2, -8, -9, and -10.
126,137,138
 
Caspases that lack a long prodomain lack the ability to self activate and require cleavage by 
activated initiator caspases.
139
  These caspases are known as effector caspases and they are 
responsible for cleaving most cellular substrates in order to induce apoptosis.  The main 
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members of this family include caspase-3, -6, and -7.
137,140
  It is well documented that 
telomerase is down-regulated in cells undergoing apoptosis and although this is currently 
believed to be a result of transcriptional regulation, we hypothesize that post-translational 
regulation also plays a role; this will be further explored in chapter IV. 
 
F. Regulation of telomerase 
 
1. hTERT transcription regulators 
Telomerase regulation occurs at various levels including transcription, mRNA 
splicing, maturation and modifications of hTR and hTERT, transport and subcellular 
localization, assembly of active telomerase ribonucleoprotein, and telomeric accessibility. 
Transcriptional regulation of hTERT is thought to be the major mechanism of telomerase 
regulation.
9,10
  The hTERT promoter contains binding sites for many transcription factors, 
suggesting that the regulation of hTERT expression may be subject to multiple levels of 
control by different factors in different cellular contexts.
141
  There are several transcription 
factors known to participate in hTERT expression.  One such activator of hTERT 
transcription is c-myc. c-Myc is an oncogene which promotes cell proliferation, growth, and 
apoptosis.
142
  The target genes of the myc family are involved in many aspects of cellular 
functions, including cell cycle, growth, differentiation, and life span.  c-Myc expression 
correlates with hTERT as they are both upregulated in highly proliferative and immortal cells 
but downregulated during terminal differentiation and in non-proliferative cells.  Therefore, it 
is not surprising that molecules, such as butein,
143
 gamboic acid,
144
 and genistein,
145
 that 
inhibit this oncogene also inhibit telomerase.  Additionally, genistein also resulted in down-
regulation of protein kinase B (Akt) and phosphorylation required for hTERT activation, 
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indicating that genistein represses hTERT transcriptional activity via c-myc and post-
translational modification of hTERT via Akt.
145
  
Ceramides, a family of lipid molecules, have been shown to inhibit hTERT promoter 
by altering functions of Sp1 and Sp3, modulation of the trans-activating function of Sp1, 
and/or increased repressor function of Sp3.
146
  Sp1 has been shown to collaborate with c-myc 
in order to initiate hTERT transcription.
147
  Agents that act on hormonal pathways have also 
been linked to telomerase activity regulation.  For example, estrogen activates telomerase in 
hormone-sensitive tissues such as mammary and ovary epithelial cells,
148,149
 while the 
selective estrogen modulator drug tamoxifen reduces telomerase activity in certain cell 
lines.
150,151
   Progesterone also has an antagonistic effect on estrogen-induced hTERT 
expression.
152
  
 
 
2. Negative regulators of hTERT transcription 
The lack of telomerase activity in somatic cells is thought to be a consequence of 
transcriptional repression of the hTERT gene.  The loss of this repression results in the 
upregulation of hTERT expression and telomerase activity seen during carcinogenesis and 
cellular immortalization.  Several chromosomes have been found to contain transcriptional 
repressors of hTERT.  One such negative regulator of hTERT transcription is Mad1. Mad, c-
Myc, and Max are part of a family of transcription factors that can dimerize and bind to E-
box containing promoters to either downregulate or upregulate gene expression.  Mad is 
upregulated in telomerase negative somatic cells, c-Myc is upregulated in cancer cell lines, 
and Max is expressed ubiquitously.
153
  Overexpression of Mad1 resulted in decreased hTERT 
promoter activity in luciferase reporter assays.  
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Another negative regulator of hTERT transcription is the tumor suppressor protein 
p53.  p53 induces cell cycle arrest and apoptosis as a response to cellular stress including 
DNA damage.  p53 has been shown to inhibit telomerase activity through the repression of 
hTERT transcription.
154
  Repression of telomerase activity was also observed by 
overexpressing pRB in human squamous cell carcinomas
155
 and by overexpressing E2F1 in 
head and neck squamous cell carcinomas.
156
  pRB and E2F have the potential to 
transcriptionally repress hTERT activity either independently or in partnership with one 
another.  Another tumor suppressor involved in the transcriptional repression of hTERT is 
the Wilm’s tumor 1 (WT1), which interacts with the hTERT promoter and thus represses 
transcription of hTERT.  WT1 has also been shown to significantly decrease hTERT mRNA 
and telomerase activity in 293 cells.
157
  The role of WT1 in hTERT repression is cell type 
dependent as the WT1 gene is observed only in specific cells such as the kidney, gonad, and 
the spleen.  
Other negative regulators of hTERT transcription include the myeloid cell-specific 
zinc finger protein 2, interferon- α, and TGF-β.  Interferon-α and –γ induced sensitization to 
apoptosis is associated with repressed transcriptional activity of the hTERT promoter in 
multiple myeloma.
158
  Transforming growth factor-β, a potent tumor suppressor, inhibits 
telomerase through SMAD3 and E2F transcription factors.
159,160
  TGF-β activated kinase 
1(TAK1) has shown to repress transcription of the human telomerase reverse transcriptase 
gene. TAK1 induced repression was caused by recruitment of histone deacetylase to Sp1 at 
the hTERT promoter.
161
  TAL 1 (T-cell acute lymphoblastic leukemia 1) is also a negative 
regulator of the hTERT promoter.  Over-expression of the proto-oncogenic protein TAL1 
leads to a decrease in mRNA level of hTERT and consequently reduced telomerase 
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activity.
162
  Histone deacetylase (HDAC) inhibitors, such as trichostatin A (TSA), have been 
shown to induce apoptosis and down-regulate telomerase activity via suppression of hTERT 
mRNA expression in leukemic U937 cells.
163-165
  Dynamic assembly of E2F-pocket protein-
HDAC complex plays a central role in the regulation of hTERT.  A small molecule, CGK 
1026, inhibits the recruitment of HDAC into E2F-pocket protein complexes assembled on the 
hTERT promoter resulting in derepression of hTERT and telomerase activity.
166
  
COX-2 inhibitors, such as etodolac, caused telomerase inhibition as well as inhibition 
of hTERT mRNA expression.
167
  GSK3 inhibition by 6-bromoindirubin-3’-oxime caused 
suppression of hTERT expression, telomerase activity, and telomere length in different 
cancer cell lines and decreased hTERT expression in ovarian cancer xenografts.
168
  Other 
repressors of hTERT transcription are retinoids, derivatives of vitamin A.  They have also 
shown to down-regulate telomerase and telomere length.
169
  Retinoic acid receptor alpha and 
retinoid-X receptor-specific agonists synergistically downregulated hTERT and induced 
tumor cell death.
170
  
 
 
3. Post-translational regulators of hTERT 
Even though transcriptional regulation of hTERT is the primary mechanism for 
controlling telomerase activity in cells, post-translational modifications of the hTERT protein 
also account for telomerase regulation.  Expression of hTERT alone is not always sufficient 
to produce active telomerase in some cells suggesting that telomerase activity depends on the 
presence of correctly modified and active hTERT.  Telomerase activity can be regulated by 
the phosphorylation of hTERT.  For instance, the protein kinase C (PKC) has been shown to 
enhance telomerase activity in certain cell types while the PKC inhibitor bisindolylmaeimide 
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I and H-7 inactivates telomerase in nasopharyngeal
171,172
 and cervical
173
 cancer cells among 
others.  Imatinib mesylate (Gleevec), a tyrosine kinase inhibitor, also down-regulates 
telomerase activity and inhibits proliferation in telomerase expressing cells.
174
  Inhibitors of 
phospholipase C (PLC), such as U-73122, are also potent inhibitors of telomerase.
175
  
Another example is the phosphatase 2A which inhibits telomerase activity whereas the 
phosphatase 2A inhibitor okadaic acid prevents telomerase inhibition by phosphatase 2A in 
breast cancer cells.
176
  These observations show that telomerase activity can be directly 
regulated by protein phosphorylation independent of transcriptional regulation.  The Akt 
protein kinase is also involved in telomerase activation.  Akt kinase has been shown to 
phosphorylate hTERT and activate telomerase in vitro, while the Akt inhibitor wortmannin 
causes inhibition of telomerase.
171
  The tyrosine kinase c-abl is also capable of 
phosphorylating hTERT.  The SH3 domain of c-abl can interact with and phosphorylate 
hTERT resulting in a decrease in telomerase activity.
177
  
 
 
4. Regulators of hTERT translocation from cytoplasm to the nucleus 
Experiments involving T-lymphocyte activation demonstrated that regulation of 
telomerase activity might be a result of hTERT phosphorylation and translocation from the 
cytoplasm to its functional nuclear compartment.  Translocation of hTERT from the 
cytoplasm to the nucleus due to phosphorylation has been shown to induce telomerase 
activity in some cell lines.
3,178
  Tumor necrosis factor alpha (TNF-α) induces translocation of 
hTERT to the nucleus by direct interaction with NF-kappaB p65.  Inhibitors of NF-kappaB 
pathway can thus block hTERT nuclear translocation induced by TNF-α.179  
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5. Chaperone Hsp90 inhibitors 
 
There are several chaperone proteins, such as Hsp90, p23, Hsp70, p60, and Hsp40/ydl 
that are important for the telomerase ribonucleoprotein complex assemblage.  Hsp90 
associates directly with hTERT and is required in order to maintain telomerase in an active 
conformation.
180-182
  Hsp90 inhibitors cause inactivation, destabilization, and degradation of 
Hsp90 target proteins, one such protein is hTERT.
183
  Since different oncogenic proteins (i.e. 
c-myc, Akt, mutant p53) require Hsp90, inhibition of this chaperone should block multiple 
oncogenic pathways.  Hsp90 inhibitors such as novobicin, radicicol, geldanamycin, and 17-
AAG also inhibited telomerase activity.
184-186
  Recently, curcumin has been shown to inhibit 
nuclear localization of telomerase by dissociating the Hsp90 co-chaperone p23 from 
hTERT.
187
  Curcumin treatment decreased the association between p23 and hTERT while not 
affecting Hsp90 interaction with the telomerase protein catalytic subunit.  The interaction of 
the Hsp90-p23 complex with hTERT is required for protein folding, assembly of active 
telomerase, and is critical for nuclear localization of telomerase.
181,182,188,189
 
 
G. Telomerase inhibitors  
1. Targeting the protein subunit of telomerase, hTERT 
 
Telomerase activity, cancer initiation, progression, and metastasis have all been 
shown to be closely related to hTERT expression.
3
  hTERT, the protein subunit of 
telomerase, is generally repressed in normal cells and up-regulated in immortal cells, 
suggesting that hTERT is the primary determinant for telomerase enzymatic activity and the 
ideal target for telomerase based therapies.  In 1999, two independent reports utilizing 
dominant-negative (DN) mutants of hTERT demonstrated that overexpressing DN-hTERT 
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resulted in dramatic telomerase inhibition, telomere shortening, morphological changes, 
growth arrest, and apoptosis in different tumor cell lines.
27,190
  These studies were the first to 
support the use of dominant negative hTERT protein mutants as telomerase inhibitors and 
correlated telomerase inhibition with an anti-cancer effect.  However, because there is a lag 
phase between the initiation of telomerase inhibition and telomere erosion leading to 
senescence or apoptosis, the application of telomerase inhibitors is challenging in cases of 
cancer cells with long telomeres.
191
  
   
 
  a. Nucleoside analogs 
 
Several nucleoside analogs have been investigated as telomerase inhibitors.  The 
chain terminating analog azidothymidine (3’-azido-2’,3’-dideoxythymidine, zidovudine, 
AZT), the first nucleoside reverse transcriptase inhibitor approved for the treatment of HIV-
1, has also been shown to inhibit telomerase by inducing telomeric shortening in 
Tetrahymena,
192
 and in a variety of human cancer cell lines 
193,194
 (Figure 1.6).  AZT targets 
the active site of hTERT but lacks selectivity for telomerase compared to other polymerases.  
Long-term AZT treatment results in shortening of telomeres in conjunction with inhibition of 
telomerase activity, cell-cycle perturbation, and increased p14 (ARF) expression.
195
  AZT 
also displays synergistic effects when combined with chemotherapy drugs.
196,197
  Another 
nucleoside analog, 6-thio-7-deaza-2’-deoxyguanosine 5’-triphosphate (TDG-TP), has been 
shown to be a potent and specific telomerase inhibitor (IC50 = 0.06 μM).
198
  Although other 
nucleoside triphosphate analogs, including arabinofuranyl-guanosine (Ara-G) and 6-thio-7-
deaza-2’-deoxyguanosine 5’ triphosphate ddGTP, ddATP, and ddTTP, produced substantial 
inhibition of telomerase and telomere shortening in cell extracts, they have not been fully 
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tested in cell cultures or in animal models and are likely to be nonspecific, thus limiting their 
clinical utility.
194,198
  Consequently, there is a lack of in vivo studies on nucleoside analogs as 
potential telomerase inhibitors.  However, as telomerase structural biology increases, it may 
be possible to rationally design nucleoside analogs with requisite specificity for telomerase 
making this a potentially viable platform. 
    
b. Non- nucleoside inhibitors 
 
Several small, non-nucleoside molecules have also been shown to inhibit telomerase 
by targeting the catalytic activity of TERT.  Screening of a large scale chemical library 
yielded an isothiazolone derivative, 2-[3-(trifluoromethyl)phenyl]isothiazolin-3-one (TMPI) 
as a potent inhibitor of telomerase (IC50 of 1 μM).
199
  The isothiazolone moiety of TMPI is 
believed to interact with the sulfhydryl group of cysteine residues at or near the active site of 
telomerase as treatment with DTT could overcome inhibition.  Other compounds identified 
from a chemical library includes a nitrostyrene derivative, 3-(3,5-dichlorophenoxy)-
nitrostyrene (DPNS)
200
 and a quinoxaline derivative, 2,3,7-trichloro-5-nitroquinoxaline 
(TNQX)
201
 (Figure 1.6).  Both were determined to display mixed-type noncompetitive 
inhibition.  Continuous delivery of DPNS (IC50 of 0.4 μM) to HeLa cells resulted in 
progressive telomere erosion followed by the induction of senescence phenotype.  Long-term 
treatment of breast cancer MCF7 cell line with TNQX resulted in telomere erosion, 
chromosome abnormalities, and senescence.
201
  Bisindole derivatives with IC50 values in the 
submicromolar range have also been described as scaffold to construct a compound library of 
telomerase inhibitors.
202
  Tea catechins such as epigallocatechin gallate (EGCG) prevent 
growth of a variety of cancer cell lines and repress telomerase activity in a concentration 
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dependent manner
203
 (Figure 1.6).  EGCG shortened the proliferation potential of U937 
monoblastoid leukemia cells and HT29 colon adenocarcinoma cells commensurate with 
telomere shortening, consistent with telomerase inhibition.
204
  EGCG induced apoptosis in 
laryngeal squamous cell carcinoma Hep-2 and small-cell lung carcinoma (SCLC) also by 
inhibiting telomerase activity.
205,206
  MST-312, a tea catechin derivative, was a more 
effective inhibitor of telomerase than EGCG.  The effective dose required for telomere 
shortening was 1-2 μM for MST-312 in U937 cell line (15 to 20 fold lower than that of 
EGCG).
207
  
Chrolactomycin and UCS1025A were identified as direct telomerase inhibitors using 
a yeast-based assay.  Chrolactomycin (IC50 of 0.5 μM) and UCS1025A (IC50 of 1.3 μM) were 
isolated from microbial metabolites produced by Streptomyces sp. and Acremonium sp.
208
 
(Figure 1.6).  Helenalin, a natural sesquiterpene lactone, is a potent and selective inhibitor of 
telomerase in hematopoietic cancer cells and likely reacts with a cysteine residue of the 
enzyme.
209
  β-rubromycin, a quinone antibiotic, inhibited telomerase with an IC50 of 3 μM, 
whereas α-rubromycin showed substantially decreased inhibitory potency toward 
telomerase.
210
  β-rubromycin revealed a competitive interaction with the telomerase substrate 
primer.  However, it also showed inhibition towards retroviral reverse transcriptases, 
mammalian DNA polymerases, and terminal deoxynucleotidyl transferase, indicating that 
rubromycins are not specific to telomerase.
211
  Recent synthetic efforts on this class of 
molecules may provide analogs that allow enhanced selectivity for the various targeted 
polymerases.  
 Perhaps, the most promising small non-nucleosidic synthetic compound thus far is 
BIBR1532, a potent (IC50 of 0.093M), and selective mixed-type non-competitive 
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telomerase inhibitor that was identified from structure-activity relationships of compounds 
with similar backbones 
212
 (Figure 1.6).  BIBR1532 mode of inhibition is distinct from 
nucleosidic compounds or antisense oligonucleotides as it does not cause chain termination 
events but rather inhibits the formation of long reaction products.  The compound does not 
prevent the catalytic steps involved in template copying but specifically impairs the unique 
ability of telomerase to catalyze addition of multiple telomeric repeats onto a DNA primer.
213
  
High concentrations of BIBR1532 caused direct cytotoxic effects on malignant cells of the 
hematopoietic system resulting in end to end fusions, phosphorylated p53, and decreased 
expression of TRF2, consistent with a telomere-associated effect.
214
  The molecule is also 
capable of sensitizing drug-resistant cells to chemotherapeutic agents.
215
  Finally, cells 
treated with BIBR1532 experience a steady erosion of telomeric DNA length leading to 
senescence.
216
  However, the lag phase between telomerase inhibition and impact on 
proliferative capacity is a major concern for this molecule.  More than 120 days, 
approximately 135 population doublings, was necessary in order for a lung cancer (NCI 
H460) cell line to experience complete inhibition of cell proliferation under BIBR1532 
treatment.
191
  Interestingly, halting treatment with BIBR1532 in telomerase positive cells 
allows recovery of telomere length.
213,216
 
 
 
2. Targeting the RNA component of telomerase, hTR 
 Though hTR is constitutively expressed in most cells, it does not appear to have an 
essential function in telomerase-negative cells, rendering it a valuable target for telomerase 
inhibition.  Inhibitors of telomerase that target the RNA include template antagonists,
217-219
 
hammerhead ribozymes,
220-222
 RNAi,
223-228
 small-molecules,
229,230
 and anti-sense sequences 
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that either degrade hTR or function as steric blocks to perturb the assemblage process.
231-235
 
The use of antisense (AS) oligonucleotides (ODNs) for telomerase inhibition is based on the 
chemical properties of nucleic acids and their ability to bind RNA and sterically block 
telomerase enzymatic activities.
228
  However, use of traditional oligonucleotides presents 
many challenges to achieving efficient telomerase inhibition.  Natural or unmodified nucleic 
acids suffer from poor pharmacokinetic properties; they are highly susceptible to nuclease 
degradation and have very poor cellular uptake.
228,231,236
  Nonetheless, studies have 
demonstrated that standard antisense oligonucleotides can in fact potently inhibit telomerase 
activity in various cancers.
237,238
  The most potent and specific inhibitors of telomerase to 
date have come from antisense oligonucleotides that target the 11-nucleotide template region 
of hTR.
239
  In particular, a 13-mer NPS oligonucleotide, GRN163, has received special 
attention as a drug development candidate.  GRN163, developed by Geron corporation, 
exhibited telomerase inhibition at nanomolar concentrations, gradual telomere shortening, 
followed by cellular senescence and/or apoptosis in tumor cells, dependent on the initial 
telomere length.
240
  As with other oligonucleotides, the cellular uptake of GRN163 was a 
major obstacle, therefore, a lipid modification of GRN163 (GRN163L) was developed 
(Figure 1.6).  Comparison studies with GRN163 proved that the lipid-modified GRN163L 
was just as potent at inhibiting telomerase in various cancers, could inhibit telomerase 
activity effectively without the use of a transfection agent, and demonstrated more cellular 
uptake in tissue and xenograft models.
218
  Many studies have been published revealing the 
extensive anticancer potential of this oligonucleotide in a variety of cancers.  Reports have 
showed that continued treatment with GRN163L for two weeks reduced colony formation in 
lung cancer, elicited morphological changes in bladder cancer, and inhibited invasion in 
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breast cancer.
217,241,242
  Additionally, longer periods of GRN163L treatment triggered 
decreased proliferation, decline in cell viability, substantial telomere shortening, G0/G1 cell 
cycle arrest, up-regulation of APG5 and DAPK2 expression (genes implicated in the 
induction of apoptosis), and promotion of apoptotic cell death.
217,241-243
  In tumor models, 
GRN163L prevented tumor formation and metastasis from breast and lung cancer xenografts, 
significantly reduced growth and overall size of tumors in hepatoma, and enhanced antitumor 
effects in combination therapy with doxorubicin.
241,242,244
  Though the over-whelming data 
presented in these pre-clinical experiments demonstrate the antitumor effectiveness of 
GRN163L with little to no toxicity, planned phase II and III clinical trials will test whether or 
not GRN163L is sufficiently efficacious to be a value in the treatment of cancer.  
  
3. Targeting the telomere 
Telomerase inhibition can be accomplished by not only affecting the holoenzyme and 
its components but also by sequestration of its substrate, the telomere itself. Since telomeres 
are present in both normal and cancer cells, there is a cytotoxicity concern in targeting 
telomeres.  Nonetheless, blocking the telomerase access to the telomeres has been well 
investigated, since it has the potential for more rapid growth inhibitory effects in tumor cells 
than some other common telomerase inhibition methods.
41,245
   
Telomeres and other DNA sequences that are rich in guanine are capable of forming 
four-stranded structures called G-quadruplexes.
246-248
  Because telomerase cannot extend G-
quadruplex structures, molecules that stabilize G-quadruplexes have the potential to be 
promising telomerase inhibitors.  G-quadruplex ligands can prevent telomerase from 
interacting with the telomere, inhibit telomerase during primer extension, suppress activation 
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of hTERT transcription by binding to c-MYC promoter, affect splicing of hTERT transcript, 
and block the interaction between telomere-binding proteins with the telomere.
249
  
A small molecule, 2,6-diamidoanthraquinone, was the first compound to support G-
quadruplex ligands as telomerase inhibitors.
250
  Since then, a large number of quadruplex 
ligands have been explored as G-quadruplex-based telomerase inhibitors.  G-quadruplex 
stabilizing agents include cationic and anionic porphyrins,
251,252
 perylenes,
253
 trisubstituted 
acridines (BRACO-19),
254,255
 bisacridines,
256
 fluoroquinophenoxazines,
257
 natural products 
(telomestatin),
258
 ethidium derivatives
259
 and others.  Two of the best studied and most 
promising G-quadruplex binding ligands are BRACO-19, a 3,6,9-trisubstituted acridine, and 
telomestatin (Figure 1.6).  BRACO-19 produced growth inhibition and senescence in the 
nanomolar range in human tumor cell lines.
255
  Additionally, a decrease in hTERT 
expression, telomere length, and growth inhibition was observed in uterus carcinoma cells 
under BRACO-19 treatment.
260
  Perhaps, the downside of this molecule is its very poor cell 
permeability, thus the development of a suitable formulation is required for proper delivery 
across cellular barriers.
261
  Another promising and selective G-quadruplex-stabilizing 
compound is telomestatin.  Telomestatin treated HT1080 human tumor cells experienced a 
rapid decrease of the telomeric G-overhang and of the double-stranded telomeric repeats, a 
decrease of POT1 and TRF2 from telomeres, and telomere uncapping.
262
  These results 
indicate that telomestatin exerts its anticancer effect not only by preventing telomere 
elongation, but also by disrupting the capping function at the end of telomeres.  
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4. Targeting hTR or hTERT mRNA using ribozymes 
Hammerhead ribozymes are small catalytic RNA molecules that catalyze self-
cleavage reactions and have the capacity to specifically cleave target RNA after GUC 
sequences.
263
  Design of these catalytic RNAs is relatively simple and can be achieved by 
incorporating flanking sequences complementary to the target.  Due to this nature, ribozymes 
have provided a good platform for telomerase inhibition via targeted RNA cleavage of hTR 
or hTERT mRNA.   
As a requisite region of hTR for processive nucleotide addition and telomeric DNA 
elongation and its containing of a GUC motif at its 5' end, the template region of hTR is an 
ideal target for catalytic RNAs.  Studies in various cancers have correlated ribozyme 
expression with a marked reduction telomerase activity resulting from diminished telomerase 
RNA expression.
221,222
  While telomere lengths were greatly attenuated in some carcinomas, 
other types did not display this phenotype.
221,222
  Template-targeting ribozymes have also 
showed significant growth retardation with proliferation rates reduced compared with parent 
cells.
264
  Furthermore, cells experienced telomere shortening in concert with altered or 
dendritic morphologies, which are indicative of senescence phenotypes.
264
   
 Unlike hTR which is detectable in all cells, hTERT expression is the rate-limiting 
factor required for telomerase activity making it a key subunit of telomerase and a good 
target for enzyme inhibition.  Telomerase activity suppression and a subsequent decrease in 
mRNA expression has been achieved with steady state expression of a hammerhead 
ribozyme targeting initial nucleotides in hTERT mRNA that may be essential for proper 
binding of the translation initiation complex to the 5' mRNA cap structure.
265
  Ribozyme 
cleavage in the middle of hTERT mRNA has also demonstrated decreased telomerase 
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activity while also affecting rapid cell death (4 days) even without decreasing telomere 
lengths, consistent with non-telomere length related functions of hTERT in preventing 
cellular apoptosis.
266
 
 
Figure 1. 6 Representative telomerase targeted inhibitors and G-quadruplex binding ligands.  BRACO-19 
and telomestatin are G-quadruplex binding ligands. BIBR1532 was identified by high throughput screening 
followed by optimization of lead compounds. UCS1025A is a natural product isolated from Acremonium sp. 
AZT was the first nucleoside reverse transcriptase approved for HIV-1.  DPNS is a nitrostyrene derivative, 
TNQX is a quinoxaline derivative and EGCG is a tea catechin.  GRN163L is a telomerase template antagonist 
that contains a unique N3'→P5' thio-phosphoramidate (NPS) backbone. 
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5. Potential Drawbacks of Telomerase Inhibitors 
Since telomerase expression is observed in highly proliferative organs such as germ 
cells, hematopoietic stem cells, intestinal crypt cells, cells lining the endometrium, and 
lymphocytes, there is an obvious concern that telomerase inhibition might affect not only 
tumor cells but also those highly proliferative telomerase positive cells.  However, telomeres 
in those cells are generally longer than in tumor cells, thus, making them less susceptible to 
telomerase inhibition since telomere loss would likely be moderate without reaching critical 
telomere dysfunction.
267
  Another major concern with direct inhibition of telomerase is the 
lag time before telomeric erosion initiates senescence or apoptosis.  This might be less of a 
concern since numerous reports have showed rapid apoptotic responses upon telomerase 
inhibition
224,226,268
 resulting from possible telomere uncapping or the induction of gene 
expression pathways.
224
  Alternatively, telomerase inhibitors could be used in combination 
with surgery, radiation treatment and conventional chemotherapy, such as paclitaxel (a 
known telomere-shortening agent), to offset any lag time to therapeutic effect.
269
  
Telomerase inhibitors may also exert a delayed effect on cells dependent upon 
telomeric attrition or they can act rapidly without bulk telomere shortening.
224,268,270-272
 
Perhaps, these outcomes are in some way related to the extratelomeric functions of 
telomerase, which include cell protection, anti-apoptotic function, DNA damage response, 
gene expression control, and tumorigenesis beyond telomere maintenance.
273,274
  Another 
significant consideration for telomerase inhibitors is that eliminating telomerase activity may 
promote stability of telomeres via the ALT (alternative lengthening of telomeres) pathway 
and may lead to anti-telomerase resistance, as was observed in a colon cancer cell line.
274-276
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Despite the various pitfalls associated with telomerase inhibition, telomerase is still 
considered a selective and ideal universal anticancer drug target with minimal side effects.  
 
 
H. Thesis overview  
The research presented in this thesis identified new post-translational regulators of 
telomerase.  In chapter II of this dissertation, we explored natural products and 
oligonucleotides as potential telomerase inhibitors.  The studying of the tanshinone class of 
natural products led to the discovery that ortho-quinone containing compounds capable of 
redox-cycling inhibited telomerase via an oxidative mechanism.  In chapter III of this 
dissertation, we reported that telomerase is directly sensitive to reactive oxygen species and 
that the catalytic protein subunit, hTERT, of telomerase is the target of oxidation.  In chapter 
IV, we identified caspases, the main executioners of apoptosis as negative regulators of 
telomerase.  Telomerase was shown to be a substrate of caspases as a mechanism to induce 
apoptosis.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER II 
 
CHARACTERIZATION AND IDENTIFICATION OF NEW TELOMERASE 
INHIBITORS 
 
 
 
A. Telomerase inhibition studies 
 
This chapter reports exploratory studies examining natural products and 
oligonucleotides as telomerase inhibitors.  One objective was to identify molecules that 
specifically and potently perturb telomerase assemblage, the other objective was to 
characterize new telomerase inhibitors and determine their mechanism of action.  We 
employed a unique telomerase assay which uses [-32P]-dGTP as one of the substrates in 
order to extend and radiolabel any telomerase mediated primer extension products (Figure 
2.1).  This assay allows us to identify small molecules that directly inhibit telomerase 
enzymatic activity or compounds that affect proper telomerase assemblage thus resulting in a 
dysfunctional telomerase complex. 
 
B. Natural products and analogs as a source of new telomerase inhibitors 
 Natural products have been a major source of currently available anticancer drugs. 
Most anticancer drugs are either natural products, natural product analogs, or mimic natural 
products in one form or another.
277
  Because telomerase is over-expressed in the majority 
(~90%) of cancer cells, we proposed that telomerase could be a potential molecular target of 
some natural products and their derivatives.  We tested phenanthrene-based tylophorine 
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derivatives, curcumin derivatives, and dictyodendrin derivatives for their ability to inhibit 
telomerase activity or result in an inactive telomerase holoenzyme complex.  
 
Figure 2.1 Telomerase assay and proposed mechanism of telomere primer extension.  The steps in primer 
extension or telomere synthesis are substrate recognition, elongation, and translocation.  Assembled telomerase 
can extend telomeric primer by the addition of nucleotides.  Translocation allows for further elongation and 
subsequent processive addition.  Note that the dashed arrows represent the figurative transition from the post-
translocation state to the state primed for elongation.  Processive elongation is interrupted when the extended 
product dissociates from telomerase.  The gel is representative of the telomerase-product ladder typically 
observed.  This figure was adapted from reference 
46
. 
 
 
1. Phenanthrene-based tylophorine derivatives (PBTs) 
Tylophorine (Figure 2.2) and its phenanthroindolizidine alkaloid analogs have been 
isolated primarily from plants of the family Asclepiadaceae, including members of the genus 
Tylophora, Vincetoxicum, Pergularia, and Cynanchum.
278
  These compounds, commonly 
called tylophora alkaloids, have been targets of synthetic modifications for many years due to 
their significant cytotoxic activities.
279,280
  In the 1960s, tylocrebrine (Figure 2.2), a positional 
isomer of tylophorine, failed in clinical trials due to its significant central nervous system 
(CNS) toxicity, manifested by ataxia and disorientation.
279
  These disappointing findings 
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discouraged further consideration of these alkaloids as drug candidates.  However, it has 
been proposed that the CNS side effects could be minimized by the use of more polar analogs 
that would be unable to cross the blood-brain barrier.
281
  As evidence of the prospective value 
of tylophorines, the National Cancer Institute (NCI) screened several tylophorine analogs for 
antitumor potential using a 60-tumor cell line panel, and several showed a potent and 
uniform growth inhibitory effect with the mean GI50 < 10
-8
 M.
282
  
Previous studies have shown that tylophorine analogs exhibit potent cytotoxic activity 
against a broad range of human cancer cell lines including drug resistant and multi-drug 
resistant cancer cells.
281,283
  Mechanistic studies of tylophorine alkaloids demonstrated that 
they irreversibly inhibit DNA synthesis and protein synthesis at the elongation stage of the 
translation cycle.
284
  Furthermore, tylophorine alkaloids were reported to target key 
metabolic enzymes such as thymidylate synthase (TS) and dihydroreductase (DHFR).
285
  Gao 
et al. revealed that these compounds also inhibited activator protein-1, CRE, and NF-B 
mediated transcription.
283
  In addition, tylophorine derivatives were found to induce 
apoptosis in cancer cells by causing nuclear condensation, activation of caspase 3, and 
release of mitochondrial cytochrome c.
286
  Here we describe the effect of polar derivatives of 
tylophorine on telomerase activity.  
 
Figure 2.2 Chemical structures of tylophorine and tylocrebrine. 
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a. Results and discussion 
The Natural Products Laboratory (NPL) at UNC-CH showed that the polar 
intermediate compound 2, an amino acid precursor of tylophorine, exhibited significant 
cytotoxic activity against a human lung cancer cell line (A549) with an IC50 value of 2.2 M 
(Table 2.1).
282
  This discovery led them to explore and synthesize a new series of novel 
phenanthrene-based tylophorine derivatives (PBTs).  In the amino side chain, when the 
terminal carboxylic acid group was substituted to the methyl ester (compare compounds 2 
and 1), the cytotoxic activity was diminished drastically, IC50 from 2.2 to 17 M (Table 2.1). 
However, reduction of the carboxylic acid to the hydroxymethyl (compare compounds 2 and 
3) increased cytotoxicity activity, IC50 from 2.2 to 1.1 M (Table 2.1).  Thus, the rank order 
of cytotoxic potency of the terminal polar substituent was hydroxy > carboxylic acid » 
methyl ester.  In order to determine if these compounds were inhibitors of human telomerase 
activity, they were first tested in an assemblage assay.  In this assay, telomerase subunits 
(hTERT and hTR) are assembled in the presence of potential inhibitors to screen for 
compounds that perturb telomerase assemblage.  After the assemblage reaction, telomerase 
activity is detected using a direct primer extension assay.  In exploratory studies, we found 
that telomerase inhibition by compounds 1, 2, and 3 (50 M each) correlated with their 
cytotoxicity activities (Table 2.1).  Furthermore, changing the benzyloxy moiety at the C-6 
position of compound 3 to a methoxy group (compound 4) increased potency and completely 
inhibited telomerase activity at 50 M (Table 2.1).  The Natural Products Laboratory further 
designed and synthesized novel C-9 substituted PBTs.  Several N-containing cyclic and 
acyclic terminal-hydroxyl moieties were introduced at the C-9 position and tested for 
cytotoxicity and telomerase activity (Figure 2.3).  
 40 
Table 2.1 Data for PBT analogs 1-4 against A549 cell line and telomerase activity  
 
Compound Structure IC50 (M)  % Telomerase Activity 
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Figure 2.3 Structures of the C-9 substituted PBTs tested for cytotoxicity and telomerase activity.  
 
  
 
 Compounds 4 to 9 showed significant cytotoxic activity against A549 cell line with 
IC50 values of 0.2, 0.22, 0.63, 0.15, 0.08, and 0.16 M respectively.
278
  These compounds 
were also tested against other human cancer cell lines, including a multi-drug resistant 
variant, and showed IC50 values in the sub-micromolar range for all cell lines.  Additionally, 
direct telomerase assays performed after telomerase assemblage assays showed that these 
compounds were potent inhibitors of telomerase and completely inhibited telomerase activity 
at 50 M with the exception of compounds 5 and 6, which still showed a 33% and 25% 
telomerase activity at 50 M, respectively (Figure 2.4).  This result showed that a piperazine 
at the C-9 position is less active towards telomerase than a piperidine (compare compounds 6 
and 7). 
 We also tested the ability of compounds 4-9 to inhibit telomerase in a post-
assemblage assay (Figure 2.5).  Contrary to the assemblage assay, in the post-assemblage 
assay, the RNA component of telomerase (hTR) is previously assembled with the protein 
subunit of telomerase (hTERT).  This allows the identification of enzyme activity inhibitors. 
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Our results show that compounds 4-9 were only able to partially inhibit telomerase in this 
post-assemblage assay with the most potent compound only inhibiting telomerase by ~65% 
at 50 M (Figure 2.5).  Since these compounds are only potent inhibitors of telomerase in the 
assemblage assay and not in the post-assemblage assay, they likely disrupt proper assembly 
of the telomerase holoenzyme complex.  We speculate that these phenanthrene-based 
tylophorine derivatives could be interacting with the hTR subunit of telomerase therefore 
preventing proper assemblage or correct RNA folding.  Further analysis between the 
interaction of these compounds with hTR would need to be performed in order to determine 
the exact mechanism.  For example, using Selective 2'-Hydroxyl Acylation analyzed by 
Primer Extension (SHAPE), a RNA footprinting technique that interrogates individual 
nucleotide flexibility could reveal the site of interaction. 
 
Figure 2.4 Inhibition of telomerase by C-9 substituted phenanthrene-based tylophorine derivatives. 
Telomerase activity was tested using 50 M of compounds 4-9 and percent telomerase activity was determined 
by comparison with a positive control containing DMSO as a carrier and normalized based on loading control 
(LC). 
 
       Assemblage Telomerase Assay 
                    DMSO   5         6        7        8        9        4 
% Activity     100    33     25      0        0       0       0    
 LC 
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Figure 2.5 Inhibition of telomerase by compounds 4-9 in a post-assemblage assay. 
   
2. Curcumin analogues 
Curcumin, a phenolic compound isolated from turmeric, the rhizome of the plant 
Curcuma Longa L., has been reported to possess anti-inflammatory, anti-tumor, anti-
proliferative, anti-oxidant, anti-angiogenic, and pro-apoptotic properties.
287-290
  In addition, 
studies demonstrated that curcumin is a potent inhibitor of mutagenesis and chemically 
induced carcinogenesis.
291,292
  Curcumin has been shown to regulate a wide array of cellular 
processes such as inhibition of lipid peroxidation, nitric oxide synthetase activity, epidermal 
growth factor (EGF) receptor intrinsic kinase activity, c-jun N-terminal kinase, NF-B 
activity, lipoxygenase and cyclooxygenase (COX-2), protein kinase C activity, and 
production of reactive oxygen species.
289,290,293,294
  Curcumin has also been shown to inhibit 
Akt/mTOR pathway and induce downregulation of transcription factors AP1 and Egr-1.
295,296
 
Moreover, it has been proposed that inhibition of telomerase followed by induction of 
apoptosis might be involved in the anti-proliferative effect of curcumin.
297
  Since many of 
these cellular processes have been implicated in telomerase regulation, telomerase inhibition 
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observed by curcumin derivatives are possibly caused mostly by indirect means.  As stated in 
chapter I, inhibitors of NF- B pathway can block hTERT translocation to the nucleus179 and 
inhibitors of COX-2 can cause telomerase inhibition as well as inhibition of hTERT mRNA 
expression.
167,293
  Akt kinase has been shown to phosphorylate hTERT resulting in nuclear 
accumulation of hTERT and telomerase activity.
171,298
  Thus, inhibition of the Akt pathway 
by curcumin would consequently result in a decrease of telomerase activity.  
The Natural Products Laboratory at UNC-CH designed and synthesized new 
curcumin analogues as potential anti-prostate cancer agents.  Because telomerase inhibition 
was considered part of curcumin pharmacology, we decided to test if curcumin analogues 
could directly affect telomerase.  The structure-activity relationship (SAR) on telomerase 
activity for the most potent compounds was therefore examined.  In order to determine if 
curcumin analogues were inhibitors of human telomerase activity, each compound was tested 
in an assemblage assay.  Compounds were added at a final concentration of 50 M prior to 
hTERT/hTR association.  After allowing assemblage, telomerase activity was assayed using 
a direct telomerase assay (Figure 2.1).  Our results showed that methoxy substituents on C-6 
and lack of substitution at the C-4 position of the linker (compound 3) were detrimental to 
curcumin’s effect on telomerase (Table 2.2).  Our results also showed that compounds 1-4 
were potent inhibitors of telomerase and showed significant cytotoxicity against both 
androgen-dependent LNCaP cells and androgen-independent PC-3 cells (Table 2.2).
299
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Table 2.2 Data for curcumin analogs 1-4 against prostate cancer cell lines and 
telomerase activity 
 
Compound Structure PC-3 
IC50 (M) 
LNCaP 
IC50 (M) 
% Telomerase 
Activity 
 
 
 
Recently, it has been revealed that curcumin inhibits telomerase activity in a time- 
and dose-dependent manner by decreasing the level of hTERT expression.  Curcumin was 
found to inhibit nuclear localization of telomerase by dissociating the Hsp90 co-chaperone 
p23 from hTERT.
187
  Moreover, Lee et al. showed that curcumin treatment resulted in a 
substantial decrease in association of p23 and hTERT but did not affect Hsp90 binding to 
hTERT.  It is believed that the interaction of the Hsp90-p23 complex with hTERT is required 
for protein folding, assembly of active telomerase, and is critical for nuclear localization of 
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telomerase.  Although curcumin prevented hTERT translocation to the nucleus, they showed 
that curcumin did not inhibit telomerase activity when added to telomerase that was 
preassembled in vivo.
187
  Taken together, curcumin has been shown to not only affect 
different cellular pathways that consequently lead to telomerase inhibition, but our data also 
shows that curcumin exerts a direct inhibitory effect on telomerase.   
 
3. Dictyodendrin analogs as telomerase inhibitors 
Dictyodendrins are a family of alkaloids isolated from the marine sponge 
Dictyodendrilla verongiformis collected off the South Japanese coast.  Dictyodendrins are 
tyramine-derived alkaloids that feature a characteristic and unique pyrrolo[2,3-c]- carbazole 
moiety that is decorated with electron-rich arene rings and carries at least one sulfate 
group.
300
  They are biogenetically related to other marine pyrrole alkaloids such as 
lamellarins, lukianol, polycitone A, ningalin, storniamide, purpurone, and halitulin, many of 
which also possess anticancer activities.
301-303
  Dictyodendrins A-E (1-5 respectively, Figure 
2.6) are the first reported marine natural products with telomerase inhibitory properties 
(100% inhibition at 50 g/ml).300  Interestingly, the sulfate group of the molecules has been 
shown to be essential for bioactivity, as a desulfated analog was completely inactive at 50 
g/ml.  
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Figure 2.6  Dictyodendrins 
 
 
In collaboration with Dr. Alois Furstner (Max-Planck-Institut für Kohlenforschung, 
Germany), we tested several new dictyodendrin derivatives as potential telomerase inhibitors 
in order to develop a SAR for this class of compounds.  As expected, derivatives containing a 
sulfate group were significantly more potent than desulfated analogues.  Compounds 8 and 9 
completely inhibited telomerase at 50 while compounds 6 and 7 inhibited telomerase by 
~65% and ~30% respectively (data not shown).  Further studies using varying concentrations 
of compounds 8 and 9 on a telomerase assemblage assay showed that these compounds 
exhibited IC50 values in the low micromolar range (Figure 2.7B).  To gain further insights 
about the specificity of dictyodendrin derivatives for telomerase, we examined the effect of 
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compounds 8 and 9 on the enzyme activity of other DNA and RNA polymerases.  As shown 
in Figure 2.8, with the exception of telomerase, none of the other enzymes were inhibited by 
compounds 8 or 9 (data only shown for 8).  
In order to characterize the mode of inhibition by dictyodendrin analogues as a 
function of the substrates required for telomerase activity in vitro, namely, the dNTPs (dATP, 
dTTP, and dGTP) and a DNA primer, enzyme kinetic experiments were performed.  As 
observed in Figure 2.9A, a hyperbolic curve was obtained when telomerase activity was 
plotted as a function of the DNA primer concentration in the absence of the inhibitor (dark 
blue line).  The maximum enzymatic reaction (Vmax) was reached with primer concentrations 
above 1.5 In the presence of increasing amounts of compounds 8 or 9, a clear reduction 
in Vmax was observed, a feature characteristic for a non-competitive inhibition.  At the 
highest inhibitor concentration tested (20 ), Vmax was decreased by ~55%.  The data were 
used to calculate the Michaelis-Menten constant of the DNA primer in the absence (Km) and 
in the presence (Km) of compound 8 and to calculate the binding constants of the inhibitor 
in the absence (Ki) and in the presence (Ki) of the DNA primer.  As shown in figure 2.9C, 
at 20 M of compound 8, the Km value for the DNA primer increased from 0.25 M to 0.66 
M, suggesting a lower affinity to the telomerase-compound 8 complex.  A small but 
significant increase of Ki (9.88 M) over Ki (7.11 M) was observed (Figure 2.9D), 
indicating a slightly higher affinity of compound 8 to the free enzyme than to the enzyme-
DNA primer complex.  In the corresponding Line-weaver-Burk plot, the intersection of the 
control (no inhibitor) and the “plus inhibitor” curve was slightly above the 1/[S]-axis, since 
Ki was larger than Ki (Figure 2.9B).  
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As observed with the DNA primer, the Vmax decreased while the Michaelis-Menten 
constant for the dNTPs increased in the presence of the inhibitor (Km increased from 7.1 M 
to 8 M (Km)) (Figure 2.10A-C).  The affinity constant of compound 8 was calculated to be 
2.4 M for the nucleotide free enzyme (Ki, Figure 2.10D) and 17 M for a telomerase-dNTP 
complex (Ki, Figure 2.10D).  This indicates a tight binding of the drug to the nucleotide-
free enzyme and an eight- fold lower affinity to the enzyme-dNTP complex.  The 
concomitant increase of the affinity constant value and a decrease in Vmax suggests a mixed-
type inhibition, with different binding sites for the substrate(s) and the inhibitor, but with 
strong influence between the binding of each other.
213
  Based on our data, compound 8 and 
thus dictyodendrins exhibit a non-competitive mode of inhibition. Recent experiments also 
showed that dictyodendrins can form reactive species in the presence of metal cations, in 
particular Cu
2+
; thus suggesting that these compounds could affect different cellular 
processes and have multiple mechanisms of action including telomerase inhibition.   
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Figure 2.7 Inhibition of telomerase by dictyodendrin derivatives.  (A) Dictyodendrin derivatives  (B) 
Assemblage assay using varying concentrations of compound 8 or 9 (from left to right: 0, 0.1, 1, 5, 10, and 20 
M).  The wedge indicates increasing concentrations of compound 8 or 9.  LC is a loading control used to 
normalize the telomerase products present in each lane.  IC50 values were calculated and inhibition curves were 
plotted as described under “Materials and Methods”. Error bars indicate standard deviation. 
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Figure 2.8 Selective inhibition of telomerase by a dictyodendrin derivative (compound 8).  The effect of 
compound 8 on telomerase activity (dark blue line), on reverse transcriptase (pink line), on DNA polymerase I 
(dark red line), and on T7 RNA polymerase (light blue line) was assayed as described under “Materials and 
Methods”.  
 
 
Figure 2.9 Compound 8 mode of inhibition for the binding of the DNA primer.  (A) Direct plot of 
telomerase activity versus the concentration of DNA primer (M) in the absence of presence of different 
concentrations of compound 8: no compound 8 (dark blue line), 5 M (light blue line), 10 M (yellow line), or 
20 M compound 8 (pink line).  (B) Double-reciprocal plot (Lineweaver-Burk) of velocity curve shown in A. 
(C) Michaelis-Menten constants of the DNA primer in the absence (Km) or in the presence (Km) of 20 M 
compound 8.  (D) Affinity constants of compound 8 in the absence (Ki) or in the presence of (Ki) of DNA 
primer. 
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Figure 2.10 Compound 8 mode of inhibition for the binding of dNTP.  (A) Direct plot of telomerase activity 
versus the concentration of dNTPs (M) in the absence of presence of different concentrations of compound 8: 
no compound 8 (dark blue line), 5 M (yellow line), or 10 M compound 8 (pink line).  (B) Double-reciprocal 
plot (Lineweaver-Burk) of velocity curves shown in A.  (C) Michaelis-Menten constants of the dNTPs in the 
absence (Km) or in the presence (Km) of 20 M compound 8.  (D) Affinity constants of compound 8 in the 
absence (Ki) or in the presence of (Ki) of dNTPs.  
 
 
C. Oligonucleotides that affect telomerase assemblage 
Several strategies that affect telomerase inhibition through direct and indirect means 
have been reported.
229,304-306
  These include reverse transcriptase inhibitors, G-quadruplex 
stabilizing compounds, natural products, ribozymes, RNAi, immunotherapy, gene therapy, 
and antisense oligonucleotides directed at the RNA subunit, particularly the template 
region.
193,194,221,228,307-312
  Previously, our laboratory has demonstrated that oligonucleotides 
capable of hybridizing to either the P3/P1 pairing region or to the CR4-CR5 domain of hTR 
can inhibit telomerase by perturbing proper assemblage.
233
  Previous studies have shown that 
human telomerase activity can be reconstituted by adding both the pseudoknot (nts 1-209) 
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and the CR4-CR5 (nts 241-330) domains to hTERT in vitro.
74
  These domains can also 
interact and bind independently to hTERT.
233
  Additionally, the P6.1 stem-loop (nts 302-314) 
of the CR4-CR5 domain has been shown to be essential for telomerase activity as well as for 
binding to hTERT.
313
  Keppler et al. found that oligonucleotides hTRas009, which targets 
nucleotides 174-195, and hTRas010, which targets nucleotides 301-322, completely inhibited 
telomerase at 10 when added to a telomerase assemblage assay.233  On the other hand, 
neither oligonucleotides significantly inhibited telomerase when added after telomerase was 
allowed to assemble.  These results suggested that these oligonucleotides prevent proper 
telomerase assemblage by blocking essential interactions between hTR and hTERT. 
Moreover, by using a scintillation proximity assay (SPA), they demonstrated that hTRas010 
blocked the interaction between the CR4-CR5 domain and hTERT.
314
  Since the P6.1 stem-
loop is important to the function of the CR4-CR5 domain, we designed oligonucleotides 
capable of interacting with this stem-loop (Figure 2.11).  We tested hTRas011, which targets 
nucleotides 303-312, and hTRas012, which targets nucleotides 298-310, for their ability to 
inhibit telomerase activity and to prevent hTR-hTERT binding.  
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Figure 2.11 Human telomerase RNA.  (A) Conserved regions (CR) of hTR are indicated. CR4-CR5 domain is 
shown in green.  Pairing regions (P) indicated include the P3 pairing region, which is part of the pseudoknot 
domain, and the P6.1 stem-loop, which is part of the CR4-CR5 domain.  (B) The CR4-CR5 domain is shown 
where the hTRas011 targeted nucleotides (nts 303-315) are shown in red and hTRas012 targeted nucleotides 
(nts 298-312) are shown in purple.  
 
  
 As expected, both hTRas011 and hTRas012 completely inhibited telomerase when 
added to a telomerase assemblage assay.  Moreover, both hTRas011 and hTRas012 yielded 
IC50 values in the nanomolar range (~114 nM and ~21 nM respectively), which were both 
lower than hTRas010 (IC50 = ~163 nM)
233
 (Figure 2.12).  As observed with hTRas010, 
neither hTRas011 nor hTRas012 significantly inhibited telomerase activity when added to 
previously assembled telomerase before performing a direct telomerase assay (~77% and 
~47% residual activity for hTRas011 and hTRas012 (10 each), respectively, in the direct 
telomerase assay using preassembled telomerase as compared to ~0% residual activity for 
either oligonucleotide in the assemblage assay) (Figure 2.13).    
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Figure 2.12 Assemblage assay using CR4-CR5 targeted oligonucleotides.  Varying concentrations of 
hTRas011 (A) or hTRas012 (B) were added to an assemblage assay at concentrations of 0.1 nM, 1 nM, 10 nM, 
100 nM, and 1 lanes 3-7 respectively).  Lane 1 is a protein only control (no RNA, negative control).  Lane 
2 is a DMSO control lane (positive control).  LC is a loading control used to normalize the telomerase products 
present in each lane.  The wedge indicates increasing concentrations of the oligonucleotides.  IC50 values were 
calculated and inhibition curves were plotted for hTRas011 (C) and hTRas012 (D) as described under 
“Materials and Methods”. IC50 curves are based on results from duplicate experiments. IC50 error indicates 
standard error. 
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Figure 2.13 Concentration dependence of telomerase inhibition by hTRas011 and hTRas012 
when added after assemblage.  Varying concentrations of hTRas011 (A) or hTRas012 (B) were added to a 
direct telomerase assay using pre-assembled telomerase.  No inhibitor (DMSO control) (blue bar), 0.1  (red 
bar), 1  (yellow bar), 5  (light blue bar), 10  (purple bar).  "Percent Activity" values indicate the 
amount of residual telomerase activity as compared to the DMSO-only control. 
 
  
 We used a scintillation proximity assay (SPA) to determine if hTRas011 and 
hTRas012 can block the interaction between the CR4-CR5 domain and hTERT.  The SPA 
assay allows detection of the interaction between [
35
S]-hTERT and biotinylated RNA (in this 
case we used biotin-labeled CR4-CR5 domain RNA).  The streptavidin-coated SPA beads 
bring the RNA and the [
35
S]-hTERT into close proximity with the scintillant contained in the 
bead, thus eliciting a signal (Figure 2.14).
314
 
 
 
Figure 2.14 Assay schematics for scintillation proximity assay.  Biotinylated CR4-CR5 RNA and radio-
labeled hTERT associate.  The addition of streptavidin-SPA beads brings the [
35
S]-hTERT into close proximity 
to the beads and produces a scintillant signal. 
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We found that the addition of hTRas011 and hTRas012 to the SPA impeded the CR4-
CR5/protein interaction in a concentration dependent manner yielding IC50 values of 118 nM 
and 96 nM, respectively (Figure 2.15).  Notably, high concentration of hTRas012 but not 
hTRas011 completely impeded RNA/protein binding in the SPA.  Previous experiments 
using hTRas010 as the oligonucleotide revealed IC50 value of 1.22 M, which is about ten 
times higher than those obtained for hTRas011 and hTRas012.  
 
 
 
Figure 2.15 Concentration dependence of hTRas011 and hTRas012 in a scintillation proximity assay. 
Each concentration of hTRas011 and hTRas012 was assayed in duplicate.  “Percent Activity” indicates the 
amount of residual activity as compared to the positive control.  IC50 curves and values were obtained as 
described under “Materials and Methods”.  Error bars indicate standard deviation and IC50 error indicates 
standard error. 
 
 
  
In addition to oligonucleotides that target the pseudoknot domain at the P3/P1 
intersection, as previously documented,
233
 our results show that targeting the CR4-CR5 
domain at the P6.1 stem-loop inhibited telomerase activity by preventing essential 
interactions between hTR and hTERT.  Therefore, targeting telomerase holoenzyme 
assemblage is an effective approach toward inhibiting telomerase activity.  The SPA 
 58 
technology can be used in order to screen for compounds that inhibit proper telomerase 
assemblage, in particular compounds that disrupt the CR4-CR5 binding to hTERT.  As 
expected, hTRas011 and hTRas012 were unable to inhibit telomerase after hTR and hTERT 
were preassembled, but their mode of inhibition is still relevant to cancer therapy.  Since 
cancer cells (hTERT-positive cells) are rapidly dividing, they require high transcription rate 
of hTR and more generation of telomerase.  Thus, molecules that sequester hTR and perturb 
telomerase assemblage could affect rapidly reproducing cells.  In fact, it has been reported 
that PNAs targeting nontemplating regions of hTR can inhibit cellular telomerase;
315
 hence it 
would be worthwhile to study telomerase assemblage and perform inhibition studies in 
cultured cells using oligonucleotides that target the P6.1 stem-loop (hTRas011 and 
hTRas012).  
 
 
D. Materials and Methods             
 
1.  Oligonucleotides and chemicals 
Modified oligonucleotides were purchased from Integrated DNA Technologies 
(IDT,Coralville, Iowa). Concentrations were determined by UV absorbance at 260 nm using 
the molar extinction coefficient supplied by the manufacturer. The sequence of hTRas011 is 
CAGAGCCCAACTC and the sequence of hTRas012 is CCCAACTCTTCGC (underlined 
bases indicate phosphorothioate linkages). Both oligonucleotides are LNAs (Locked Nucleic 
Acid), a novel type of nucleic acid analog that contains a 2'-O, 4'-C methylene bridge. This 
bridge restricts the flexibility of the ribofuranose ring and locks the structure into a rigid C3-
endo conformation, conferring enhanced hybridization performance and exceptional 
biostability. Phenanthrene-based tylophorine derivatives and curcumin derivatives were a gift 
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from Dr. KH Lee (UNC-CH), and dictyodendrin derivatives were a gift from Dr. Alois 
Furstner (Max-Planck-Institut für Kohlenforschung, Germany). These compounds were made 
available from previous studies 
282,299,301
 and were stored as 5 mM stocks in sterile DMSO. 
 
2.  pET-28c-hTERT and phTR+HH expression plasmids 
An hTERT plasmid (pCl-neo-hTERT) was a gift from Dr. Lorel Colgin (Children's 
Medical Research Institute, Westmead Australia) and CAMBIA (Canberra Australia).
316
 The 
hTERT-containing insert from this plasmid was subcloned into the EcoRI and SalI sites of 
the T7-tag-containing plasmid pET-28c (Novagen) to give the construct pET-28c-hTERT. 
phTR+HH, a plasmid designed for in vitro transcription of human telomerase RNA with a 
self-cleaving hammerhead ribozyme that generates the natural 5’ end, was a gift from Dr. 
Jamie Sperger (University of Colorado, Boulder). 
 
 3.  In vitro transcription and purification of hTR  
hTR was transcribed in vitro from the plasmid phTR+HH which encodes for a 
modified form of hTR that contains a self-cleaving hammerhead ribozyme at the 5′ end of the 
RNA. 15 μg of phTR+HH was linearized by digestion with Fok-1 followed by extraction 
with phenol/chloroform/isoamyl alcohol, precipitation with ethanol and resuspension in a 
suitable volume of TE (10 mM Tris-HCl, pH 7.5 and 1 mM EDTA). In vitro transcription 
was carried out at 37 ºC for 18 h using the linearized DNA, 1× Ampliscribe T7 Reaction 
Buffer (Epicentre Technologies), 7.5 mM each NTP, 10 mM DTT and 10 μL Ampliscribe T7 
Enzyme Solution (containing an RNase inhibitor) (Epicentre Technologies). Cleavage by the 
hammerhead ribozyme was initiated by the addition of MgCl2 to a final concentration of 12 
mM followed by incubation at 45 ºC for 1 h. The entire reaction was then treated with 5 μL 
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RNase-Free DNase 1 (Epicentre, 1 MBU/μL) for 20 min at 37 ºC followed by extraction with 
phenol/chloroform/ isoamyl alcohol and ethanol precipitated in the presence of 0.3 M 
NaOAc. The RNA was resuspended in a suitable volume of denaturing loading buffer (7 M 
urea/10% glycerol/1×TBE) and purified on a 4% denaturing polyacrylamide gel. The RNA 
was recovered using a modified version of the "crush and soak" method.
317
 Briefly, the RNA 
was located in the gel by UV shadowing, cut out, crushed by passing through a sterile plastic 
syringe and extracted into 2 volumes of 1× TEN (10 mM Tris-HCl, pH 7.5, 1 mM EDTA and 
200 mM NaCl) at 4 ºC for 16 h. After centrifugation, the supernatant was collected and a 
second extraction was performed with 2 volumes of 1× TEN at room temperature for 1 h. 
The combined supernatants were filtered through a Whatman
 GF/C filter, precipitated with 
ethanol and resuspended in a suitable volume of TE and quantified by UV absorbance. 
 
4.  In vitro transcription and translation of hTERT 
hTERT was transcribed and translated using the TNT

 Coupled Reticulocyte Lysate 
Systems kit (Promega). A 400 μL reaction contained 8 μg of pET-28c-hTERT, 16 μL of 
[
35
S]-methionine (1175 Ci/mmol, 10 μCi/μL; Perkin Elmer) and other components provided 
in the kit as described by the manufacturer. The reaction was incubated at 30 ºC for 90 min, 
flash-frozen in a dry ice/ethanol bath and stored at –80 oC. hTERT used in the direct 
telomerase assay and the assemblage assay was made without [
35
S]-methionine as described 
by the manufacturer. A reticulocyte lysate reaction with pET-28c (empty vector control) in 
place of pET-28c-hTERT served as a negative control in several experiments. 
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5.  Reconstitution of telomerase 
Pre-assembled telomerase was prepared by adding 4 μg of in vitro transcribed hTR to 
the 400 μL reticulocyte lysate reaction prior to incubation for 90 min at 30 oC. Direct 
telomerase assays contained 10 μL of pre-assembled telomerase. Reconstitution of 
telomerase in the assemblage assay was initiated by combining 10 μL (~50 fmol) of hTERT 
from a reticulocyte lysate reaction, 212.5 ng of in vitro transcribed hTR and the appropriate 
amount of water, DMSO or inhibitor to a final volume of 15 μl followed by incubation at 30 
ºC for 90 min. The pre-assembled telomerase complex and the hTERT protein were used in 
assays without further purification from the reticulocyte lysate. 
 
6.  Direct telomerase assay 
Telomerase activity was measured using a modification of a previously described 
direct assay.
233
 Each 25 μL reaction contained 50 mM Tris-HCl, pH 8.0, 50 mM KCl, 1 mM 
MgCl2, 5 mM β-mercaptoethanol, 1 mM spermidine, 1 μM human telomere primer (5'-
TTAGGGTTAGGGTTAGGG), 0.5 mM dATP, 0.5 mM dTTP, 2.9 μM dGTP, 0.33 μM [α-
32
P]-dGTP (3000 Ci/mmol, 10 μCi/μL; Perkin Elmer) and 10 μL of preassembled 
telomerase. Inhibition studies also included varying amounts of inhibitor. Primer extension 
was carried out at 30 ºC for 90 min. After the addition of a 
32
P labeled 
loading control (114 nucleotide, 5’-end labeled DNA oligonucleotide, 1000 cpm per 
reaction), the primer extension products were extracted with phenol/chloroform/isoamyl 
alcohol and ethanol precipitated in the presence of 0.6 M NH4OAc and 35 ng/μL glycogen. 
Products were precipitated at –80 ºC in 2.5 volumes of absolute ethanol for 30 min followed 
by centrifugation at 22 000 g at 4 ºC for 25 min and washing with 2 volumes of 70% ethanol. 
Pellets were resuspended in a suitable volume of TE and ethanol precipitation was repeated 
 62 
to ensure the removal of all unincorporated [α-32P]-dGTP. The final pellets were dissolved in 
a formamide loading buffer containing 40% formamide, 10 mM Tris-HCl, pH 8.0, 10 mM 
EDTA, 0.05% xylene cyanol and 0.05% bromophenol blue. The products were heated at 95 
ºC for 5 min and resolved on a pre-warmed, 0.4 mm thick, 20 x 20 cm, 10% 
polyacrylamide/7 M urea/1× TBE gel. The gel was run at 800 V for 1h in 1× TBE. After 
drying the gel and exposing it to a phosphorimager screen (Molecular Dynamics) overnight, 
telomerase activity was imaged using a phosphorimager (Molecular Dynamics Storm 860) 
and quantified with ImageQuant (version 5.2). The intensities of each band in each sample 
were summed and normalized to the loading control. 
 
7.  Assemblage assay 
Recombinant hTERT was transcribed and translated from pET28c-hTERT 
233
 using 
the TNT

 Coupled Reticulocyte Lysate Systems kit (Promega) following the manufacturer’s 
instructions. Telomerase assemblage assays were initiated by combining 10 L (~50 fmol) of 
hTERT from a reticulocyte lysate reaction, 212.5 ng of in vitro transcribed hTR, and the 
appropriate amount of DMSO or inhibitor to a final volume of 15 L followed by incubation 
at 30 ºC for 90 min as previously described in detail.
232,233
  Inhibition studies contained 
varying concentrations of inhibitor as noted in the text. After assemblage, telomerase-
catalyzed primer extension was carried out by adding 50 mM Tris-HCl, pH 8.0, 50 mM KCl, 
1 mM MgCl2, 5 mM β-mercaptoethanol, 1 mM spermidine, 1 μM human telomere primer 
(5'-TTAGGGTTAGGGTTAGGG), 0.5 mM dATP, 0.5 mM dTTP, 2.9 μM dGTP, and 0.33 
μM [α-32P]-dGTP (3000 Ci/mmol, 10 μCi/μL; Perkin Elmer) to the 15 μL of reconstituted 
telomerase. Primer extension was carried out at 30 ºC for 90 min and the samples were 
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processed as described for the direct telomerase assay. Notably, the inhibitor concentration 
was maintained during both the assembly reaction and extension reaction. 
 
8. Effects of compound 8 on nucleic acid processing enzymes 
 
To test the effect of compound 8 on T7 RNA Polymerase, varying concentrations of 
compound 8 was added to a transcription reaction using a short, PCR product as the template. 
The pseudoknot PCR fragment (nucleotides 46-209) was synthesized using the T7 promoter-
containing forward primer 5'-GGGTACCTAATACGACTCACTATAGG 
CTAACCCTAACTGAGAAGGGCGTAGGCGCCGTG-3' and the reverse primer  
5'-CCCCGGGAGGGGCGAACGGGCCA-3'. The RNA fragment starts with two guanosine 
residues on the 5' end in order to aid in T7 transcription efficiency. The PCR product was 
resolved on a 0.8% agarose gel and purified using a Wizard

 PCR Preps DNA Purification 
System (Promega). In vitro transcription was carried out at 37 ºC for 3 hours using the 
purified PCR product, varying concentrations of compound 8, 1× Ampliscribe T7 Reaction 
Buffer (Epicentre Technologies), 7.5 mM each NTP, 10 mM DTT, 0.17 μM [α-32P]-rGTP 
(3000 Ci/mmol, 10 μCi/μL; Perkin Elmer), and 10 μL Ampliscribe T7 Enzyme Solution 
(containing an RNase inhibitor) (Epicentre Technologies). The reaction was then treated with 
1 μL RNase-Free DNase 1 (Epicentre, 1 MBU/μL) for 20 min at 37 ºC and passed through 
Microspin G-25 columns (Amersham) to ensure the removal of all unincorporated [α-32P]-
rGTP.
 
The RNA was resolved on a denaturing gel and compared to RNA transcribed in the 
presence of DMSO as a carrier. 
To test the effect of compound 8 on M-MLV reverse transcription, varying 
concentrations of the compound was added to a reaction containing 0.5 mM dNTPs, 0.33 μM 
[-32P]-dGTP (3000 Ci/mmol, 10 μCi/μL; Perkin Elmer), 20 units RNasin (Promega), 10 ng 
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tTR (Tetrahymena RNA template), 1 M primer, 100 units M-MLV reverse transcriptase 
(Promega) and 1× M-MLV buffer (Promega). The dNTPs, RNA, primer, compound 8 and 
buffer were first combined and incubated at 95 ºC for 5 min followed by 0 ºC for 3 min. The 
[-32P]-dGTP and enzymes were then added and the reaction was incubated at 37 ºC for 2 h 
followed by 95 ºC for 5 min. After passing through a Microspin G-25 column (Amersham), 
the sample was resolved on a denaturing gel and compared to a reaction containing DMSO in 
place of compound 8. 
To test the effect of compound 8 on the Klenow Fragment of DNA Polymerase I, 
we first performed a double digestion on pET-28c using Sal I and Xho I in order to generate 
a 21 base-pair piece of DNA with sticky ends. About 2 μg pET-28c was combined with 20 
units Sal I (New England Biolabs, NEB), 20 units Xho I (NEB), 100 g/mL BSA and 1× SalI 
buffer (NEB) and incubated at 37 ºC for 90 min, followed by 65 ºC for 20 min to heat 
inactivate the enzymes. ~600 ng of the digested DNA was then combined with 50 μM 
dNTPs, 0.165 μM [-32P]-dGTP (3000 Ci/mmol, 10 μCi/μL; Perkin Elmer), 5 units Large 
(Klenow) Fragment of DNA Polymerase I (NEB), 1× NEB buffer #2 and varying 
concentrations of compound 8. The reaction was incubated at 25 ºC for 30 min followed by 
75 ºC for 20 min and passed through a Microspin G-25 column. The degree of compound 8-
induced Klenow inhibition was quantified by resolving the final product on a native gel along 
side a positive control reaction containing DMSO instead of compound 8. 
 
 9.  Determination of kinetic constants 
 In order to determine Ki and the mechanism of inhibition for 8, direct telomerase 
assay was performed in duplicates in the presence of varying concentrations of substrate and 
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inhibitor. The amount of incorporated radioactivity was determined by ImageQuant (version 
5.2). For velocity plots, the incorporated radioactivity (in counts/min) was blotted against the 
variable substrate. Km values were calculated as the concentration of variable substrate 
required to reach ½ Vmax. The inhibition constants (Ki and Ki) were determined from 
secondary plots (Lineweaver and Burk). 
 
10. Inhibition studies 
Direct telomerase or assemblage assays were conducted as described above with 
varying concentrations of inhibitors. IC50 values were calculated using the Regression Wizard 
program of SigmaPlot (version 7.0). The following four-parameter logistic curve 
equation was used: y = D + [(A-D)/(1 + (x/C)^B)] where x is the concentration of inhibitor, y 
is the percent activity relative to the DMSO control, A is the maximal activity, B is the slope 
factor, C is the IC50 (i.e. the concentration required for 50% inhibition) and D is the minimal 
activity. Inhibition data were plotted as percent activity vs. log inhibitor concentration and fit 
using the same equation. 
 
11. Synthesis of biotinylated CR4-CR5 RNA fragment 
A 100 μL Ampliscribe T7 Transcription reaction contained 1× Ampliscribe T7 
Reaction Buffer, 7.5 mM GTP, 7.5 mM UTP, 7.5 mM ATP, 6.25 mM CTP, 1.25 mM bio-11-
CTP (ENZO Life Sciences), 10 mM DTT, 10 μL Ampliscribe T7 Enzyme Solution and the 
appropriate DNA template. Reactions were incubated for 4 h at 37 °C, treated with DNase, 
extracted with phenol/chloroform/isoamyl alcohol, ethanol precipitated and purified by 
PAGE as described. 
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12.  Scintillation Proximity Assay 
Each 15 μL assembly reaction contained 10 μL (50 fmol) [35S]-hTERT from an in 
vitro translation reaction and 2.9 pmol biotinylated CR4-CR5 RNA. Negative controls 
contained either non-biotinylated RNA, no RNA or 10 μL of a translation reaction using an 
empty vector (pET-28c) in place of pET-28c-hTERT. Inhibition-control reactions also 
included varying concentrations of the oligonucleotide. Prior to use, all reticulocyte lysate 
reactions were centrifuged at 17000g for 10 min at 4 °C to remove any precipitates. 
Protein/RNA assembly reactions were incubated at 30 °C for 90 min in 96-well polystyrene 
microplates (OptiPlate-96, Packard). For each SPA reaction, 0.4 mg Streptavidin PVT-SPA 
beads (Amersham Biosciences, Cat. # RPNQ0006) were used. Prior to use, beads were 
washed four times with 200 μL SPA buffer 1 (10 mM Tris-acetate, pH 7.5, 5% glycerol, 0.5 
mM EDTA, 2.5 mM MgCl2, 50 mM potassium glutamate, 0.05% IGEPAL, 0.5 mM DTT) 
and blocked twice for 15 min at 4 °C with 200 μL of SPA blocking buffer (20 mM Tris-
acetate, pH 7.5, 10% glycerol, 1 mM EDTA, 5 mM MgCl2, 100 mM potassium glutamate, 
0.1% IGEPAL, 1 mM DTT, 0.05 mg/mL lysozyme, 0.5 mg/mL BSA, 0.05 mg/mL glycogen, 
0.1 mg/mL herring sperm DNA (Promega)). The beads were precipitated by centrifugation at 
4000g for 2 min. Precipitating the beads from the SPA blocking buffer first required the 
addition of an equal volume of H2O in order to prevent bead buoyancy due to high glycerol 
concentrations. Large batch preparations of beads were possible by scaling up the above 
procedure. To initiate the SPA, 15 μL assembly reactions were combined with 15 μL 
blocking buffer and 0.4 mg blocked beads and incubated for 30 min at room temperature. 
Reactions were transferred to a 96-well MultiScreen
®
 HTS filter plate (Millipore, Cat. 
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#MSDNV6B) that had been pre-wet with 200 μL SPA buffer 2 (10 mM Tris-acetate, pH 7.5, 
5% glycerol, 0.5 mM EDTA, 2.5 mM MgCl2, 150 mM potassium glutamate, 0.05% 
IGEPAL, 0.5 mM DTT). Samples were filtered using a MultiScreen
®
 Resist Vacuum 
Manifold (Millipore, Cat. #MAVM0960R). The trapped beads were washed four times with 
200 μL of SPA buffer 2, ceasing the vacuum pressure in between each wash. Once 
completed, the underdrain was removed from the filter plate and the top and bottom of the 
plate were covered with clear and opaque tape, respectively, per the manufacturer’s 
instructions. The plate was then read on a TopCount™ NXT scintillation counter (Packard, 
version 1.06). TopCount™ instrument settings used can be found at 
www.amershambiosciences.com/spa. After subtracting the background signal (negative 
control with no RNA), the SPA signals for the experimental samples were compared to that 
for the positive control. Unused beads were stored in SPA buffer 1 (minus the DTT) at 4 °C 
and were used within 10 days. All liquid transfer steps could be conducted with multichannel 
pipettors or robotic liquid handling devices. 
 
 
 
 
 
 
 
 
  
CHAPTER III 
ORTHO-QUINONE TANSHINONES INHIBIT TELOMERASE THROUGH AN 
OXIDATIVE MECHANISM MEDIATED BY H2O2 
 
 
A. Introduction 
 Tanshinones are diterpene pigments isolated from the root of Salvia miltiorrhiza 
Bunge (Danshen), which has been used in numerous traditional Chinese folk remedies.
318,319
  
Several tanshinones possess a variety of pharmacological activities such as antibacterial, 
antioxidant, anti-inflammatory, and antineoplastic.
320
  The best studied and most abundant 
tanshinone, tanshinone II-A (Tan II-A), has been shown to exert cytotoxic activity, induce 
differentiation, inhibit proliferation, and induce apoptosis in many cancer cells.
321,322
 
Previous studies revealed that induction of apoptosis was the key factor contributing to the 
cytotoxic property of Tan II-A.
323-326
  Triggering of the apoptotic pathway has been 
considered as one of the main strategies for anticancer therapy.
327
  Although, the anti-cancer 
potential of tanshinone IIA has been of interest, the mechanism of Tan II-A-induced 
apoptosis is not yet understood.  Since telomerase directly affects apoptosis and the general 
interest in new telomerase inhibitors, we hypothesized that telomerase may be one of the 
molecular targets of Tan II-A.  
In this chapter, we tested the effect of several natural tanshinones on telomerase 
activity.  Here, we show that the ortho-quinone tanshinones, Tan II-A, tanshinone I, and 
cryptotanshinone inhibit telomerase activity.  Interestingly, previous studies showed that
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ortho-quinone tanshinones exhibited significant cytotoxicity, while tanshinones with a para-
quinone or a lactone C ring were devoid of cytotoxicity demonstrating that their cytotoxicity 
coincided with telomerase activity.
320
  Our studies on the quinone moiety showed a time 
dependent inhibition of assembled telomerase and further demonstrated that inhibition was 
dependent on DTT.  Moreover, addition of catalase completely protected telomerase from 
inactivation caused by ortho-quinone compounds and DTT under aerobic conditions.  These 
findings suggested an alternative mode of telomerase inhibition by tanshinones.  We 
concluded based on the data that ortho-quinone tanshinones undergo redox cycling in the 
presence of tissue-reducing equivalents, such as DTT, to produce reactive oxygen species 
including hydrogen peroxide, which is damaging to cells by several mechanisms.
115
 
Importantly, the data suggest that telomerase is sensitive to oxidative damage caused by 
reactive oxygen species.      
 
B. Results 
 1. Telomerase assemblage assay 
 We have developed a telomerase assemblage assay 
232,233
 that allows for the 
identification of small molecules that affect telomerase activity through several mechanisms 
including direct inhibition of its enzymatic activity, blocking specific protein-RNA 
interactions required for assemblage of telomerase, and inhibiting the chaperone hsp90, a 
protein required for telomerase activity.
180
  The assay includes assembling recombinant 
telomerase in rabbit reticulocyte lysates (RRL)
328,329
 followed by a direct assay that allows 
telomerase to extend telomeric primer using [-32P]-dGTP as one of the substrates.  In this 
study, we focused on the natural products, tanshinones, because the exact mechanism for 
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their therapeutic basis is poorly understood and they have broad anti-proliferative effects that 
we reasoned could be related to inhibition of telomerase-mediated activities (Figure 3.1).  
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Tanshinone II-A                                  Cryptotanshinone
 Tanshinone I                                      Neo-tanshinlactone  
Figure 3.1 Tanshinones tested in this study 
      
 
 
 2. Tanshinone II-A is a potent and specific telomerase inhibitor  
 Varying concentrations of Tan II-A was added to a reaction mixture containing in 
vitro translated hTERT in RRL and in vitro transcribed hTR followed first by an assemblage 
reaction and then a primer extension assay to evaluate telomerase activity. Our results 
demonstrate that Tan II-A was a potent inhibitor of telomerase in this assemblage assay with 
an IC50 = 4.8 M (Figure 3.2A-B, curve with ● symbols). To analyze Tan II-A effect on the 
telomerase enzyme already in complex, different concentrations of Tan II-A was incubated 
with telomerase in a post-assemblage assay (Figure 3.2A). Again, Tan II-A proved to be an 
inhibitor of telomerase with an IC50 = 0.5 M (Figure 3.2B, curve with ○ symbols), however, 
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30% was the maximum inhibition observed when Tan II-A was added to assembled 
telomerase, compared to >95% when Tan II-A was added before assemblage.   
 
 
Figure 3.2 Inhibition of telomerase by tanshinone II-A and by 9,10-phenanthrenedione.  (A) Increasing 
concentrations of Tan II-A was used for assemblage and post-assemblage assays. LC represents a loading 
control used to normalize the telomerase products present in each lane. (B) Quantification of telomerase assays. 
The curve with ● symbols represents the assemblage assay, while the curve with ○ symbols represents the post-
assemblage assay. Percent telomerase activity was determined by comparison with a positive control containing 
DMSO as a carrier. (C) Increasing concentrations of 9,10-phenanthrenedione was used for assemblage and 
post-assemblage assays. The structure of 9,10-phenanthrenedione is shown. (D) Quantification of telomerase 
assays. The curve with ● symbols represents the assemblage assay, while the curve with ♦ symbols represents 
the post-assemblage assay. Percent telomerase activity was determined by comparison with a positive control 
containing DMSO as a carrier. 
 
 
The selectivity of Tan II-A for telomerase was further validated by using the Klenow 
fragment of DNA polymerase I, T7 RNA polymerase, and MMLV reverse transcriptase as 
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examples of other nucleic acid processing enzymes. At 50 M, over ten times the IC50 for 
telomerase, Tan II-A did not inhibit the other nucleic acid polymerases (Figure 3.3). 
 
 
Figure 3.3 Tanshinone II-A does not inhibit other nucleic acid processing enzymes.  50 µM of Tan II-A or 
an equal volume of DMSO was used in each experiment. DMSO served as a control. Relative activity refers to 
the amount of Tan II-A effect on enzymatic activity compared to DMSO only control.  
 
 
 
3. The tanshinone ortho-quinone moiety is essential for inhibition   
To determine the salient features of the tanshinone structure required for inhibition, 
we examined several natural tanshinones for their ability to affect telomerase activity (Figure 
3.1).  Tan II-A, Tan I, and cryptotanshinone, which all have an ortho-quinone C ring, 
inhibited telomerase, while neo-tanshinlactone,
330
 which has a lactone C ring, was a less 
potent inhibitor (Table 3.1).  Our results also showed that an aromatic A ring (compare 
tanshinone I to Tan II-A) and a heteroaromatic D ring (compare Tan II-A to 
cryptotanshinone) are not required for telomerase inhibition.  
 
Tan II-A:          -                      +                      -                     +                        -                       + 
  DMSO:          +                      -                      +                     -                        +                       - 
T7 RNA Poly                        M-MLV RT                     Klenow DNA Poly                         
Relative activity            1                   0.9                     1                   1.8                       1                     1.2 
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To examine the importance of the ortho-quinone moiety, we performed a direct 
telomerase assay using 9,10-phenanthrenedione (Figure 3.2C). The compound was a potent 
inhibitor of telomerase in this direct assemblage assay with an IC50 = 5.3 M (Figure 3.2D, 
curve with ● symbols), which is comparable to that found for Tan II-A. We also tested the 
ability of 9,10-phenanthrenedione to inhibit telomerase in a post-assemblage assay (Figure 
3.2C).  The compound showed inhibition of telomerase with an IC50 = 0.7 M (Figure 3.2D, 
curve with ♦ symbols). As observed with Tan II-A, 9,10-phenanthrenedione only partially 
inhibited the telomerase holoenzyme with the maximum amount of inhibition being only 
~50% when the compound was added to previously assembled telomerase.  
 
4. Telomerase inactivation by 9,10-phenanthrenedione in the presence of DTT   
It has been documented that reactive oxygen species (ROS) are formed in the 
presence of a reducing equivalent (such as DTT), oxygen, and catalytic amounts of quinones 
that are capable of redox cycling.
115
 To test the importance of DTT on the 9,10-
phenanthrenedione inhibition of telomerase, we incubated 9,10-phenanthrenedione with 
varying concentrations of DTT for different time periods followed by a direct telomerase 
Table 3.1 Inhibition of telomerase by tanshinone derivatives 
 
75 Neo-tanshinlactone 
22 Cryptotanshinone 
35 Tanshinone I 
26 Tan II-A 
Percent Telomerase Activity at 50 Ma Compound 
a
 Percent telomerase activity is the quantified level of residual telomerase activity in the presence of 
inhibitor relative to reactions in the absence of inhibitor.  Values are the average of at least two separate 
experiments and have standard errors < 2%. 
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assay using purified telomerase to evaluate telomerase activity. 9,10-phenanthrenedione 
inhibited telomerase activity ~35% when pre-incubated with DTT (5 mM) for 5 minutes, 
however, it completely inhibited activity when telomerase was incubated in the presence of 
DTT (5 mM) for 1 hour (Figure 3.4A).  It was also observed that DTT concentration had a 
direct correlation with the 9,10-phenanthrenedione inhibition of telomerase (Figure 3.4B). 
Importantly, DTT concentrations below 100 M were not sufficient to inactivate telomerase 
(Figure 3.4B, lanes 2-3). In agreement with these findings, Bova et al. demonstrated that 
ortho-quinone compounds did not generate sufficient H2O2 to inactivate protein tyrosine 
phosphate  (PTP) when DTT concentrations were below 100 M.116 In conclusion, our 
experiments show that telomerase inhibition by 9,10-phenanthrenedione was markedly 
enhanced by the presence of DTT in a time- and dose- dependent manner. 
 
 
Figure 3.4 Inhibition of telomerase by 9,10-phenanthrenedione is DTT dependent. (A) Telomerase was 
incubated with or without 9,10-phenanthrenedione (50 M) and DTT (5mM) for different time points prior to 
telomerase assay. Lane 1, DMSO only; lane 2, 5 min incubation; lane 3, 1hr incubation. (B) Telomerase was 
incubated with or without 9,10-phenanthrenedione (50 M) and different concentrations of DTT for 1hr prior to 
telomerase assay. Lane 1, DMSO only; lane 2, 500 nM DTT; lane 3, 50 M DTT; lane 4, 5 mM DTT. Percent 
telomerase activity was normalized based on the loading control (LC).  
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5. Protection of telomerase by catalase  
Because catalase is a H2O2 scavenger, we investigated the ability of catalase to 
prevent the inhibition of telomerase by ortho-quinone containing compounds. If the ortho-
quinones inhibit telomerase via ROS, we predict that catalase will afford protection from 
inhibition. Therefore, we pre-incubated purified telomerase with 9,10-phenanthrenedione, 
DTT, and catalase for 1 hour before performing a telomerase assay.  As predicted, catalase 
completely blocked telomerase inhibition by 9,10-phenanthrenedione (Figure 3.5). In order 
to test if the inactivation of telomerase by 9,10-phenanthrenedione is reversible, purified 
telomerase was pre-incubated with 9,10-phenanthrenedione and DTT  for 1 hour prior to the 
addition of catalase. We found that telomerase inhibition by ROS is irreversible as the 
addition of catalase after 1 hour did not rescue telomerase activity (Figure 3.5, lane 4).  
 
Figure 3.5 Catalase protects telomerase inhibition by 9,10-phenanthrenedione in the presence of DTT. 
Lane 1, DMSO only; lane 2, telomerase was incubated with 9,10-phenanthrenedione (50 M), DTT (5mM), and 
catalase (3.5U) for 1hr; lane 3, telomerase was incubated with 9,10-phenanthrenedione (50 M) and DTT 
(5mM) for 1hr; lane 4, telomerase was incubated with 9,10-phenanthrenedione (50 M) and DTT (5mM) for 
1hr prior to addition of catalase (3.5U). Percent telomerase activity was determined by comparing each lane 
with the DMSO control (lane 1) and normalizing based on the loading control (LC).  
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6. Generation of H2O2 by Tan II-A and 9,10-phenanthrenedione  
The observation that catalase can protect telomerase from ortho-quinone inhibition 
raised the possibility that ortho-quinone containing compounds could be producing active 
oxygen species such as superoxide and H2O2 that could subsequently inactivate telomerase. 
To examine this possibility, we incubated Tan-IIA or 9,10-phenanthrenedione with DTT in 
PBS and monitored the production of hydrogen peroxide. The generation of H2O2 by Tan-IIA 
was time-dependent and plateaued at 60 minutes resulting in about 2.5 mM H2O2 formation 
(Figure 3.6A). In contrast, when the Tan-IIA was incubated in PBS alone without DTT, we 
did not observe formation of H2O2 (Figure 3.6A). Additionally, incubating catalase with the 
compound and DTT completely blocked the generation of H2O2 as expected (Figure 3.6). 
Similar results were obtained for 9,10-phenanthrenedione (20 M) with 2.72 mM H2O2  
formation at 60 minutes (data not shown). Notably, as mentioned above, low concentrations 
of DTT or the absence of DTT also precluded ortho-quinones inhibition of telomerase. Thus 
suggesting that telomerase is directly affected by H2O2 and that DTT is a limiting factor in 
the production of H2O2 by ortho-quinone containing compounds. To test telomerase 
sensitivity towards hydrogen peroxide, we performed a telomerase assay with varying 
concentrations of H2O2 using either immunopurified recombinant telomerase or cell-extracts 
from cells that over-express telomerase. As expected inactivation of telomerase by H2O2 was 
both dose- and time-dependent (data not shown). Furthermore, catalase protected telomerase 
from H2O2 damage further validating that H2O2 is a key regulator of telomerase (Figure 
3.6B).  
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Figure 3.6 Production of hydrogen peroxide by Tan-IIA and effect of H2O2 on telomerase. (A) Tan II-A 
(20 M) in PBS was incubated with 5 mM DTT (blue bar), with 5 mM DTT and 30 U catalase (red bar), or 
without DTT (white bar) for the time points indicated in the figure. Production of H2O2 was measured as 
described in materials and methods. (B) Telomerase assay using over-expressed telomerase cell extracts with 
DMSO (lane 1), with H2O2 (25 mM) and 3.5 U catalase (lane 2), or with H2O2 alone. Telomerase activity was 
determined by comparing each lane with DMSO only control lane and normalizing using loading control (LC) 
band.  
 
 
7. Effect of 9,10-phenanthrenedione redox cycling on Tetrahymena telomerase 
We next wanted to identify the ROS sensitive residues in order to generate an ROS-
resistant hTERT telomerase mutant. It is established that reactive oxygen species and SQ
-. 
radicals derived from quinone-catalyzed redox cycling can be involved in the oxidation of 
the thiol group of the active site cysteine.
331-333
 If a catalytic important cysteine is being 
oxidized, we would expect the cysteine to be conserved between species. Therefore, we 
tested the ability of 9,10-phenathrenedione to inhibit Tetrahymena thermophila telomerase. 
Tetrahymena thermophila is a unicellular organism that is widely used as a model system to 
study the mechanism and structure of all telomerases. We found that pre-incubation of 9,10-
phenanthrenedione and DTT for 1 hour before performing a telomerase assay using 
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Tetrahymena purified telomerase showed ~85% inhibition of telomerase activity (Figure 
3.7). Additionally, inactivation of Tetrahymena telomerase by 9,10-phenantherenedione was 
dependent on the presence of 5mM DTT as 9,10-phenantherenedione alone was not capable 
of inhibiting telomerase (Figure 3.7). Based on these results and the fact that Tetrahymena 
thermophila is evolutionarily distant from humans, it is promising that telomerase inhibition 
by 9,10-phenanthrenedione in the presence of DTT is due to oxidation of a conserved and 
catalytically important cysteine residue.  
 
Figure 3.7 Effect of 9,10-phenanthrenedrion on Tetrahymena telomerase. Tetrahymena telomerase was 
incubated with DMSO (lane 1), with 9,10-phenanthrenedione (50 M) and 5 mM DTT (lane 2), or with 9,10-
phenanthrenedione (50 M) without DTT.  
 
Since there are four conserved cysteine residues between Tetrahymena TERT and 
human TERT, we produced hTERT mutants C413S, C842S, C998S, and C1043S and tested 
their sensitivity to oxidation. Our results showed that hTERT C413S, C998S, and C1043S 
formed inactive telomerase complexes (Figure 3.8). Though hTERT C842S retained 
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telomerase activity, telomerase reconstituted with the mutant was still sensitive to 9,10-
phenanthrenedione oxidation in the presence of DTT meaning that another specific cysteine 
is being oxidized (data not shown). These results identified several cysteine residues that are 
crucial for telomerase activity but did not allow the identification of the key residues that are 
responsible for ROS sensitivity. Perhaps cysteine 413, a cysteine residue conserved among 
several species, is catalytically significant and sensitive to thiol oxidation.   
 
 
Figure 3.8 Telomerase is sensitive to mutations at conserved cysteine residues. 
 
 
 
8. Telomeric primer and telomerase RNA sensitivity to 9,10-phenanthrenedione 
 ROS can affect biological macromolecules in a variety of ways. For example, reactive 
oxygen species can cause DNA damage. With reference to the telomerase assay, oxidative 
damage of guanine in DNAs that contain telomeric sequence generates 8-oxoguanine (8OG). 
This oxidation has been reported to affect the formation of intramolecular G quadruplexes, 
depending on the position of 8OG.
334
 The position of 8OG in the GGG triplet of telomeric 
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sequences also affects telomerase activity and synthesis of telomeric repeat products. It has 
been shown that telomerase activity is decreased significantly when 8OG is substituted in the 
5' -position of the GGG triplet, but not when 8OG is substituted in the middle of the triplet.
334
 
Thus, biological oxidation of G to 8OG in telomeres has the potential to modulate telomerase 
activity. Therefore we tested the sensitivity of telomerase to a telomeric DNA primer that 
was exposed to 9,10-phenanthrenedione in the presence of DTT. A telomeric DNA primer, 
5-d[(TTAGGG)3]-3was incubated for 1 hour with 9,10-phenanthrenedione and 5mM DTT 
before performing a telomerase assay. The “oxidized” primer was a productive telomerase 
substrate demonstrating only a minor (<20%) reduction in activity (Figure 3.9A).  
Furthermore, though increasing the concentration of the “oxidized” primer by 2-fold did not 
produce telomerase activity comparable to that of “unoxidized” primer (Figure 3.9A, 
compare lanes 3 and 1), it did show an increase in telomerase activity relative to lane 2, 
suggesting that oxidation of telomeric primer does not significantly affect telomerase’s 
ability to generate telomeric products. Though telomeric DNA primer was to some level 
sensitive to oxidation, it only resulted in an 18% decrease in telomerase activity, therefore, 
not accounting for the complete telomerase inhibition observed in the previous experiments. 
Similar results were obtained when human telomerase RNA was pre-incubated with 9,10-
phenanthrenedione and DTT prior to reconstitution of telomerase (15% decrease in 
telomerase activity, Figure 3.9B).   
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Figure 3.9 Effect of 9,10-phenanthrenedione redox cycling on telomeric primer and telomerase RNA. (A) 
Telomerase assay using untreated telomeric DNA primer (1 M) (lane 1), using telomeric primer (1 M) pre-
treated with 9,10-phenanthrenedione (50 M) and 5 mM DTT (lane 2), or using 2 M of pre-treated telomeric 
primer (lane 3). (B) Telomerase assay using untreated telomerase RNA, hTR (lane 1) or using telomerase RNA 
pre-treated with 9,10-phenanthrenedione and DTT (lane 2).  
 
 
 
 9. Effect of Tan II-A on telomerase activity in cultured cells and cytotoxicity studies 
 We tested the cytotoxicity of tanshinone II-A in both telomerase-positive and 
telomerase-negative cell lines to determine if telomerase inhibition correlated with observed 
cytotoxicity of Tan II-A. As expected, Tan II-A was a potent cytotoxin of the telomerase 
positive breast cancer cell line MCF-7 (EC50 0.90 M) and prostate cancer cell line PC-3 
(EC50 1.2 M), consistent with previous reports using a variety of cancer cell lines (Figure 
3.10A).
321,324,330,335
  Furthermore, telomerase activity was reduced by 50% in MCF-7 cells 
after 24 hr exposure to cytotoxic concentrations of Tan II-A (Figures 3.10B and 3.10C). In 
contrary, telomerase negative GM847 and Saos-2 cell lines were significantly less sensitive 
to Tan-IIA cytotoxicity (EC50 of >20 M) (Figure 3.10A).  
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Figure 3.10 Consequences of treating immortalized cells with tanshinone II-A.  (A) Cytotoxicity assays of 
Tan II-A using telomerase positive (MCF-7 and PC-3) cell lines and telomerase negative (GM847 and Saos-2) 
cell lines. (B) Residual telomerase activity of MCF-7 cells 24 hr after Tan II-A exposure.  Lane 1, heat 
inactivated MCF-7 extracts; lane 2, extract from untreated MCF-7 cells; lane 3 extract from MCF-7 cells treated 
with 0.2 M Tan II-A; lane 4 extract from MCF-7 cells treated with 0.8 M Tan II-A; lane 5 extract from MCF-
7 cells treated with 3.2 M Tan II-A.  ITAS, internal amplification standard. (C) Graphical representation of 
telomerase assays.  Telomerase activity is the percent of residual telomerase activity in treated cells relative to 
untreated control cells and is the average of two independent calculations. 
 
 
 
 10. Induction of ROS in cells decrease telomerase activity 
 The mitochondrial respiratory chain is one of the major sources of ROS production 
under physiological conditions,
336,337
 and it has been well documented that mitochondrial 
ROS play an essential role in apoptosis. Detoxification of mitochondrial ROS is regulated by 
the manganese-dependent superoxide dismutase (MnSOD), which is coded for by the SOD2 
gene. The manganese-dependent superoxide dismutase is the primary mitochondrial 
enzymatic defensive mechanism that converts superoxide to hydrogen peroxide, which is 
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then further degraded by catalase and peroxiredoxins.
338
 Inhibition of mitochondrial 
respiratory chain complex I by rotenone has been shown to induce mitochondrial ROS 
production and apoptosis in a variety of cells.
339-341
 Moreover, rotenone-induced apoptosis is 
closely related to its ability to generate ROS.
342
 To test the correlation between endogenous 
ROS generation and telomerase in cells, we incubated HEK293 cells with rotenone and 
tested for effects on telomerase activity. We also used HEK293 cells that stably expressed a 
shRNA targeting SOD2 and therefore expressed reduced levels of MnSOD (Figure 3.11A) to 
evaluate the relationship between elimination of ROS by SOD2 and telomerase activity. Our 
results showed that rotenone at a concentration of 200nM for 6 hrs increased ROS production 
and decreased telomerase activity while not affecting apoptosis (Figure 3.11B). Additionally, 
knockdown of SOD2 resulted in higher ROS generation and greater telomerase inhibition 
when compared to shGFP control cells (Figure 3.11B). Similar results were observed when 
telomerase was over-expressed in shGFP control cells and shSOD2 cells, except that a higher 
concentration of rotenone (10 M instead of 200 nM) and a longer incubation time (24 hrs 
instead of 6 hrs) was required to observe telomerase inhibition and ROS generation (Figure 
3.11C). Additionally, by comparing telomerase activity in shGFP and shSOD2 cells, we 
observed that the decrease in telomerase activity was proportional to the amount of SOD2 
knockdown. Our data suggests that telomerase activity is sensitive to levels of ROS in a 
manner separate from apoptosis.  
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Figure 3.11 Rotenone-induced reactive oxygen species generation. (A) Western blot showing knockdown of 
SOD2. (B)  Cells were treated with rotenone (200 nM) for 6 hrs to generate ROS. Cellular levels of reactive 
oxygen species was detected by dihydroethidium (DHE). Apoptosis was determined using the MitoPT kit 
according to manufacturer’s protocol and relative fluorescence units (RFU) were recorded. Telomerase activity 
was determined by the TRAP assay. ITAS is the internal amplification standard. (C) Over-expressed telomerase 
cells were treated with rotenone (10 M) for 24 hrs to induce ROS. Percent telomerase activity was determined 
by the direct telomerase assay and normalized based on the loading control (LC).  
 
 
C. Discussion 
In the current study, we investigated the ability of the tanshinone natural products to 
affect telomerase activity.  This compound class was examined because the underlying 
mechanism of tanshinone-induced cytotoxicity had not been determined, and because the 
broad cytotoxicity of tanshinones against cancer cells suggests they target a pathway, perhaps 
telomerase, that is shared by many cancer cell types.
321
 We found that tanshinones containing 
an ortho-quinone moiety were potent inhibitors of telomerase and were initially thought to be 
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more active when present during telomerase assemblage. Since hsp90 inhibitors inhibit 
telomerase
180,186
 by perturbing telomerase assemblage, we first hypothesized that Tan II-A 
was an hsp90 inhibitor. However, additional studies of the ortho-quinone moiety led to 
different conclusions.  
Our data showed that 9,10-phenanthrenedione inactivated assembled telomerase in 
the presence of DTT in a time- and dose-dependent manner. Ortho-quinone compounds have 
the ability to undergo redox-cycling, in the presence of oxygen and tissue reducing 
equivalents, such as DTT, glutathione, ascorbate, and NAD(P)H, to produce reactive oxygen 
species including hydrogen peroxide, superoxide anion radical, and semiquinone anion 
radical, which cause DNA and protein damage (Figure 3.12).
343,344
 Our results showed that 
catalase completely protected telomerase from inactivation caused by 9,10-
phenanthrenedione in the presence of DTT, further supporting the direct participation of 
reactive oxygen species derived from quinone-catalyzed redox cycling in its inactivation. 
Moreover, we observed that 9,10-phenanthrenedione and tanshinone II-A generated the 
formation of significant amounts of H2O2 and that telomerase inhibition was proportional to 
H2O2 concentration.  
In the telomerase reaction cycle, ROS can in theory reduce telomerase activity by 
damaging telomerase or by oxidizing telomeric DNA.
119
 We showed that neither the 
telomeric DNA primer nor the telomerase RNA were significantly sensitive to 9,10-
phenanthrenedione oxidation in the presence of DTT, suggesting that hTERT is the 
molecular target. Furthermore, cell studies using MnSOD knockdown cells provide strong 
evidence that telomerase is sensitive to cellular ROS. ROS derived from quinone-catalyzed 
redox cycling are known to be involved with the oxidation of the active site cysteine of 
  86 
protein tyrosine phosphatases.
115,116
 Evidence suggests that 9,10-phenanthrenedione and the 
o-quinone containing tanshinones inhibit telomerase by oxidizing an important cysteine 
residue.  This hypothesis was supported by our results from a direct telomerase assay using 
purified Tetrahymena telomerase. Similar effects were observed between human and 
Tetrahymena telomerase inhibition by o-quinone compounds in the presence of DTT, 
suggesting that the thiol of a catalytically important and conserved cysteine is being oxidized.  
 
 
 
Figure 3.12 Proposed scheme for the catalytic inactivation of telomerase by ortho-quinones capable of 
redox cycling.  In the presence of DTT in vitro, 9,10-phenanthrenedione rapidly undergoes reduction to a 
semiquinone anion radical (SQ
-), which reduces oxygen to superoxide anion radical  (O2
-) and re-forms the 
quinone. Both SQ
- and O2
- radicals could contribute to the specific oxidation of the catalytic cysteine(s), via a 
transient (telomerase-SH/ SQ
-) intermediate for SQ
-. Telomerase-SH, telomerase-SOH, telomerase-SO2H, and 
telomerase-SO3H represent the thiol and sulfenic, sulfinic, and sulfonic acid states of the catalytic nucleophile. 
Telomerase-SSR represents a putative disulfide adduct with DTT. Telomerase-SOH and telomerase-SSR would 
be sensitive to DTT–mediated reactivation. This figure was adapted from reference 115. 
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The cell-based assays demonstrated that Tan II-A was cytotoxic to both telomerase-
positive and telomerase-negative cells, but that telomerase-positive cell lines were more 
sensitive to Tan II-A cytotoxicity than telomerase-negative cells.  Thus, even though Tan II-
A is cytotoxic independent of telomerase status, in telomerase negative cells a higher 
concentration of Tan II-A is required for the effect. Tan II-A has been shown to affect several 
biological targets independent of telomerase.  For example, Tan II-A inhibited differentiation 
of precursor cells to osteoclasts and inhibited bone reabsorption by differentiated osteoclasts 
in cultured mouse cells.
345
  It was suggested that Tan II-A affected the gene expression of 
proteins required for osteoclast differentiation and activity while not inducing apoptosis. 
Human osteoblasts and osteoclasts are generally considered telomerase negative, though the 
telomerase activity of these cells were not examined.
346,347
  Another study showed that Tan 
II-A-induced apoptosis of human hepatocellular carcinoma cells coincided with up-
regulation of pro-apoptotic genes such as fas, bax, and p53, which was concomitant with 
down-regulation of bcl2, and c-myc.
324
  Down-regulation of c-myc may also account for the 
observed inhibition of telomerase in cultured cells as c-myc can upregulat hTERT 
transcription.
348
  These results suggest that Tan II-A has variable effects depending on cell 
type and can affect multiple cellular pathways. The multiple effects of Tan II-A presumably 
arise from its ability to affect several targets. As a result, tanshinones and other ortho-
quinone compounds capable of redox-cycling would not be suitable clinical candidates due to 
their cytotoxic effects, but they could be helpful in the study of the catalytic cysteine of 
telomerase. 
In summary, it is known that cellular environment plays an important role in 
regulating telomere length and telomerase activity and that reactive oxygen species can 
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accelerate telomere loss in diverse cell types.
19,84
 The well known free radical theory of aging 
suggests that oxidative damage accumulates with age and therefore aging is accelerated via 
damage generated by ROS.
19,84,349,350
 Moreover, the loss of telomere repeats in stem cells and 
lymphocytes has been linked to the process of aging.
351,352
 Although telomere loss occurs 
naturally with each round of DNA replication, telomere shortening can be intensified by the 
presence of reactive oxygen species due to oxidation of telomeric DNA.
19
 While telomeres 
can be directly damaged by oxidative stress, there is no reported evidence to date 
demonstrating that reactive oxygen species oxidize telomerase. The data reported here 
indicates that ROS is indeed another mechanism of telomerase regulation. We found that 
telomerase is directly sensitive to oxidative damage and that telomere shortening observed in 
the presence of ROS is also due to the ability of ROS to oxidize telomerase, which therefore 
limits its ability to form an active complex and extend telomeres. Since reactive oxygen 
species can post-translationally modify a variety of proteins via the oxidation of redox-
sensitive cysteine residues,
353,354
 we speculate that a catalytic important cysteine of hTERT is 
being oxidized. The data presented here provides a basis for elucidating the crucial roles of 
oxidative damage to telomeres and telomerase in cellular aging and in understanding the 
underlying principles of the aging process. 
 
D. Materials and Methods 
1. Expression constructs  
The construction of pET28c-hTERT expression plasmid and the construction of in 
vitro transcription and phTR+HH expression plasmid for hTR were described in chapter II. 
Site directed mutagenesis, based on the Stratagene Quick Change site-directed mutagenesis 
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protocol, was used to generate pET28c-hTERT constructs coding for specific cysteine to 
serine substitutions.  
 
2. Chemicals and Reagents  
 Tanshinones were made available from a previous study and were stored as 5 mM 
stocks in sterile DMSO.
330
 9,10 Phenanthrenedione, catalase from bovine liver (2000~5000 
units/mg), and rotenone were from Sigma Chemical Co (St. Louis, MO).  
 
3. Cells and cell culture 
The human breast cancer cell line MCF7 (telomerase positive, from ATCC, 
Manassas, VA) was cultured in MEM medium (Gibco, Carlsbad, Calif.) supplemented with 
10% fetal bovine serum (FBS) (Sigma, St. Louis, Mo.), 10µg/ml insulin (Gibco), and sodium 
pyruvate (Gibco). The human prostate cancer cell line PC-3 (telomerase positive, from 
ATCC) was cultured in Dulbecco's
 
modified Eagle/F12 medium (DMEM/F12) (Gibco) 
supplemented with 10% FBS. The human osteosarcoma cell line Saos-2 (telomerase 
negative, from ATCC) was cultured in McCoy’s 5A medium (Gibco) supplemented with 
15% FBS.  The immortalized fibroblast cell line GM847 was a gift from Shelia Stewart and 
Robert Weinberg at the Massachusetts Institute
 
of Technology (Cambridge, Mass.) and was 
cultured in DMEM supplemented
 
with 10% FBS and
 
50 µg/ml of gentamicin (Sigma).  The 
highly transfectable human embryonic kidney cell line HEK293T (telomerase positive, from 
ATCC) was cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 
10% FBS.  
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4. Effects of Tanshinone II-A on nucleic acid processing enzymes 
 
To test the effect of 50 μM Tan II-A on T7 RNA Polymerase, the compound was 
added to a reaction transcribing 
32
P-labeled pseudoknot RNA fragment. The RNA was 
resolved on a denaturing gel and compared to RNA transcribed in the presence of 
DMSO as a carrier. 
To determine if 50 μM Tan II-A influenced M-MLV reverse transcription, the 
compound was added to a reaction containing 0.5 mM dNTPs, 0.33 μM [α-32P]-dGTP (3000 
Ci/mmol, 10 μCi/μL; Perkin Elmer), 20 units RNasin (Promega), 10 ng RNA template, 1 μM 
primer, 100 units M-MLV reverse transcriptase (Promega) and 1× M-MLV buffer 
(Promega). The dNTPs, RNA, primer, Tan II-A and buffer were first combined and 
incubated at 95 ºC for 5 min followed by 0 ºC for 3 min. The [α-32P]-dGTP and enzymes 
were then added and the reaction was incubate at 37 ºC for 2 h followed by 95 ºC for 5 min. 
After passing through a Microspin G-25 column (Amersham), the sample was resolved on a 
denaturing gel and compared to a reaction containing DMSO in place of Tan II-A. 
To test the effect of 50 μM Tan II-A on the Klenow Fragment of DNA Polymerase I, 
we first performed a double digestion on pET-28c using Sal I and Xho I in order to generate 
a 21 base-pair piece of DNA with sticky ends. About 2 μg pET-28c was combined with 20 
units Sal I (New England Biolabs, NEB), 20 units Xho I (NEB), 100 μg/mL BSA and 1× Sal 
I buffer (NEB) and incubated at 37 ºC for 90 min, followed by 65 ºC for 20 min to heat 
inactivate the enzymes. ~600 ng of the digested DNA was then combined with 50 μM 
dNTPs, 0.165 μM [α-32P]-dGTP (3000 Ci/mmol, 10 μCi/μL; Perkin Elmer), 5 units Large 
(Klenow) Fragment of DNA Polymerase I (NEB), 1× NEB buffer #2 and Tan II-A to a final 
concentration of 50 μM. The reaction was incubated at 25 ºC for 30 min followed by 75 ºC 
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for 20 min and passed through a Microspin G-25 column. The degree of Tan II-A-induced 
Klenow inhibition was quantified by resolving the final product on a native gel along side a 
positive control reaction containing DMSO instead of Tan II-A. 
  
5. Generation of stable SOD2 knockdown cell lines  
HEK293T knockdown SOD2 cells were a kind gift from Dr. Judith Campisi (UC 
Berkeley). HEK293T transfected with shGFP were used as control. HEK293T cells were 
infected with viral supernatant, supplemented with 10 μg/mL polybrene, and selected with 1 
μg/mL puromycin. Knockdown of SOD2 was confirmed by western blot (anti-SOD2, BD 
biosciences).  
 
6. Direct telomerase assay 
To measure activity of recombinant telomerase, we utilized a previously described 
direct assay.
233
  Each reaction contained 50 mM Tris-HCl, pH 8.0, 50 mM KCl, 1 mM 
MgCl2, 5 mM -mercaptoethanol, 1 mM spermidine, 1 M human telomere primer (5'-
TTAGGGTTAGGGTTAGGG), 0.5 mM dATP, 0.5 mM dTTP, 2.9 M dGTP, 0.33 M [-
32
P]-dGTP (3000 Ci/mmol, 10 Ci/L; Perkin Elmer), and 10 L of pre-assembled 
telomerase in RRL, 20 L of immunopurified telomerase, or 3 L of super-telomerase 
extract.  Inhibition studies also included varying amounts of inhibitor.  Primer extension was 
carried out at 30 ºC for 90 min.  After the addition of a 
32
P-labeled loading control (114 
nucleotide, 5′-end labeled DNA oligonucleotide, 1000 cpm per reaction), the primer 
extension products were extracted with phenol/ chloroform/isoamyl alcohol and ethanol 
precipitated in the presence of 0.6 M NH4OAc and 35 ng/L glycogen.  Products were 
concentrated by ethanol precipitation and dissolved in a formamide loading buffer containing 
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40% formamide, 10 mM Tris-HCl, pH 8.0, 10 mM EDTA, 0.05% xylene cyanol, and 0.05% 
bromophenol blue.  The products were heated at 95 ºC for 5 min and resolved on a pre-
warmed, 0.4 mm thick, 20 x 20 cm, 10% polyacrylamide/7 M urea/1 TBE gel.  A small 
amount of the human telomere primer was labeled with [-32P]-ATP and T4 polynucleotide 
kinase (Fisher) and loaded in a separate lane to be used as a marker for the start of primer 
elongation.  After drying the gel and exposing it to a phosphorimager screen (Molecular 
Dynamics) overnight, telomerase products were imaged using a phosphorimager (Molecular 
Dynamics Storm 860) and quantified with ImageQuant (version 5.2).  The intensities of each 
band in each sample were summed and normalized to the loading control.  
  
7. Reconstitution of human telomerase 
Wild-type hTR was in vitro transcribed and purified as previously described
233
 except 
that the Ampliscribe T7 Transcription Kit was used (Epicentre Technologies). Flag-tagged 
hTERT was transcribed and translated from pCR3.1-Flag-hTERT using the TNT Coupled 
Rabbit Reticulocyte Lysate Systems Kit (Promega). The expression construct for Flag-
hTERT was a gift from Dr. Lea Harrington (University of Toronto). A 400 µL reaction 
contained 8 µg of pCR3.1-Flag-hTERT, 16 µL of [
35
S]-methionine (1175 Ci/mmol, 10 
μCi/μl; Perkin-Elmer), 4 µg of in vitro transcribed hTR, and other components provided in 
the kit as described by the manufacturer.  
 
8. Immunopurification 
Flag-tagged hTERT was immunoprecipitated with anti-FLAG M2 affinity agarose 
beads (Sigma-Aldrich, St. Louis, MO). Prior to use, beads (50 µL) were washed four times in 
400 µL of 1xTris IP buffer (10 mM Tris-Cl, pH 7.5, 100 mM KCl, 1 mM MgCl2, 10% 
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glycerol, 0.1 mM DTT), centrifuging at 1500 x g for 2 min between washes. Reticulocyte 
lysate translation reaction (45 µL) was added to 450 µL of 1xTris IP buffer and centrifuged 
at 16,000 × g for 15 min at 4°C to remove any particulates. The supernatant was added to 
beads and allowed to nutate at 4°C for 2 h. The beads were washed six times in 400 µL 
1×Tris IP buffer centrifuging at 1500 × g for 2 min between washes and resuspended in 20 
µL 1×Tris IP buffer. Beads were transferred to Protein LoBind tube (Eppendorf) and washed 
once with 500 µL TMG (10 mM Tris acetate, pH 8, 1 mM MgCl2, 10% glycerol) 
centrifuging at 1500 × g for 2 min. BSA (3 µL of 10 mg/ml) was added to the beads to 
prevent protein from sticking to the tubes.  50 µL of peptide solution [41 µL TMG, 9 µL 
FLAG peptide (5 mg/ml)] was added to the beads and nutated at 4°C for 1h. FLAG peptide 
(5 mg/ml) was prepared by adding 3×FLAG peptide (Sigma-Aldrich) to 20 mM Tris acetate, 
pH 7.5. The beads were centrifuged at 1500 × g for 2 min and the eluent was removed and 
added to a fresh LoBind tube. 
 
9. Telomerase assemblage assay 
 Recombinant hTERT was transcribed and translated from pET28c-hTERT 
233
 using 
the TNT

 Coupled Reticulocyte Lysate Systems kit (Promega) following the manufacturer’s 
instructions. Telomerase assemblage assays were initiated by combining 10 L (~50 fmol) of 
hTERT from a reticulocyte lysate reaction, 212.5 ng of in vitro transcribed hTR, and the 
appropriate amount of DMSO or inhibitor to a final volume of 15 l followed by incubation 
at 30 ºC for 90 min as previously described in detail.
232,233
 Inhibition studies contained 
varying concentrations of inhibitor as noted in the text.  After assemblage, telomerase-
catalyzed primer extension was carried out as described above. Inhibitor concentrations were 
maintained in the extension reaction.  In assays examining inhibition of the holoenzyme 
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complex, inhibitors were only added after assemblage. Control reactions with the appropriate 
amount of DMSO were conducted in parallel.  
 
10. Oxidation of telomeric primer and telomerase RNA 
Telomeric primer (TTAGGG)3 or telomerase RNA were incubated with 9,10-
phenanthrenedione (50 M) and DTT (5 mM) for 1 hr followed by extraction with 
phenol/chloroform/ isoamyl alcohol and ethanol precipitation. Telomeric DNA or telomerase 
RNA were resuspended in TE and quantified by nanodrop. Direct telomerase assay was 
performed with treated primer. Treated telomerase RNA was tested using the telomerase 
assemblage assay. 
 
11. Telomerase activity of cell extracts 
 Telomerase activity in cell extracts was determined by a modified telomere repeat 
amplification protocol (TRAP assay).
355
  In short, cell lysates were prepared from 4 104 
cells in 100 L of lysis buffer (10 mM Tris, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM 
benzamidine, 0.5 mM -mercaptoethanol, 0.5% CHAPS, 10% glycerol) by incubating the 
suspended cells on ice 30 min followed by three freeze thaw cycles using liquid N2 to freeze 
the samples. Cell lysates were clarified by centrifugation (10,000 × g, 30 min at 4 ºC), and 
protein levels in the cell extracts were determined by the method of Bradford.
356
  Cell 
extracts (100 ng of total protein) were incubated with 0.1 g TS primer (5′-
AATCCGTCGAGCAGAGTT) in a 25 l reaction containing TRAP buffer (20 mM Tris-
HCl, pH 8.3, 1.5 mM MgCl2, 63 mM KCl, 0.05% Tween20, and 1 mM EGTA) and 50 M of 
each dNTP at 30 ºC for 30 min. Telomerase extension reactions were then heated to 95 ºC for 
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5 min before the products were amplified by adding 0.1 g ACX primer (5′-
GCGCGG(CTTACC)3CTAACC), 0.1 g NT primer (5′-ATCGGCTTCTCGGCCTTTT),  
0.001 amol TSNT template (5′-
AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCGAT, used as a PCR and loading 
control), 0.5 units HotMaster Taq DNA polymerase (Eppendorf), 5 l of 10 Taq buffer, and 
dNTPs to a final concentration of 50 M.  The reactions were then subjected to 33 PCR 
cycles at 95 ºC for 30 s, 60 ºC for 30 s, 72 ºC for 60 s.  Reaction products were separated on a 
12.5% nondenaturing polyacrylamide gel, stained with SYBR Green I (Molecular Probes), 
and imaged on a phosphorimager.  Reactions were quantified using ImageQuant and the 
product intensity for each reaction was normalized to the TSNT internal standard. 
 
12. Super telomerase extracts preparation 
HEK293T cells were transfected with 4 μg of plasmid DNA and Lipofectamine 2000 
(Invitrogen) in 6-well plates following manufacturer’s protocol. The optimal mass ratio of 
hTERT- and hTR- expressing plasmids is 1:5 (0.66 μg pVan107 and 3.33 μg pBS-U1-hTR). 
One day post transfection, cells were trypsinized, transferred to a 25 cm
2
 flask, and grown 
one more day. Forty-eight hours post-transfection, cells were detached by trypsinization, 
washed once in PBS and lysed in 400 μl of CHAPS lysis buffer (10 mM TrisHCl pH 7.5, 1 
mM MgCl2, 1 mM EGTA, 0.5 % CHAPS, 10 % glycerol, supplemented before use with 
protease inhibitor cocktail III (Calbiochem) and 5 mM β-mercaptoethanol). After incubation 
at 4 °C for 30 min on a rotating wheel, cell debris was removed by spinning down extracts at 
4 °C for 10 min at 13000 × g. The supernatant (~ 4 mg/ml) was aliquoted, quick frozen in dry 
ice and stored at -80°C. 
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13. Effect of catalase on telomerase inhibition 
20 l of immunopurified telomerase was incubated with 9,10-phenanthrenedione (50 
 and DTT (5 mM) in the presence or absence of catalase (3.5 U) for 1 hour at room 
temperature. In a separate assay, 3l of super-telomerase extracts was incubated with varying 
concentrations of H2O2 in the presence or absence of catalase (3.5 U) for 1 hour at room 
temperature. Telomerase activity was then measured by adding 50 mM Tris-HCl, pH 8.0, 50 
mM KCl, 1 mM MgCl2, 1 mM spermidine, 1 M human telomere primer (5'-
TTAGGGTTAGGGTTAGGG), 0.5 mM dATP, 0.5 mM dTTP, 2.9 M dGTP, and 0.33 M 
[-32P]-dGTP (3000 Ci/mmol, 10 Ci/L; Perkin Elmer). Primer extension was carried out at 
30 ºC for 90 min, and the samples were processed as described for the direct telomerase 
assay. 
 
14. Measurement of hydrogen peroxide  
Hydrogen peroxide (H2O2) was assayed using a colorimetric hydrogen peroxide kit 
from Assay Designs (Ann Arbor, MI). Varying concentrations of compound in PBS were 
incubated with DTT for 10, 30, 60, and 90 minutes with the reaction being quenched with the 
addition of 0.1 N HCl. The samples were diluted as needed and 100 L of color reagent was 
added to all samples and incubated for 15-30 minutes at room temperature. The optical 
density of each sample at 550 nm was recorded. Concentrations of H2O2 were determined by 
a standard curve created using known amounts of H2O2. 
 
15. Measurement of cellular ROS
 
The oxidation-sensitive fluorescent probe dihydroethidium (DHE, Invitrogen, 
Carlsbad, CA, USA) was employed to detect cellular levels of ROS. DHE was added at 10 
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μM for 45 min at 37°C after cells were treated with rotenone. The cells were then washed 
and fluorescence was measured at excitation 480 nm and emission 567 nm using a 
fluorescence plate reader. 
 
16. Mitochondrial permeability transition and indication of apoptosis 
HEK293T cells were incubated with rotenone and tested for apoptosis using the 
MitoPT kit (Immunochemistry Technologies, LLC) according to the manufacturer’s 
protocol. Briefly, cells were incubated with MitoPT
TM
 JC-1 solution for 15 min. at 37 °C and 
examined under fluorescence plate reader (excitation at 490 nm and emission at 590 nm). 
Untreated cells served as a control. JC-1 dye fluoresces red when it aggregates inside 
mitochondria (nonapoptotic cells), but the monomeric form of the dye fluoresces green when 
diffused in the cytosol (apoptotic cells). 
 
17. Cytotoxicity assay   
Acute cell growth inhibition by drugs was determined using a sulforhodamine B 
(SRB) assay. 
357
   Between 3,000 and 6,000 cells/well were seeded into 96-well microtiter 
plates in 0.2 ml of media and allowed to attach overnight.  A range of concentrations of Tan 
II-A was added from a 5 mM stock in DMSO to quadruplicate wells and cells were incubated 
for 96 hr.  Cell numbers of treated and untreated cells were compared.  Cells were fixed by 
adding 50 L of cold 50% trichloroacetic acid to the top of the 200 L culture medium and 
incubated for 30 min at 4 ºC.  Fixed cells were washed extensively with deionized water and 
dried for 2 hr at room temperature.  Cells were stained for 20 min in 0.4% SRB, 1% acetic 
acid then rinsed with 1% acetic acid and air dried.  The bound SRB was solubilized with 200 
l of 10 mM Tris-base and the absorbance at 562 nm was measured.  
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18. Western-blot analysis 
Approximately 50 μg of proteins was loaded into each well, separated by 15% SDS-
PAGE, and transferred to a nitrocellulose membrane. After blocking with non-fat dry milk 
(5% w/v) in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 1hr, the membrane 
was incubated with primary antibody for MnSOD (BD biosciences) for 1hr at room 
temperature. After sufficient washing, the membrane was incubated with HRP-conjugated 
goat anti-mouse secondary antibody (Thermo Scientific) for 1 hour at room temperature. 
Blots were developed using the ECL chemiluminescence detection reagent (Amersham 
Bioscience). The membranes were then reprobed with β-actin antibody (Sigma, St. Louis, 
MO) as loading reference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
CHAPTER IV 
TELOMERASE  IS  INCAPACITATED  BY  CASPASE  CLEAVAGE  
    
A. Introduction 
It is well established that telomerase protects telomere repeats from erosion and the 
consequent induction of replicative senescence or apoptosis. Telomerase is usually silenced 
in normal somatic cells, but is specifically activated in most malignant tumors, suggesting a 
key role in cell immortalization and carcinogenesis.
26,358
 As mentioned in chapter I, the 
human telomerase RNA (hTR) is expressed ubiquitously in many tissues and throughout 
development independent of telomerase activity while hTERT expression is repressed in 
normal somatic cells but is up-regulated in most human tumors.
8,10
 As a result, hTERT is 
considered the limiting factor for cellular telomerase enzymatic activity. Regulation of 
telomerase is a poorly understood and highly controlled process as observed by its 
differential expression pattern in normal and tumor cells. Thus, elucidating the mechanism of 
telomerase activation or repression in vivo is an important step in understanding the basic 
roles of telomerase in cellular biology and physiology. In addition to the clear role of 
telomerase in maintaining telomere length, growing evidence suggests that telomerase has 
additional (non-canonical) physiological functions beyond the telomeres.
190,359-361
 
Telomerase has been implicated in several important cellular processes including apoptosis, 
DNA damage response, tumorigenesis, and gene expression control that are not involved in 
telomere extension.
5
 The canonical function (telomere maintenance) of telomerase requires
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both the telomerase reverse transcriptase protein subunit (TERT), which adds telomere 
repeats to the chromosome ends and the telomerase RNA component (TR), which provides 
the template for reverse transcription.
10,362
 In contrary, some non-canonical functions of 
telomerase, for example DNA repair, are dependent on telomerase catalytic activity but not 
on telomere lengthening.
363,364
 Other non-canonical functions of telomerase, such as 
inhibition of apoptosis, do not require telomerase catalytic activity nor telomere lengthening 
as catalytically inactive forms of hTERT were shown to confer anti-apoptotic effects.
270,365,366
 
Several studies have indicated that telomerase has anti-apoptotic functions that are 
not associated with telomere length maintenance.
273
 For example, it has been reported that 
expression of telomerase increased cell resistance to apoptosis and necrosis against serum 
starvation-induced apoptosis and agents that induce cellular stress.
124,367,368
 Additionally, 
TERT has been shown to protect various post-mitotic neurons from apoptosis independently 
of TR and telomerase.
127,361,369
 Transgenic mice overexpressing murine TERT (mTERT) 
manifested significant resistance to ischemic brain injury and N-methyl-D-aspartic acid 
(NMDA) receptor-mediated excitotoxicity.
370
 Moreover, overexpression of catalytically 
inactive TERTs have also been documented to prevent apoptotic cell death.
270
 One study 
showed that ectopic expression of a catalytically inactive TERT muted p53-mediated 
apoptosis in lymphoma and colon carcinoma lines,
366
 and another showed that a dominant 
negative TERT rescued mammary lines from apoptosis induced by antisense knockdown of 
TERT.
270
 Anti-apoptotic function of telomerase is further supported by studies of mice 
lacking either the telomerase RNA subunit (TR) or the catalytic subunit (TERT). Knockout 
TR or TERT mice can be propagated for only a limited number of generations before they 
show a decreased viability with age and a series of deficiencies including infertility and 
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atrophy of organs.
19,101,371
 Taken together, these results show that the protective function of 
TERT is not always associated with telomerase activity.  
Since hTERT expression is up-regulated in cancer cells and is concomitantly 
expressed with the activation of telomerase during cellular immortalization and tumor 
progression, one would expect a direct relationship between TERT expression and 
telomerase activity, however, this is not always the case. Several studies have shown a 
negative correlation between telomerase activity and hTERT mRNA and protein 
expression.
372-375
 One possible explanation for this includes the presence of hTERT splice 
variants. Some hTERT alternative splice products (dominant negative phenotype) have been 
shown to inhibit telomerase activity, while other splice variants exhibit either pro-apoptotic 
or anti-apoptotic functions that are not necessarily related to telomerase.
316,376,377
 We 
speculate that transcriptional regulation of TERT is not sufficient to account for all regulation 
of telomerase activity. Instead, telomerase is likely regulated by other post-transcriptional 
factors. Telomerase is a highly controlled and complex enzyme and a thorough 
understanding of its regulation is still ill-defined. Since telomerase is down-regulated in cells 
undergoing apoptosis and since telomerase protects cells from apoptosis, we hypothesize that 
post-translational modification also plays a role.  In chapter I, we discussed in depth several 
reported post-translational regulators of telomerase and here we interrogate and demonstrate 
(for the first time) post-translational regulation of telomerase by caspases.  
Apoptosis is a controlled form of cell death characterized by distinct morphological 
changes that include cell rounding, membrane blebbing, nuclear fragmentation, cytoskeletal 
disassembly, chromatin condensation, and DNA fragmentation.
378,379
 Defects in the 
regulation of apoptosis have been associated with a variety of human diseases including 
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neurodegenerative and cardiovascular disorders, autoimmune disease, and cancer.
380-382
 
Induction of apoptosis is a highly regulated process that can be initiated by a variety of 
extracellular ligand-directed or intracellular stress-induced stimuli. One of the earliest and 
most consistent observed features of apoptosis is the induction of caspases. Caspases are a 
family of cysteine proteases that cleave substrates at specific tetrapeptide sites (denoted
 
P4-
P3-P2-P1) with a highly conserved aspartate at the P1
 
position.
133
 Each caspase has a specific 
consensus recognition sequence; therefore, they have different substrate preferences. These 
enzymes are present in the cytosol as inactive zymogens that require oligomerization or 
cleavage for activation.
134
 Caspases involved in apoptosis can be separated into two groups: 
initiator caspases and effector caspases.
383
 Caspases that get activated via recruitment to 
signaling complexes are known as the initiator caspases, such as caspases-2, -8, -9, and -10, 
as they provide a link between cell signaling and apoptotic execution.
137,138
 Initiator caspases 
can then in turn cleave and activate effector caspases, caspases-3, -6, and -7.
137,140
 Effector 
caspases are responsible for cleaving most cellular substrates during the apoptotic 
process.
137,139,140
 It has been documented that caspase cleavage can result in loss or gain of 
function of the cleaved substrate, or its fragment, and can also influence its subcellular 
localization.
132,134,384
 Because telomerase and caspases play pivotal but opposite roles in the 
apoptosis pathway, we hypothesized that telomerase is negatively regulated during the 
induction of apoptosis as a result of TERT cleavage by caspases.  
 
B. Results  
1.  Telomerase is a caspase substrate in vitro 
 A bioinformatics analysis of the TERT polypeptide chain did not reveal any 
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consensus caspase cleavage motifs suggesting that telomerase is not a substrate of any 
caspases. However, bioinformatics analysis may miss important substrates as it is dangerous 
to assume that a consensus is very meaningful per se for discovering natural substrates. 
Therefore, we directly tested the hypothesis that hTERT is a caspase substrate. Full length 
FLAG tagged hTERT was synthesized in rabbit reticulocyte lysates (RRL) in the presence of 
[
35
S]-methionine and hTR. The telomerase complex was immunopurified using anti-FLAG 
M2 affinity agarose beads and eluted with FLAG peptide. The purified, soluble telomerase 
was incubated with ten of the human caspases for 6 hours and analyzed by SDS-PAGE gel 
electrophoresis. Remarkably, proteolytic fragments were produced by caspases-6 and -7, 
demonstrating for the first time that telomerase is a caspase substrate (Figure 4.1). To ensure 
that the cleavage of telomerase was not due to the enzyme degradation over time, we 
incubated the telomerase complex in the presence of caspase-7 and a general caspase 
inhibitor, z-VAD-fmk (Figure 4.1, compare lane 12 to lane 8). As observed, the general 
caspase inhibitor, z-VAD-fmk, inhibited cleavage of telomerase, thus implicating telomerase 
as a substrate of caspases-6 and -7 in vitro. Additionally, the same proteolytic fragments were 
observed when purified FLAG-tagged hTERT (in the absence of hTR) was incubated with 
the series of caspases mentioned above. Therefore, our results indicate that caspase-6 and -7 
can cleave hTERT in vitro independently of telomerase assemblage.  
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Figure 4.1 SDS-PAGE gel of telomerase in the presence of various caspases.  Affinity purified recombinant 
telomerase was incubated with 1 unit of different caspases for 6 h. Caspases-6 and -7 cleaved hTERT (lanes 7 
and 8 respectively). Caspase inhibitor z-VAD-fmk prevented telomerase cleavage by caspase-7 (lane 12). 
 
   
 
 2.  Telomerase activity correlates with cell viability 
 If hTERT is a caspase substrate in vivo, then telomerase activity should be inhibited 
in cells undergoing apoptosis.  To determine whether the level of telomerase activity would 
be modulated by drug induced apoptosis in cancer cells, we studied the effect of vincristine 
on apoptosis and telomerase activity in Jurkat cells. We chose Jurkat cells because they have 
a relative higher telomerase activity compared to other cell lines and they are especially 
sensitive to vincristine (a microtubule interfering anticancer agent) induced apoptosis. 
Vincristine (0.1 μM) was added to cells and allowed to incubate for 24, 48, or 72 hours.  
Telomerase activity and cell viability were analyzed at each time point. Consistent with 
previous studies,
375,385,386
 the extent of vincristine induced apoptosis, determined by FACS 
analysis, directly correlated with inhibition of telomerase activity (Figure 4.2). The 
experiment demonstrated that telomerase activity is directly proportional to cell viability, 
consistent with a role of caspase-mediated hTERT cleavage during apoptosis.  
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Figure 4.2 Telomerase activity and cell viability after treatment with vincristine. (A) Telomerase activity 
was determined in vincristine-treated cells using the TRAP assay as described under materials and methods. 
Lane 1, control template; lane 2, DMSO was used instead of vincristine to serve as a control; lanes 3-5, 
vincristine (0.1 μM) treated cells at 24 hrs (lane 3), at 48 hrs (lane 4), or at 72 hrs (lane 5); lanes 6-10, heat 
inactivate samples to ensure experiment validation. ITAS, internal amplification standard. (B) Bar graph 
showing percent of live cells at each time point (24, 48, or 72 hrs) determined by FACS as described under 
materials and methods. (C) Correlation between telomerase activity (blue line) and cell viability (pink line). 
Telomerase activity decreases during apoptosis.  
 
 
 
3. A caspase inhibitor rescued telomerase activity in apoptotic cancer cells  
Since caspases-6 and -7 cleave telomerase in vitro, we hypothesized that vincristine 
treatment would result in the activation of caspase-6 or -7, which would in turn cleave 
hTERT.  If this was the case, then a general caspase inhibitor, z-VAD-fmk, should rescue 
telomerase activity in vincristine-treated cells. We, therefore, incubated Jurkat cells with 
vincristine (0.1 μM) in the presence or absence of a general caspase inhibitor (5 μM) for 24 
hours. We observed a modest rescue of telomerase activity by comparing cells treated with 
vincristine alone with cells treated with vincristine in the presence of a caspase inhibitor 
(Figure 4.3A, compare lanes 4 and 3). On the other hand, FACS analysis demonstrated no 
significant difference in the percentage of cells undergoing apoptosis between the two 
experiments (Figure 4.3B). It is significant to note that the recommended concentration for a 
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caspase inhibitor is 100 μM,387 however, we only used 5 μM in order to avoid complete 
inhibition of apoptosis. This experiment demonstrated that 5 μM of caspase inhibitor was not 
sufficient to protect cells from apoptosis, but that 5 μM of the caspase inhibitor was able to 
partially rescue telomerase activity, suggesting for the first time that telomerase is a 
biologically significant substrate of caspases in cultured cancer cells. 
   
 
 
Figure 4.3 Parial rescue of telomerase activity with caspase inhibitor. (A) TRAP assay of telomerase 
activity. Lane 1, control template; lane 2, DMSO control; lane 3, Jurkat cells pre-incubated with 5 μM of a 
general caspase inhibitor, z-VAD-fmk, for 1 hr prior to incubation with vincristine (0.1 μM) for 24 hrs; lane 4, 
Jurkat cells treated with vincristine (0.1 μM) for 24 hrs; lanes 5-8, heat inactivated samples to ensure 
experiment validation. ITAS, internal amplification standard. (B) Bar graph comparing percentage of live cells 
determined by FACS and telomerase activity by TRAP. A rescue of telomerase activity was observed between 
vincristine treated cells and z-VAD-fmk plus vincristine treated cells (18% and 26% respectively), while no 
significant change of live cells (59% and 52%) was detected.  
 
 
4. hTERT is a caspase-6 and -7 substrate in apoptotic cancer cells  
There are two primary pathways used to initiate the apoptosis pathway. In general, 
the intrinsic pathway is initiated as a response to cellular stress, such as DNA damage, and 
results in the release of cytochrome c and consequently the activation of initiator caspase-
9.
388
 The extrinsic pathway is triggered by extracellular signals such as Fas or TNF binding 
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to its cognate death receptor and leads to the activation of initiator caspase-8.
389
 In both 
pathways, initiator caspases cleave and activate downstream executioner caspases, such as 
caspase-6 and-7.
390-392
 Since telomerase activity decreased during vincristine induced 
apoptosis in Jurkat cells and since z-VAD-fmk rescued telomerase activity in apoptotic cells, 
we next wanted to determine if hTERT was a caspase-6 and -7 substrate in apoptotic cells. 
Therefore, we pre-incubated Jurkat cells with either the general caspase inhibitor z-VAD-
fmk, the caspase-6 inhibitor z-VEID-fmk, the caspase-7 inhibitor ac-DEVD-fmk, or with a 
combination of both caspase-6 and -7 inhibitors for 1 hour prior to vincristine treatment for 
24 hours. Western blot results showed that hTERT was cleaved in the presence of vincristine 
after 24 hours and that z-VAD-fmk protected hTERT cleavage by caspases after vincristine 
treatment, which activates the intrinsic apoptosis pathway (Figure 4.4). More importantly, 
pre-incubation with a caspase-6 or -7 inhibitor alone only partially protected hTERT from 
caspase cleavage while preincubation with a combination of z-VEID-fmk and ac-DEVD-fmk 
prevented the majority of the proteolysis of hTERT (Figure 4.4).   
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Figure 4.4 hTERT is a caspase substrate in apoptotic cells.  (A) Schematic representation of proposed 
hTERT nexus in the apoptosis program. (B) Schematic representation of caspase activation and caspase-
mediated hTERT proteolysis via the intrinsic pathway.  Pro-apoptotic stimuli cause cytochrome c release from 
the mitochondria. Cytochrome c can then bind to the adaptor apoptotic protease activating factor-1 (Apaf-1), 
and form a large multiprotein structure known as the apoptosome. Initiator caspase-9 is then recruited into the 
apoptosome. Activated caspase-9 can then activate downstream effector caspases, such as caspases-3,  
-6, and -7. (C) hTERT caspase cleavage in the presence of different caspase inhibitors. Vincristine (50 nM) 
treated Jurkat cells for 24 hours resulted in hTERT cleavage. Pre-incubation of cells with a general caspase 
inhibitor, z-VAD-fmk, or with a combination of caspase-6 and -7 inhibitors, z-VEID-fmk and ac-DEVD-fmk, 
blocked cleavage of hTERT. Pre-incubation with caspase-6 inhibitor, z-VEID-fmk, or with caspase-7 inhibitor, 
ac-DEVD-fmk, alone only partially blocked hTERT proteolysis. Caspase inhibitors were used at a 
concentration of 100 μM 
 
 
 
Since hTERT was cleaved in apoptotic Jurkat cells and since specific caspase 
inhibitors protected hTERT from caspase proteolysis, we studied the effect of different 
apoptosis inducing agents in different cell lines in order to determine if hTERT was generally 
a caspase substrate in apoptotic cells. We incubated a human embryonic kidney cell line, 
HEK293T, and a human leukemic cell line, K562, with etoposide (50 μM) or with a 
mitochondrial depolarizing agent, carbonyl cyanide m-chlorophenylhydrazone, CCCP (50 
  109 
μM) for different time points and detected caspase cleavage of hTERT by western blot. We 
observed hTERT fragments with sizes comparable to the in vitro data, suggesting that 
hTERT is cleaved at the same residues in vitro and in cells. Interestingly, lane 4 of Figure 4.5 
showed an increase of full-length hTERT as compared to lanes 3 and 2, indicating that 
perhaps cells that did not go through apoptosis are proliferating and thus an increase in 
telomerase expression is observed.   
 
 
 
 
Figure 4.5 hTERT cleavage in HEK293T cells and K562 cells treated with apoptosis inducing agents. 
Cells were treated with or without CCCP (50 μM) for 1.5, 7, or 18 hours, analyzed by SDS-PAGE and 
immunoblotted for hTERT protein. HEK293T cells were also incubated with 50 μM etoposide (VP-16) for 24 
hours. hTERT proteolysis was assessed by western blot. -actin was used as a loading reference.  
 
 
 
5.  Identification of caspase cleavage sites in hTERT 
In order to more carefuly study the biological role of hTERT cleavage, caspase-
resistat hTERT mutants were required.  First, the sites of cleavage had to be determined.  As 
mentioned above, none of the peptide recognition motifs for caspases, based on the 
specificity profiles of caspases-6 and -7,
393
  were found in hTERT. Therefore, in order to 
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identify cleavage sites, we first analyzed the cleavage patterns of hTERT truncation mutants 
(hTERT fragments 1-927, 201-1132, and 401-1132). We found that hTERT was possibly 
cleaved at four different sites. Based on the truncation mutants, we speculated that one of the 
cleavage sites was between amino acids 100 and 200, another was between 250 and 400, and 
the other two were around amino acid 650. After establishing regions in which cleavage 
appeared to take place, we used a mutagenesis strategy in order to mutate possible cleavage 
residues to alanine and then analyzed their effect on caspase cleavage. hTERT mutants were 
cloned into pCR3.1 FLAG construct and immunopurified using anti-FLAG M2 affinity 
agarose beads and eluted with FLAG peptide. The purified hTERT mutants were incubated 
with caspases-6 or -7 to determine caspase resistant mutants. We identified aspartic acids 129 
and 637 as caspase-6 cleavage sites and aspartic acid 628 and glutamic acid 286 as cleavage 
sites for caspase-7 (Figure 4.6). Although caspases are thought to
 
selectively cleave after an 
aspartic acid residue, a notable
 
number of substrates are cleaved at tetrapeptide sites bearing
 
glutamic acid at the P1 position.
133
 Importantly, the same cleavage sites were observed when 
mutant hTERTs were allowed to assemble with hTR before caspase treatment, indicating that 
hTR doesn’t prevent hTERT cleavage by caspases.  
 
Figure 4.6 Proteolytic cleavage of hTERT by caspases-6 and -7 
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Since we wanted to introduce caspase resistant hTERT mutants into cells and 
examine their effect on apoptosis, we first needed to perform a telomerase assay in vitro to 
determine if the mutants were telomerase positive. In vitro reconstitution of telomerase was 
accomplished by expressing the hTERT mutants in RRL in the presence of in vitro 
synthesized and purified hTR. Activity of the hTERT mutant was tested using a direct 
telomerase assay that uses the incorporation of [-32P]-dGTP to visualize telomerase 
products. Caspase-6 resistant mutants, D129A, D637A, and D129A/D637A, were all 
telomerase positive only experiencing a slight decrease in telomerase activity as compared to 
wild-type (Figure 4.7, lanes 1-4). Caspase-7 resistant mutant, D628A, retained telomerase 
activity while E286A and the double mutant E286A/D628A were inactive (Figure 4.7, lanes 
5-7). The caspase-6 and -7 resistant mutant (D129A/D637A/E286A/D628A) was completely 
inactive of telomerase activity (Figure 4.7, lane 8).   
 
Figure 4.7 Telomerase activity of caspase-6 and -7 hTERT resistant mutants. Lane 1, wild-type hTERT; 
lane 2, D129A hTERT mutant; lane 3, D637A hTERT mutant; lane 4, D129A/D637A hTERT mutant; lane 5, 
E286A hTERT mutant; lane 6, D628A hTERT mutant; lane 7, E286A/D628A hTERT mutant; lane 8, 
D129A/D637A/E286A/D628A hTERT mutant. Wild-type hTERT and hTERT mutants were assembled with 
hTR and assayed for telomerase activity as described under materials and methods. Telomerase activity was 
determined by comparing each lane with WT hTERT (lane 1) and normalized using loading control (LC) band. 
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6. Caspase cleavage and telomerase activity of hTERT mutants in apoptotic cells  
In order to introduce hTERT resistant mutants into cells, we first needed to know if 
overexpression of telomerase affected caspase cleavage of hTERT. We, therefore, 
overexpressed wild-type hTERT and hTR into different cell lines and determined the 
concentration of CCCP required for telomerase cleavage. We observed that the cleavage of 
hTERT by CCCP was both dose and time dependent and that telomerase activity correlated 
with hTERT cleavage as 50 μM of CCCP treatment for 40 minutes resulted in a 25% 
decrease of telomerase activity while treatment for 24 hours resulted in almost a complete 
inhibition of telomerase (Figure 4.8). These results demonstrated that hTERT is still sensitive 
to caspase cleavage in cells overexpressing telomerase.  
 
Figure 4.8 Caspase cleavage and telomerase activity of overexpressed telomerase cells during CCCP 
treatment.  (A) hTERT cleavage of overexpressed telomerase cells in the absence or presence of CCCP (50 
μM) at different time points (40 minutes or 24 hours).  (B) Telomerase activity assay of overexpressed 
telomerase cells. Lane 1, DMSO was used instead of CCCP to serve as a control; Lane 2, cells treated with 
CCCP (50 μM) for 40 minutes; Lane 3, cells treated with CCCP (50 μM) for 24 hours. Telomerase activity 
was determined by comparing each lane with DMSO treated overexpressed telomerase cells (lane 1) and 
normalized using loading control (LC) band.  
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In order to introduce hTERT caspase resistant mutants into cells, we first cloned them 
into pVan107 construct and transiently transfected them in the presence or absence of hTR. 
Western blot showed that hTERT mutants capable of forming an active telomerase complex 
expressed more hTERT protein when transfected in the presence of hTR than inactive 
mutants (Figure 4.9). Conversely, the same amount of hTERT protein was observed when 
hTERT mutants were transfected in the absence of hTR, indicating that both exogenous 
hTERT and hTR are required in order to stabilize and overexpress the telomerase complex in 
transiently transfected cells.  
 
Figure 4.9 Western blot and telomerase activity assay of cells transfected with hTERT mutants and hTR.   
(A) K562 cell extracts expressing specific hTERT mutants were analyzed by SDS-PAGE and immunoblotted 
for hTERT as indicated under “Materials and Methods.”  (B) Telomerase activity of hTERT mutants.  Lane 1, 
wild-type hTERT; lane 2, D129A hTERT mutant; lane 3, E286A hTERT mutant; lane 4, D628A hTERT 
mutant; lane 5, D637A hTERT mutant; lane 6, D129A/D637A hTERT mutant; lane 7, E286A/D628A hTERT 
mutant; lane8, D129A/D637A/E286A/D628A hTERT mutant. 
 
 
 
To confirm that hTERT is cleaved at the same residues in vitro and in cells, we 
induced apoptosis in K562 cells transfected with hTERT mutants by adding 50 μM of CCCP 
for 1.5 hours and analyzed hTERT cleavage by western blot. Our results showed that only 
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the hTERT mutant (D129A/D637A/E286A/D628A) containing mutations in all caspase-6 
and -7 cleavage sites was resistant to proteolytic cleavage (Figure 4.10A). This result was 
expected since K562 cell line expresses both caspase-6 and caspase-7, therefore allowing 
caspase-6 resistant mutants to be cleaved by caspase-7 and caspase-7 resistant mutants to be 
cleaved by caspase-6. Interestingly, we also demonstrated that at 1.5 hours of CCCP (50 μM) 
treatment, both caspase-6 and -7 were activated, indicating that hTERT cleavage occurred 
concomitantly with caspase activation (Figure 4.10B). 
 
   
 
Figure 4.10 Western blots of hTERT cleavage and caspase activation.  (A) Proteolytic cleavage of hTERT 
mutants during induction of apoptosis by 50 μM CCCP (1.5 hours). (B) Caspase-6 and caspase-7 are activated 
at 1.5 hours of CCCP (50 μM) treatment.    
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Because hTERT caspase-6 resistant mutants were still cleaved in apoptotic cells due 
to the presence of caspase-7 and because hTERT caspase-7 resistant mutants were still 
cleaved due to the presence of caspase-6, we decided to generate caspase-6 knockdown cells 
and caspase-7 knockdown cells in order to prevent proteolytic cleavages by the other 
caspase. Both the double mutants D129A/D637A and E286A/D628A were resistant to 
cleavage in caspase-7 knockdown cells and caspase-6 knockdown cells, respectively (Figure 
4.11). Taken together, our results confirm that caspase-6 and caspase-7 are solely responsible 
for cleaving hTERT during apoptosis and between them, they can cleave at four different 
residues (D129, E286, D628, and D637).    
 
Figure 4.11 hTERT proteolytic cleavage in caspase-6 knockdown cells and in caspase-7 knockdown cells. 
(A) Caspase-6 knockdown K562 cells were confirmed by western blot. Cleavage products of caspase-7 resistant 
mutants were analyzed in caspase-6 knockdown cells after CCCP treatment (50 M for 1.5 hours). The double 
mutant E286A/D628A is resistant to caspase cleavage. (B) Caspase-7 knockdown K562 cells were confirmed 
by western blot. Cleavage products of caspase-6 resistant mutants were analyzed in caspase-7 knockdown cells 
after CCCP treatment (50 M for 1.5 hours). The double mutant D129A/D637A is resistant to caspase cleavage. 
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7. Effect of caspase resistant hTERT mutants on apoptosis threshold  
Several studies have demonstrated that expression of telomerase protects cells from 
apoptosis in a variety of cell lines.
307,359
 In addition, hTERT has been shown to have both 
pro-survival functions, thus rendering cells more resistant to apoptosis, as well as have pro-
apoptotic roles.
122-124,394,395
 It has been documented that overexpression of hTERT can 
increase telomerase activity in cells and extend cellular lifespan.
26,365,396
 Therefore, in order 
to investigate the effect of caspase resistant hTERT mutants on apoptosis threshold, we first 
needed to evaluate the effect of overexpressing only the protein subunit of telomerase, or 
only the RNA subunit, or the protein-RNA (hTERT-hTR) complex on drug induced 
apoptosis. We observed no significant difference in IC50 values or the percentage of apoptotic 
cells after three days treatment with CCCP between cells transfected with an empty vector 
(negative control), or with hTERT plasmid only, or with hTR plasmid only, or with hTERT 
and hTR plasmids (IC50 values were ~44, ~28, ~22, and ~34 M, respectively) (Figure 
4.12A). Furthermore, only cells transfected with both hTERT and hTR plasmids 
overexpressed telomerase as detected by the direct telomerase assay (Figure 4.12B). Thus, 
indicating that unlike long term overexpression of telomerase, perhaps transient expression of 
hTERT or transient overexpression of telomerase in cancer cells is not sufficient to protect 
cells from apoptosis.   
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Figure 4.12 Dose response curves of K562 cells and telomerase activity assay. (A) Dose response curves of 
K562 cells transfected with empty vector (red line), with hTERT only (purple line), with hTR only (blue line), 
or with hTERT-hTR (green line). (B) Telomerase activity assay. Lane 1, K562 cells transfected with hTERT-
hTR; lane 2, K562 cells transfected with empty vector; lane 3, K562 cells transfected with hTERT plasmid 
only; lane 4, K562 cells transfected with hTR only.  
 
 
 
We next transiently transfected K562 cells with wild-type hTERT or with the 
different caspase resistant hTERT mutants in the presence or absence of hTR and evaluated 
the effect of hTERT mutants on cell viability after CCCP treatment. Based on our results, we 
observed that cells expressing either D628A or D637A hTERT mutants resulted in resistance 
to apoptosis as compared to cells overexpressing wild-type hTERT (Figure 4.13). 
Additionally, mutation at aspartic acid 129 caused cells to be even more sensitive to 
apoptosis than wild-type hTERT (Figure 4.13). Perhaps, mutation at site 129 affects the 
translocation and localization of hTERT to the mitochondria. hTERT is known to contain a 
mitochondrial localization signal peptide located at the first 20 amino acids at its N-terminal 
region, which targets hTERT to the mitochondria.
121
 Some studies have shown that hTERT 
has a pro-apoptotic role in the mitochondria
118,122
 while other groups have suggested that 
mitochondrial hTERT can inhibit apoptotic processes.
123,395
 On another note, the fact that the 
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hTERT mutant containing mutations at every caspase cleavage site rendered cells more 
resistant to apoptosis (Figure 4.13) indicates that cell viability in this experiment was directly 
related to hTERT and the ability of caspases to cleave hTERT during apoptosis. 
Interestingly, similar results were obtained when hTERT and mutant hTERTs were 
transfected in the absence of hTR, thus suggesting that overexpression of telomerase activity 
or ability of mutants to form an active telomerase complex did not affect cell viability during 
CCCP treatment.  
 
 
Figure 4.13 Caspase resistant mutants on CCCP induced apoptosis. Cells were transfected with WT hTERT 
(red columns), D129A mutant (green columns), E286A mutant (blue columns), D628A (purple columns), 
D637A (maroon columns), D129A/D637A (pink columns), E286A/D628A (brown columns), or with 
D129A/E286A/D628A/D637A (black columns) and were treated with CCCP (50 M) for 72 hours. Cell 
viability was then determined using the MTT assay as described under “Materials and Methods.” Results 
represent the mean  SEM of three independent experiments performed in triplicates. Statistical significance: P-
values are ( ) P<0.05, ( ) P<0.01, and ( ) P<0.001 for cells transfected with resistant mutants versus WT 
hTERT. P-values <0.05 were considered significant. 
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To verify that telomerase and therefore hTERT were in the same pathway and 
downstream of caspase activation, we expressed caspase-6 resistant hTERT mutants in 
caspase-7 knockdown cells and caspase-7 resistant hTERT mutants in caspase-6 knockdown 
cells and analyzed cell viability after CCCP treatment for 72 hours. We observed that cells 
overexpressing wild-type hTERT were more sensitive to CCCP induced apoptosis than 
caspase resistant mutants in both caspase-7 knockdown cells and in caspase-6 knockdown 
cells (Figure 4.14 and 4.15). In caspase-6 knockdown cells, we demonstrated that both the 
double mutant E286A/D628A and the D129A/E286A/D628A/D637A mutant were 
significantly more resistant to apoptosis than wild-type hTERT, suggesting that lack of 
caspase cleavage protects cells from apoptosis (Figure 4.14). It is also significant to note that 
although D628A hTERT mutant was slightly more resistant to apoptosis than E286A mutant 
in caspase-6 knockdown cells, statistical analysis showed no significant difference between 
them (Figure 4.14B). This result was contradictory to the results found for wild-type K562 
cell line, which showed a statistically significant difference in cell viability between the 
D628A and E286A mutants at varying concentrations of CCCP (Figure 4.14A). Perhaps this 
is due to the fact that D628A mutant can only be cleaved at E286 site in caspase-6 
knockdown cells instead of D129, E286, and D637 sites in wild-type K562 cell line and 
E286A mutant can only be cleaved at D628 site in caspase-6 knockdown cells instead of 
D129, D628, and D637 residues in wild-type K562 cells thus implying that hTERT 
proteolytic fragments have different effects on apoptosis. Moreover, one could speculate that 
caspases could have a preference for cleaving at one site over another or that cleavage at one 
site could be preceded by cleavage at another site. We also observed that E286A mutant was 
significantly more resistant to apoptosis as compared to cells transfected with WT hTERT in 
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caspase-6 knockdown cells than in wild-type K562 cells (Figure 4.14), indicating that 
caspase cleavage at only one residue (D628) might not be as efficient in inducing apoptosis 
as compared to cleavage at multiple sites.   
In caspase-7 knockdown cells both the double mutant resistant to caspase-6 cleavage, 
D129A/D637A, as well as the hTERT mutant containing mutations at every caspase cleavage 
site (D129A/E286A/D628A/D637A) protected cells considerably from CCCP induced 
apoptosis as compared to cells overexpressing wild-type hTERT (Figure 4.15B). These 
results further validate the hypothesis that caspases cleave hTERT as part of the apoptosis 
pathway. Interestingly, as opposed to our results observed in the WT K562 cells, the D129A 
mutant was notably more resistant to apoptosis than cells overexpressing WT hTERT (Figure 
4.15A-B). One explanation for this could be that although cleavage at D129 could have pro-
survival functions, which means that the D129A mutant is resistant to such cleavage, D129A 
is still undergoing multiple proteolytic cleavages by caspases-6 and -7 in WT K562 cells 
while only cleavage at aspartic acid 637 (generating only two fragments 1-637 and 637-
1132) is accessible in D129A mutant in caspase-7 knockdown cells.  It is possible that 
hTERT might need to be cleaved at more than one site in order to have a significant impact 
on the apoptosis process by either preventing the formation of the telomerase holoenzyme 
complex, by generating apoptotic fragments, or by becoming dysfunctional.   
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Figure 4.14 Caspase-7 resistant mutants on CCCP induced apoptosis. (A) Caspase-7 resistant mutants were 
transfected in WT K562 cell line and treated with CCCP (50 M) for 72 hours. (B) Caspase-7 resistant mutants 
were transfected in caspase-6 knockdown K562 cells and treated with CCCP (50 M) for 72 hours. WT hTERT 
(red columns), E286A mutant (blue columns), D628A (purple columns), E286A/D628A (brown columns), 
D129A/E286A/D628A/D637A (black columns). Cell viability was determined after 72 hrs of treatment using 
the MTT assay. Results represent the mean  SEM of three independent experiments performed in triplicates. 
Statistical significance: P-values are ( ) P<0.05, ( ) P<0.01, and ( ) P<0.001 for cells transfected with 
caspase-7 resistant mutants versus WT hTERT. P-values are (
#
) P<0.05, (
# #
) P<0.01, and (
# # #
) P<0.001 versus 
E286A mutant. P-values <0.05 were considered significant. 
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Figure 4.15 Caspase-6 resistant mutants on CCCP induced apoptosis. (A) Caspase-6 resistant mutants were 
transfected in WT K562 cell line and treated with CCCP (50 M) for 72 hours. (B) Caspase-6 resistant mutants 
were transfected in caspase-6 knockdown K562 cells and treated with CCCP (50 M) for 72 hours. WT hTERT 
(red columns), D129A mutant (green columns), D637A (maroon columns), D129A/D637A (pink columns), 
D129A/E286A/D628A/D637A (black columns). Cell viability was determined after 72 hrs of treatment using 
the MTT assay. Results represent the mean  SEM of three independent experiments performed in triplicates. 
Statistical significance: P-values are ( ) P<0.05, ( ) P<0.01, and ( ) P<0.001 for cells transfected with 
caspase-6 resistant mutants versus WT hTERT. P-values are (
#
) P<0.05, (
# #
) P<0.01, and (
# # #
) P<0.001 versus 
D129A mutant. P-values <0.05 were considered significant. 
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C.  Discussion 
Telomerase activity is high in many cancer cell types supporting the role of 
telomerase in retaining cancer cells in an immortal state.
397
 In addition to telomerase’s main 
role in maintaining telomere length, telomerase is also believed to have anti-apoptotic roles 
beyond the chromosome ends. Studies have shown that cancer cells that are resistant to 
apoptosis have relatively high levels of telomerase activity and that tumor cells undergoing 
apoptosis experience a decrease in telomerase activity.
360,398
  Notably, TERT plays a role in 
the anti-apoptotic action of telomerase as overexpression of TERT resulted in decreased 
vulnerability to apoptosis, while suppression of TERT with antisense oligonucleotides 
promoted apoptosis.
127,360,361,399,400
 Inhibition of hTERT by antisense strategies can induce 
short-term apoptosis, without affecting telomere length, thus implicating that inhibition of 
telomerase affects cell survival through pathways independent of telomere erosion.
27,28,401
  
Evidence suggests that there are mechanisms for suppressing telomerase activity 
downstream of hTERT transcription and mRNA splicing. It has recently been recognized that 
alternative splicing of hTERT mRNA, a post-transcriptional mechanism, is actively involved 
in the regulation of telomerase activity in both normal and malignant human tissues.
376,402-404
 
In human malignant cells, the vast majority of hTERT variants are non-functional or even 
dominant-negative while less than 10% of them are full-length transcript.
405,406
 Many types 
of normal tissues and cells only express the spliced variants of hTERT mRNA.
402,404
 Perhaps 
some of the observed hTERT variants could be in part a result of caspase activation and 
cleavage of TERT in order to maintain cell homeostasis. In this study, we investigated if 
telomerase is regulated by caspases, the main executioners of apoptosis. Cysteine proteases 
of the caspase family play fundamental roles in coordinating various structural and functional 
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changes that occurs during the apoptotic pathway. Many proteins are substrates for caspases, 
and their cleavages can potentially impact the cell death process. Here, we showed for the 
first time that hTERT, the catalytic subunit of telomerase, is a caspase-6 and -7 substrate in 
vitro and in apoptotic cancer cells. We also showed that caspase inhibitors (a general caspase 
inhibitor, a caspase-6 inhibitor and a caspase-7 inhibitor) protected telomerase from 
proteolytic cleavage in cells undergoing apoptosis. We further demonstrated that hTERT can 
be cleaved at four different sites; two sites were caspase-6 dependent (D129 and D637) and 
two sites were caspase-7 dependent (E286 and D628). Though caspases were thought to 
selectively cleave after an aspartic acid residue, studies are showing a growing number of 
substrates that get cleaved after a glutamic acid residue.
133
 Our experiments performed in 
K562 apoptotic cells, further validated the direct correlation between hTERT cleavage and   
caspase-6 and -7 activation. Moreover, the fact that the double mutant resistant to caspase-6 
cleavage (D129A/D637A) was resistant to proteolytic cleavage in caspase-7 knockdown cells 
and the fact that the double mutant resistant to caspase-7 cleavage (E286A/D628A) was 
resistant to caspase cleavage in caspase-6 knockdown cells, supported our previous findings 
that caspases-6 and -7 were solely responsible for telomerase cleavage during apoptosis.   
Caspases selectively target specific biochemical pathways, including substrates that 
regulate DNA repair and block apoptosis, and can generate a unique set of stable protein 
fragments possessing new functionality within the dying cell.
407,408
 Recently, it has been 
suggested that more than one-third of proteolytic fragments generated by caspase cleavage 
are stable for at least four hours in cells that died after six hours of apoptotic stimulation.
409
 
This was in contrast to the alleged notion that cleaved caspase substrates were rapidly 
degraded. A substantial portion of caspase substrates are cleaved into domain-containing 
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fragments, thus suggesting that physical separation of functional domains can lead to protein 
inactivation, production of dominant negative fragments, or the yield of protein fragments 
with new activities.
409,410
 Here, we showed that aspartic acid 129, which is located in motif 
GQ of the highly conserved N-terminus, is one of the sites cleaved by caspases. The GQ 
motif contains residues and subregions that are critical for in vitro telomerase activity in 
Tetrahymena, S. cerevisiae and human, and are implicated in telomerase RNA-binding by 
hTERT.
50,411,412
 Small deletions within the GQ motif resulted in a 10-15% reduction in hTR 
binding.
50
 hTERT truncation and deletion analysis also suggested that the GQ motif is not 
required for functional multimerization of hTERT molecules.
50,57
 Additionally, some 
mutations in the GQ motif of hTERT cause the uncoupling of in vitro telomerase activity and 
in vivo telomere length maintenance, suggesting that the GQ motif may be involved in 
interactions with proteins that regulate the proper subcellular and telomeric localization of 
telomerase.
411
 Caspase cleavage at residue 129, results in a fragment containing the extreme 
N-terminus and a DAT (dissociates activities of telomerase) domain, which is required for 
telomere length maintenance but not catalytic activity.
50,411
 Moreover, the mitochondrial 
localization leader sequence of hTERT is located in the first 20 amino acids of its N-
terminus.
121
 Contradictory results have been documented regarding hTERT’s role in 
mitochondria, some reports suggest that hTERT has a pro-apoptotic role in the 
mitochondria
118,122
 while others suggest that mitochondrial hTERT can inhibit apoptotic 
processes.
123,395
 Our results suggest that mutation at aspartic acid 129 caused cells to be even 
more sensitive to apoptosis than wild-type hTERT. Perhaps, mutation at site 129 affects the 
translocation and localization of hTERT to the mitochondria. Thus suggesting that hTERT 
N-terminal proteolytic fragment (1-129) could possibly have anti-apoptotic functions when 
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exported from the nucleus. Another possibility is that mutation at aspartic acid 129, which 
prevents cleavage at this site, allows for the mitochondrial localization leader sequence to 
remain associated with hTERT thus allowing hTERT translocation to the mitochondria 
consequently enhancing apoptosis. Taken together, both nuclear as well as mitochondrial 
TERT play important roles in apoptotic processes,
121,122,395
 though further elucidation is 
required.  
Another caspase cleavage site in the N-terminus of hTERT is glutamic acid 286, 
which is located in the QFP motif. The QFP motif has been shown to be implicated in 
telomerase RNA binding and functional multimerization with other TERT proteins.
44,50,57
 We 
showed that mutation of glutamic acid 286 to alanine completely inhibited telomerase 
activity both in vitro and in cells suggesting that this residue is crucial for telomerase stability 
and activity, possibly due to its importance in RNA binding. Other hTERT caspase cleavage 
sites identified were aspartic acids 628 and 637, which are surrounded by highly conserved 
residues between different TERT species. Both residues are located in the reverse 
transcriptase (RT) domain where D628 is located at the end of motif 1 and D637 is located in 
motif 2. The RT domains of TERT are essential for catalytic activity but they are not 
sufficient for high-affinity binding of the RNA components of Tetrahymena and human 
telomerases.
44,57
 Our results showed that introducing either D628A or D637A hTERT 
mutants to K562 cells resulted in resistance to apoptosis as compared to cells overexpressing 
wild-type hTERT or cells overexpressing D129A or E286A mutants. Perhaps cleavage at one 
of these RT residues is preferred by caspases instead of cleavage at the N-terminal residues, 
or perhaps D628 or D637 cleavage is more detrimental to hTERT and thus telomerase and 
cell viability. Importantly, the fact that the hTERT mutant (D129A/E286A/D628A/D637A) 
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resistant to both caspase-6 and -7 cleavage was significantly more resistant to apoptosis as 
compared to cells transfected with WT hTERT, indicates that cell viability is directly 
correlated to TERT cleavage independently of telomerase activity since the 
D129A/E286A/D628A/D637A mutant is incapable of forming an active telomerase complex.  
Caspase activation can be both cell type- and insult-dependent. Caspase-6 has been 
shown to be implicated in human neuronal apoptosis and to have a role in Alzheimer’s 
disease.
413-415
 Caspase-6 proenzyme is detected in human adult brain tissue and the active 
p10 fragment is detected in Alzheimer’s disease (AD) brain.415 Here we suggest that caspase-
6 may cleave hTERT in neurodegenerative diseases. Mounting evidence suggests that there 
is a link between neuronal telomere length and telomerase activity and neurodegenerative 
disorders.
416,417
 A decrease in telomere length in AD brains has been associated with decrease 
in telomerase expression.
417-419
 Importantly, though telomerase (hTERT) is not detected 
easily after development, studies have shown that hTERT levels are higher in nuclei of 
pyramidal neurons in control cases compared with AD cases.
420
 Since caspase-mediated 
cleavage of critical proteins contributes to neuronal degeneration in AD, and since caspase-6 
is the principle caspase involved in AD pathogenesis, one can speculate that the decrease in 
hTERT levels and the loss of nuclear localization of TERT in AD is due to proteolytic 
cleavage of hTERT by caspase-6. Although neurons do not require TERT for replication, 
TERT has been shown to prevent cell death and promote survival in many cell types 
including neurons.
127,360,398
 For example, TERT has been implicated to protect against 
neuronal apoptosis induced by ischemic brain injury.
370,421
 The presence of TERT in post-
mitotic neurons suggests that its anti-apoptotic function may be independent of maintenance 
of chromosome ends.
420
 Though telomerase activation and repression is a factor in 
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tumorigenesis, telomerase activation could be further implicated in degenerative diseases.
417
 
Our results provide a basis for further studies linking neuronal damage, telomere 
deterioration, caspase activation, and TERT cleavage. Taken together, caspase cleavage of 
hTERT could have both beneficial, as is the case in cancer cells, as well as detrimental 
consequences, as is the case in neurodegenerative disorders.  
 
 
D. Materials and Methods 
1. Materials 
The following antibodies were used: anti-rabbit anti-hTERT (Abcam), anti-caspase-6 
(Cell Signaling), anti-caspase-7 (Cell Signaling), and anti-β-actin antibody (Sigma, St. Louis, 
MO). The peptides z-VAD-fmk, z-VEID-fmk, and ac-DEVD-fmk were purchased from 
Calbiochem. Carbonyl cyanide m-chlorophenylhydrazone (CCCP), Etoposide (VP-16), and 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] were purchased from 
Sigma-Aldrich. Active recombinant caspases (caspases-1, -2, -3, -4, -5, -6, -7, -8, -9, and -10) 
were from BioVision.  
 
2. Cells and cell culture 
The human leukemia cell line K562 (telomerase positive, from ATCC) was cultured 
in Dulbecco's
 
modified Eagle/F12 medium (DMEM/F12) (Gibco) supplemented with 10% 
FBS. The highly transfectable human embryonic kidney cell line HEK293T (telomerase 
positive, from ATCC) was cultured in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% FBS. The peripheral T-cell leukemia cell line, Jurkat, were 
maintained in RPMI 1640 supplemented with 10% FBS. 
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3. Proteolytic cleavage reactions in vitro 
Flag-tagged hTERT and flag-tagged hTERT-hTR complex were immunopurified as 
described below and incubated (10 µL) with caspase buffer (50 mM Hepes, pH 7.2, 50 mM 
NaCl, 0.1% CHAPS, 10 mM EDTA, 5% glycerol, and 10 mM DTT) and 1 unit of  a specific 
caspase (caspase-1, -2, -3, -4, -5, -6, -7, -8, -9, or -10) for 6 hours at 37 °C. A general caspase 
inhibitor (10 µM), z-VAD-fmk, was pre-incubated with caspase 7 for 30 min prior to 
inbubation with flag-tagged hTERT-hTR complex in order to ensure that telomerase 
cleavage was related to caspase and not unspecific degradation over time. The reaction 
products were analyzed by SDS-PAGE and exposed to a phosphorimager screen. To identify 
caspase cleavage site of hTERT in vitro, we selectively altered residues at potential cleavage 
sites to alanine based on the Stratagene QuickChange site-directed mutagenesis protocol. The 
resulting hTERT mutations were verified by DNA sequencing. 
35
S-labeled hTERT mutants 
were immunopurified and incubated with caspase buffer and 1 unit of caspase-6 or -7 for 1 
hour to determine whether the hTERT mutants were resistant to caspase proteolysis. The 
reaction products were analyzed as above.  
 
4. Immunopurification 
Flag-tagged hTERT was immunoprecipitated with anti-FLAG M2 affinity agarose 
beads (Sigma-Aldrich, St. Louis, MO). Prior to use, beads (50 µL) were washed four times in 
400 µL of 1xTris IP buffer (10 mM Tris-Cl, pH 7.5, 100 mM KCl, 1 mM MgCl2, 10% 
glycerol, 0.1 mM DTT), centrifuging at 1500 x g for 2 min between washes. Reticulocyte 
lysate translation reaction (45 µL) was added to 450 µL of 1xTris IP buffer and centrifuged 
at 16,000 × g for 15 min at 4 °C to remove any particulates. The supernatant was added to 
beads and allowed to nutate at 4 °C for 2 hours. The beads were washed six times in 400 µL 
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1×Tris IP buffer centrifuging at 1500 × g for 2 min between washes and resuspended in 20 
µL 1×Tris IP buffer. Beads were transferred to a Protein LoBind tube (Eppendorf) and 
washed once with 500 µL TMG (10 mM Tris acetate, pH 8, 1 mM MgCl2 , 10% glycerol) 
centrifuging at 1500 × g for 2 min. BSA (3 µL of 10 mg/ml) was added to the beads to 
prevent protein from sticking to the tubes.  50 µL of peptide solution [41 µL TMG, 9 µL 
FLAG peptide (5 mg/ml)] was added to the beads and nutated at 4 °C for 1 hour. FLAG 
peptide (5 mg/ml) was prepared by adding 3×FLAG peptide (Sigma-Aldrich) to 20 mM Tris 
acetate, pH 7.5. The beads were centrifuged at 1500 × g for 2 min and the eluent was 
removed and added to a fresh LoBind tube.  
 
5. Telomerase activity of cell extracts (TRAP assay) 
 Telomerase activity in cell extracts was determined by a modified telomere repeat 
amplification protocol (TRAP assay).
355
  In brief, cell lysates were prepared from 4  104 
cells in 100 L of lysis buffer (10 mM Tris, pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.1 mM 
benzamidine, 0.5 mM -mercaptoethanol, 0.5% CHAPS, 10% glycerol) by incubating the 
suspended cells on ice 30 min followed by three freeze thaw cycles using liquid N2 to freeze 
the samples. Cell lysates were clarified by centrifugation (10,000 × g, 30 min at 4 ºC), and 
protein levels in the cell extracts were determined by the method of Bradford.
356
  Cell 
extracts (100 ng of total protein) were incubated with 0.1 g TS primer (5′-
AATCCGTCGAGCAGAGTT) in a 25 l reaction containing TRAP buffer (20 mM Tris-
HCl, pH 8.3, 1.5 mM MgCl2, 63 mM KCl, 0.05% Tween20, and 1 mM EGTA) and 50 M of 
each dNTP at 30 ºC for 30 min. Telomerase extension reactions were then heated to 95 ºC for 
5 min before the products were amplified by adding 0.1 g ACX primer (5′-
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GCGCGG(CTTACC)3CTAACC), 0.1 g NT primer (5′-ATCGGCTTCTCGGCCTTTT),  
0.001 amol TSNT template (5′-
AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCGAT, used as a PCR and loading 
control), 0.5 units HotMaster Taq DNA polymerase (Eppendorf), 5 l of 10 Taq buffer, and 
dNTPs to a final concentration of 50 M.  The reactions were then subjected to 33 PCR 
cycles at 95 ºC for 30 s, 60 ºC for 30 s, 72 ºC for 60 s.  Reaction products were separated on a 
12.5% nondenaturing polyacrylamide gel, stained with SYBR Green I (Molecular Probes), 
and imaged on a phosphorimager.  Reactions were quantified using ImageQuant and the 
product intensity for each reaction was normalized to the TSNT internal standard. 
 
6. Flow cytometry 
Apoptosis was measured using the annexin V-FITC apoptosis detection kit from 
BioVision (USA). Conformational changes of the membrane by phosphatidylserine 
translocation and membrane hole formation were observed by counting the percentages of 
cells that were stained with fluorescein isothiocyanate (FITC)- labeled annexin V and 
propidium iodide (PI) in a FACSCalibur flow cytometer (Becton Dickinson). Briefly, cells 
were plated in 6 well plates before drug treatment. Cells (5 x 10
5
 to 10 x 10
5
) were cultured 
with or without vincristine (1 M) for different time points. In some experiments, the general 
caspase inhibitor z-VAD-fmk (5 μM) was added to cells (one well) 1 hour prior to vincristine 
treatment. Cells were centrifuged at 350 x g for 2 min and washed with PBS. Cells were 
resuspended with 500 μl of 1 x binding buffer, 5 μl of annexin V-FITC and 5 μl of propidium 
iodide. Cells were incubated for 5 min at room temperature in the dark. 10,000 cells were 
analyzed in the FACSCalibur instrument. The data obtained were processed by quadrant 
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population analysis, using CellQuest software (Becton Dickinson). The living cell population 
was determined by counting cells that were negative for both annexin V and PI (distributed 
in the lower left of the quadrant). Cells stained for annexin V only (early apoptotic) and cells 
stained for both annexin V and PI (late apoptotic) were combined and classified as apoptotic 
cells, and cells stained for PI only were classified as dead cells. Experiments were performed 
3 times to obtain a mean  SEM for n=3.   
 
7. Induction of Apoptosis and Immunoblotting 
HEK293T cells and K562 cells were incubated with or without CCCP (50 μM ) or 
etoposide (50 μM) for various time points. Jurkat cells were incubated with vincristine (50 
nM) for 24 hours. In the caspase inhibitor experiments, Jurkat cells were untreated or treated 
with 100 μM of specific caspase inhibitors (z-VAD-fmk as a general caspase inhibitor, ac-
DEVD-fmk as a caspase-7 inhibitor, and z-VEID-fmk as a caspase-6 inhibitor) (Calbiochem) 
for 1 hour prior to treatment with vincristine. Cells were lysed using CHAPS lysis buffer (10 
mM TrisHCl pH 7.5, 1 mM MgCl2, 1 mM EGTA, 0.5 % CHAPS, 10 % glycerol, 
supplemented before use with protease inhibitor cocktail III (Calbiochem) and 5 mM β-
mercaptoethanol). hTERT cleavage products were analyzed by immunoblotting using an 
anti- hTERT antibody (1:1000 dilution).  
 
8. In vitro transcription and translation of hTERT and reconstitution of telomerase 
35
S-labeled full length human flag-tagged hTERT was transcribed and translated from 
pCR3.1-Flag-hTERT using the TNT T7 Coupled Rabbit Reticulocyte Lysate Systems Kit 
(Promega) according to the manufacturer’s instructions. The expression construct for Flag-
hTERT as well as hTERT truncation mutants (1-927, 201-1132, and 401-1132) were a gift 
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from Dr. Lea Harrington (University of Toronto). Wild-type hTR was in vitro transcribed 
and purified as previously described
233
 except that the Ampliscribe T7 Transcription Kit was 
used (Epicentre Technologies). A typical 400 µL reaction contained 8 µg of pCR3.1-Flag-
hTERT, 16 µL of [
35
S]-methionine (1175 Ci/mmol, 10 μCi/μl; Perkin-Elmer), and other 
components provided in the kit as described by the manufacturer. 
35
S-labeled flag-tagged 
hTERT was also transcribed and translated in the presence of in vitro transcribed hTR in 
order to reconstitute human telomerase. This was accomplished by adding 4 µg of in vitro 
transcribed and purified hTR to the 400 µL reaction described above. 
 
9. Direct telomerase assay 
To measure activity of recombinant telomerase, we utilized a previously described 
direct assay.
233
  Each reaction contained 50 mM Tris-HCl, pH 8.0, 50 mM KCl, 1 mM 
MgCl2, 5 mM -mercaptoethanol, 1 mM spermidine, 1 M human telomere primer (5'-
TTAGGGTTAGGGTTAGGG), 0.5 mM dATP, 0.5 mM dTTP, 2.9 M dGTP, 0.33 M [-
32
P]-dGTP (3000 Ci/mmol, 10 μCi/μL; Perkin Elmer), and 10 μL of pre-assembled 
telomerase in RRL, 10 μL of each pre-assembled mutant telomerase, or 10 μL of super-
telomerase extract.  Primer extension was carried out at 30 ºC for 90 min.  After the addition 
of a 
32
P-labeled loading control (114 nucleotide, 5′-end labeled DNA oligonucleotide, 1000 
cpm per reaction), the primer extension products were extracted with phenol/ 
chloroform/isoamyl alcohol and ethanol precipitated in the presence of 0.6 M NH4OAc and 
35 ng/μL glycogen.  Products were concentrated by ethanol precipitation and dissolved in a 
formamide loading buffer containing 40% formamide, 10 mM Tris-HCl, pH 8.0, 10 mM 
EDTA, 0.05% xylene cyanol, and 0.05% bromophenol blue.  The products were heated at 95 
ºC for 5 min and resolved on a pre-warmed, 0.4 mm thick, 20 x 20 cm, 10% 
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polyacrylamide/7 M urea/1 TBE gel.  A small amount of the human telomere primer was 
labeled with [-32P]-ATP and T4 polynucleotide kinase (Fisher) and loaded in a separate lane 
to be used as a marker for the start of primer elongation.  After drying the gel and exposing it 
to a phosphorimager screen (Molecular Dynamics) overnight, telomerase products were 
imaged using a phosphorimager (Molecular Dynamics Storm 860) and quantified with 
ImageQuant (version 5.2).  The intensities of each band in each sample were summed and 
normalized to the loading control.  
 
10. Transient expression of telomerase  
HEK293T cells or K562 cells were transfected with 4 μg of plasmid DNA using 
Lipofectamine 2000 (Invitrogen) in 6-well plates following manufacturer’s protocol. The 
optimal mass ratio of hTERT- and hTR- expressing plasmids is 1:5 (0.66 μg pVan107 and 
3.33 μg pBS-U1-hTR). Cells were also transfected with empty vector, hTERT or mutant 
hTERTs expressing plasmids only, or with hTR expressing plasmid only. One day post 
transfection, cells were trypsinized, transferred to a 25 cm
2
 flask, and grown one more day. 
Forty-eight hours post-transfection, cells  were detached by trypsinization, washed once in 
PBS and lysed in 400 μl of CHAPS lysis buffer (10 mM TrisHCl pH 7.5, 1 mM MgCl2, 1 
mM EGTA, 0.5 % CHAPS, 10 % glycerol, supplemented before use with protease inhibitor 
cocktail III (Calbiochem) and 5 mM β-mercaptoethanol). After incubation at 4 °C for 30 min 
on a rotating wheel, cell debris was removed by spinning down extracts at 4 °C for 10 min at 
13000 × g. The supernatant (~ 4 mg/ml) was aliquoted, quick frozen in dry ice and stored at -
80 °C. For inhibition experiments, cells were treated with CCCP (50 μM) fourty-eight hours 
post-transfection for the desired time points and lyzed as above or treated with different 
concentrations of CCCP for 72 hours followed by the MTT assay.  
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11. Generation of stable caspase-6 and caspase-7 knockdown cell lines 
K562 cells were plated in six-well plates and infected with different shRNA-lentiviral 
vectors produced by the 293T cell line. Briefly, 1 ml virus stock (obtained from UNC Viral 
Vector Core Facility, UNC-CH) was thawed and added to each well in the presence of 1 L 
of 10 mg/ml polybrene (Sigma-Aldrich). The virus-containing medium was removed after 6 
hours incubation at 37 
o
C and changed to 2 ml growth medium for an additional 24 hours. 24 
hours after transduction, cells were transferred to 75 cm
2
 flasks and grown under selection 
medium (growth medium containing 12 g/ml puromycin; Invitrogen, San Diego, CA). 
Cultures were grown to confluence and knockdown of caspase-6 or -7 was detected by 
western blot (anti-caspase-6 or anti-caspase-7, cell signaling). K562 transfected with shGFP 
were used as control. Lentivirus for caspase-6 and caspase-7 were produced by the UNC 
Viral
 
Vector Core Facility.  
 
12. Western-blot analysis 
Approximately 50-100 μg of proteins was loaded into each well, separated by SDS-
PAGE, and transferred to a nitrocellulose membrane. After blocking with non-fat dry milk 
(5% w/v) in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 1 hour, the 
membrane was incubated with primary antibody for hTERT (Abcam), caspase-6 (Cell 
Signaling), or caspase-7 (Cell Signaling) for 1 hour at room temperature. After sufficient 
washing, the membrane was incubated with HRP-conjugated anti-rabbit secondary antibody 
(BD biosciences) for 1 hour at room temperature. Blots were developed using the ECL 
chemiluminescence detection reagent (Amersham Bioscience). The membranes were then 
reprobed with β-actin antibody (Sigma, St. Louis, MO) as loading reference. 
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13. Cell Viability, MTT assay 
The [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide, Sigma-Aldrich) 
MTT assay is based on the cleavage of the yellow dye MTT to purple formazan crystals by 
mitochondrial dehydrogenases; this conversion only occurs in viable cells.  MTT was 
dissolved in phosphate-buffer saline (PBS, pH 7.4) at a concentration of 5 mg/ml and stored 
at 4 °C in the dark.  Cells were seeded on a 96-well microplate 24 hours before drug 
treatment to allow cells to attach to the wells.  The cells were then incubated with or without 
CCCP (50 μM) for 72 hours at 37 °C, 5% CO2. After 72 hours incubation, 10 μL of MTT 
solution (5 mg/ml) was added to each well and incubated for 3 hours. Formazan crystals 
(MTT metabolic product) were then dissolved in 20% SDS/50% DMF solution overnight at 
37° C. Absorbance was measured with a microplate reader at a test wavelength of 570 nm 
and a reference wavelength of 655 nm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
Cancer is the third leading cause of death worldwide, only preceded by heart disease 
and infectious diseases.
422,423
 According to the National Center for Heath Statistics, the 
cancer death rate is about 200 deaths a year per 100,000 people of all ages and 1,000 deaths 
per 100,000 people over age 65.
424,425
 Although more people die of heart disease, cancer 
deaths have been edging closer to heart disease deaths each year.
424
 Although billions of 
dollars are invested in cancer research annually, including cancer prevention, control, and 
treatment, the world continues to suffer from unacceptably high rates of the disease. As a 
result, there is a strong need for new and improved anticancer therapies. Most cancer 
research and existing treatments focus on targeting a specific type of cancer, thus limiting 
their therapeutic potential. Identifying and exploiting biological targets that are universal to 
and specific for cancer cells has proven to be an arduous task in the development of new anti-
cancer therapies. A commonality between different cancers however, has been identified. 
Over the past few years, there has been a growing and considerable interest in telomerase, an 
enzyme that is observed in approximately 90% of all cancers, as a target for therapeutic 
intervention in oncology.  
It is well established that expression of telomerase alone is sufficient to elongate and 
maintain telomere length in cancer cells thus leading to cellular immortalization.
26,358
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Besides telomerase role in cancer cells, telomerase is also necessary for the long-term 
proliferation potential of stem cells and for normal tissue renewal.
19,351,394,426,427
 Telomere 
shortening has been shown to correlate with organism aging, and it is intensified in human 
diseases associated with mutations in telomerase, such as aplastic anemia, dyskeratosis 
congenita, and idiopathic pulmonary fibrosis.
19
 People suffering from these diseases, as well 
as telomerase RNA (TR)-deficient mice, show decreased lifespan coincidental with a 
premature loss of tissue renewal, suggesting that telomerase is rate-limiting for tissue 
homeostasis and organism survival.
19,23,84
 Additionally, telomere shortening is accelerated in 
other human diseases associated with aging, such as atherosclerosis, cardiovascular disease, 
diabetes, and infections.
119,428
 Though telomerase was previously believed to have a sole role 
in elongating and maintaining telomeres, increasing evidence implicates that telomerase has 
purposes beyond the chromosome ends in both cancer and aging.
190,359-361
  Telomerase has 
been implicated in the process of apoptosis, DNA repair, stem cell function, and in the 
regulation of gene expression independent of telomere lengthening.
5,429
  
The antagonistic effects of telomerase in aging and cancer present a conundrum and 
highlight the importance of having a complete understanding of the telomerase holoenzyme 
and its biological functions. Taken together, the development of rational approaches to 
control telomerase activity could have the potential to combat cancer, cardiovascular disease 
(the leading cause of death worldwide), aging and premature aging syndromes. Despite the 
great interest in telomerase, current understanding of telomerase and its regulation is lacking. 
The research presented in this thesis provides a more comprehensive and thorough 
understanding of telomerase regulation during different cellular processes. In chapter III of 
this dissertation, we identified biological agents in cellular environment, such as reactive 
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oxygen species, as regulators of telomerase. Our data indicated that reactive oxygen species 
can damage telomerase by oxidizing its catalytic subunit and therefore perturb the formation 
of an active telomerase complex. In chapter IV of this dissertation, we identified cellular 
pathways that control telomerase activity. We demonstrated for the first time that telomerase 
is negatively regulated by pro-apoptotic caspases as an integral part of the apoptotic pathway.  
 
 
A. Chapter III: summary of results, conclusions, and future directions 
  
1. Summary of results and conclusions 
 
Mounting data support the notion that the loss of telomere repeats in stem cells and 
lymphocytes contribute to human aging.
19,351
 Even though the progressive shortening of 
telomeres is one of the best known intrinsic cellular events associated with aging, the speed 
at which telomeres shorten is dependent on many factors. It has been observed that telomere 
length can vary between men and women and can be influenced by socioeconomic status, 
perceived stress, smoking, and obesity.
19
 Importantly, telomere shortening can be intensified 
by the presence of reactive oxygen species due to oxidation of telomeric DNA and can thus 
accelerate the aging process.
105-107
 Additionally, many cancer cells are associated with 
mitochondrial dysfunction and an increase in ROS levels promoting genetic instability.
430-432
 
Reactive oxygen species are formed by a multitude of processes such as the mitochondrial 
respiratory system and are highly reactive molecules that can damage cellular components by 
oxidizing DNA, amino acids in proteins, and polydesaturated fatty acids in lipids, among 
others.
110
 While previous reports demonstrate that telomeres can be directly damaged by 
oxidative stress, there is no reported evidence to date demonstrating that reactive oxygen 
species oxidize telomerase. Our data demonstrate for the first time that telomerase is indeed 
  140 
sensitive to reactive oxygen species and thus oxidative damage. Since telomerase is inhibited 
by ROS, it is logical to conclude that telomere length is commensurately affected. Thus the 
increased telomere erosion experienced by the presence of reactive oxygen species is 
probably not only due to direct oxidation of telomeric DNA but also due to telomerase 
sensitivity to ROS, which consequently prevents telomere maintenance or elongation.  
The experiments performed in chapter III of this dissertation, indicated that the ortho-
quinone moiety of the tanshinone class of compounds was responsible for their observed 
telomerase inhibition in vitro. Ortho-quinone containing compounds have the ability to 
undergo redox-cycling in the presence of oxygen and tissue reducing equivalents, such as 
DTT, to produce reactive oxygen species including hydrogen peroxide, superoxide anion 
radical, and semiquinone anion radical, which can in turn cause protein and DNA damage, 
including DNA strand breaks and DNA base modification.
116,433-435
 In support of this 
conclusion, we demonstrated that an ortho-quinone compound, 9,10-phenanthrenedione, 
inactivated assembled telomerase in the presence of DTT in a time- and dose-dependent 
manner. Furthermore, addition of catalase to the reaction completely protected telomerase 
inhibition caused by 9,10-phenanthrenedione in the presence of DTT, further supporting the 
direct participation of reactive oxygen species derived from quinone-catalyzed redox cycling 
in telomerase inactivation. Moreover, we observed that ortho-quinones generated the 
formation of significant amounts of H2O2 and that telomerase inhibition was proportional to 
the amount of H2O2 generated in the assay. Cell studies using MnSOD knockdown cells, 
further demonstrated that telomerase was sensitive to cellular ROS, providing evidence for 
the first time that ROS can regulate telomerase in a real cellular environment.  
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Since ROS can accelerate telomere loss during replication, particularly because the 
guanine-rich nature of telomeric DNA makes it vulnerable to oxidative damage, we tested the 
ability of ortho-quinone containing compounds to oxidize different factors of the telomerase 
assay. No significant decrease in telomerase activity was observed when either the telomeric 
primer or the telomerase RNA subunit were pre-incubated with ortho-quinones and DTT. 
These results suggest that the loss of telomerase activity was due to a direct oxidative 
damage to telomerase catalytic subunit TERT and not to damage to other components of the 
assay including telomeric DNA. Additionally, these data suggest, as is the case for protein 
tyrosine phosphatases,
115,116,333
 that ROS may directly inhibit telomerase by a direct oxidation 
of a critical cysteine residue in TERT. If this is the case, then similar levels of telomerase 
inhibition should be observed when telomerase from other organisms is incubated with 
ortho-quinone containing compounds in the presence of DTT. Interestingly, the percent of 
telomerase inhibition from Tetrahymena species by ROS generating compounds 
corresponded with the percent of telomerase inhibition examined in humans. Mutations of 
conserved cysteine residues proved to be detrimental to telomerase activity indicating that 
conserved cysteines are crucial for forming an active holoenzyme complex. Since 
Tetrahymena is evolutionarily distant from humans, these results are consistent with the 
hypothesis that a thiol of a catalytically important and conserved cysteine residue is being 
oxidized and is therefore perturbing the telomerase active complex.  
 
 
2. Future directions 
Oxidative stress plays a role in the tissue damage that is associated with various 
diseases such as diabetes,
436
 cancer,
437,438
 and aging.
439
 An increase in the concentration of 
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transition metals such as copper and iron is observed with age, diabetes, cardiovascular 
disease, and cancer.
331,350,440
 These metals have been shown to catalyze the production of 
ROS in the presence of oxygen and quinone-type compounds.
433
 They can readily catalyze 
reactions related to the formation of H2O2 and free radicals such as the superoxide anion (O2
-
) 
and hydroxyl radical. The hydroxyl radical (HO) is the most powerful oxidizing species 
among several reactive-oxygen radicals and reacts rather unselectively with all amino acids 
via addition (aromatic amino acids), electron transfer (Met), and/or hydrogen abstraction 
(Cys and all Cand side chain C-H bonds).
332,441-443
  HOradicals can be produced when 
certain transition metals react with H2O2 in a “Fenton-type” reaction.
444
 Metal-catalyzed 
oxidation systems can catalyze the inactivation of enzymes, and the fragmentation of DNA 
and proteins.
332
 Future experiments should be performed in order to elucidate if hydroxyl 
radical plays a role in the inactivation of telomerase by ortho-quinones capable of redox 
cycling. The hydroxyl radical scavenger, mannitol, should be added to the telomerase assay 
in the presence of quinone-type compounds to evaluate if there is an effect on telomerase 
activity. Additionally since transition metals induce the formation of HOradicals from H2O2, 
it would be beneficial to evaluate the effect of metals such as copper and iron on telomerase 
activity in the presence of H2O2 and also in the presence of H2O2 and DTPA, a chelating 
agent for Cu(II), or EDTA, a chelating agent for Fe
2+
 (or Fe
3+
). These experiments would 
elucidate if the hydroxyl radical play a role in inactivating telomerase and if one-electron or 
two-electron reaction is predominant in telomerase oxidation.  
The ultimate goal would be to identify the cysteine residue(s) undergoing oxidation 
using mass spectrometry. The two electron oxidation of Cys yields sulfenic acid (CysSOH), 
which further oxidizes to sulfinic acid (CysSO2H) and sulfonic acid (CysSO3H) or it forms a 
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disulfide bond through a reaction with a second CysSH.
443,445
 Though Cohen et al. have 
sequenced hTERT peptides using nanoLC-MS/MS,
446
 the identification of the oxidized 
cysteine(s) will be quite challenging and costly due to the low abundance level of telomerase 
in cells (thus large scale production of telomerase is necessary), the fact that the catalytic 
cysteine of telomerase has yet to be identified, and the high number of cysteine residues (29) 
in hTERT, which consists of 1132 amino acids. Additionally, expertise is required in order to 
successfully obtain mass spectrometry results using such low concentrations of telomerase 
(100-200 fmol).  
 
 
B. Chapter IV: summary of results, conclusions, and future directions 
1. Summary of results and conclusions 
 
In addition to telomerase role in telomeric DNA synthesis, telomerase plays an 
essential role in protecting cancer cells from apoptosis, and loss of telomerase activity 
correlates with drug-induced apoptosis in different cancer cell types.
3,375,447
 However, the 
mechanisms of this regulation are unknown. Regulation of telomerase expression may be 
subject to multiple levels of control by different factors in various cellular contexts. Even 
though transcriptional regulation of hTERT is the primary mechanism for controlling 
telomerase activity in cells, post-translational modifications of the hTERT protein also 
account for telomerase regulation. Because telomerase can inhibit apoptosis, we 
hypothesized that pro-apoptotic signals could overcome this block. Therefore, in chapter IV 
of this dissertation, we examined if telomerase was regulated by caspases at the post-
translational level. Since caspases act in the central role to both initiate and execute the 
intracellular cascade of events that result in substrate cleavage and ultimately cell death,
134,383
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our hypothesis was that telomerase is negatively regulated by caspases as part of a life-death 
axis. We proposed that caspases cleave hTERT, promoting apoptosis.  
Though hTERT contained no caspase recognition motifs, our results showed for the 
first time that hTERT, the catalytic subunit of telomerase, is a caspase substrate. We 
demonstrated that hTERT is cleaved by both caspases-6 and -7 in vitro and in apoptotic 
cancer cells. Caspase-6 cleaved hTERT at aspartic acids 129 and 637 while caspase-7 
cleaved hTERT at glutamic acid 286 and aspartic acid 628. Pre-incubation of drug induced 
apoptotic cells with either a general caspase inhibitor, z-VAD-fmk, or with a combination of 
caspase-6 and -7 inhibitors, z-VEID-fmk and ac-DEVD-fmk, blocked proteolytic cleavage of 
hTERT thus suggesting that caspase-6 and -7 were solely responsible for cleaving 
telomerase. Furthermore, our experiments showed that pre-incubating drug-induced apoptotic 
cells with 5 μM of a general caspase inhibitor did not protect cells from apoptosis, but it was 
able to partially rescue telomerase activity, suggesting for the first time that telomerase is a 
biologically significant substrate of caspases in apoptotic cancer cells. 
We further demonstrated that overexpressing telomerase in cells did not affect 
hTERT sensitivity to caspase cleavage and that telomerase activity decreased in correlation 
with hTERT cleavage. Mutagenesis studies showed that only the hTERT mutant 
D129A/D637A/E286A/D628A containing mutations in all caspase-6 and -7 cleavage sites 
was resistant to proteolytic cleavage in CCCP induced K562 apoptotic cells. Moreover, the 
fact that the double mutant resistant to caspase-6 cleavage (D129A/D637A) was resistant to 
proteolytic cleavage in caspase-7 knockdown cells and the fact that the double mutant 
resistant to caspase-7 cleavage (E286A/D628A) was resistant to caspase cleavage in caspase-
6 knockdown cells, supported our conclusion that caspases-6 and -7 were utterly responsible 
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for telomerase cleavage during the apoptosis process. Importantly, cleavage of hTERT 
occurred concomitantly with cleavage of caspases-6 and -7, further validating a direct 
correlation between hTERT cleavage and caspase-6 and -7 activation. 
 Overexpressing K562 cells with caspase resistant hTERT mutants revealed that 
mutation at aspartic acid 129 (D129A) caused cells to be even more sensitive to apoptosis 
than cells overexpressing WT hTERT. Though further experiments are required in order to 
elucidate this result, one explanation for this observation could be that mutation at site 129 
prevents the translocation and localization of hTERT to the mitochondria since the 
mitochondrial localization signal peptide of hTERT is located at the first 20 amino acids at 
its N-terminal region. Though controversial roles of hTERT in the mitochondria have been 
reported by several groups,
118,121,122,124,125,448
 our results indicate that perhaps hTERT N-
terminal proteolytic fragment (1-129) could possibly have anti-apoptotic functions when 
translocated to the mitochondria. We also showed that the hTERT mutant containing 
mutations at every caspase cleavage site rendered cells more resistant to apoptosis, thus 
indicating that cell viability was directly related to hTERT and the ability of caspases to 
cleave hTERT during apoptosis.  
 
 
2. Future directions 
Our experiments showed that most caspase resistant hTERT mutants, with the 
exception of D129A mutant, experienced an increase in the apoptotic threshold as compared 
to wild-type hTERT. Additionally, some hTERT mutants such as D628A and D637A were 
significantly more resistant to apoptosis than WT hTERT. These results suggested that 
hTERT proteolytic fragments produced by caspases yielded protein fragments with pro-
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apoptotic or anti-apoptotic functions or that the full length TERT itself is anti-apoptotic. 
Therefore, in order to test if there is a gain or loss of function by the TERT fragments, 
specific hTERT fragments (such as 1-129, 1-286, 1-637, 1-628, 129-637, 286-628, 129-1132, 
286-1132, 637-1132, 628-1132) should be transfected into cancer cell lines and the effect on 
the apoptotic threshold determined. This experiment would clarify if the hTERT fragments 
produced by caspase-6 or -7 play a role in the induction or prevention of apoptosis. Provided 
that at least one of the hTERT fragments has a pro-apoptotic or anti-apoptotic function, it 
would be important to study the effect of such fragments using murine models. Determining 
the role of caspase-mediated cleavage of hTERT in tumors derived from human cancer cells 
using nude mouse xenograft models and analyzing for tumor growth, apoptosis, telomerase 
activity and hTERT cleavage after drug treatment will demonstrate important features of the 
underlying role of hTERT in cancer cells. Besides the fact that telomerase is considered a 
useful prognostic marker and a universal target for cancer therapy, hTERT is now receiving 
special attention as a target for novel immunotherapies against different cancer types.
307,449,450
 
Chapter IV of this dissertation provides a basis to further interrogate the mechanism of 
telomerase repression by key players during the apoptosis pathway and could potentially lead 
to the identification of inactive hTERT variants with potential therapeutic value. Taken 
together, the results described in this thesis help clarify how different cellular processes 
modulate telomerase during cancer, aging, and other age-related diseases.  
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